

CURRICULUM VITAE

NAME: STEINER, Meir

BUSINESS ADDRESS: Women's Health Concerns Clinic
St. Joseph's Healthcare
301 James Street South
Hamilton, Ontario, L8P 3B6
TEL: (905) 522-1155, ext. 33246
FAX: (905) 521-6098
E-MAIL: mst@mcmaster.ca

PERSONAL: Date of Birth: February 11, 1940
Place of Birth: Jerusalem, Israel
Marital Status: Married, 4 children, 5 grandchildren
Citizenship: Canadian

Dated: August 31, 2011

A handwritten signature in black ink, appearing to read "M. Steiner". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

EDUCATIONAL BACKGROUND:

YEARS	CERTIFICATE	INSTITUTION
1954-58		High School, Tel Aviv
1960-63		Dental School, Hebrew University, Jerusalem
1963-64		Medical School, University of Freiburg, Freiburg im Breisgau, West Germany
1964-68	MD	Sackler School of Medicine, Tel Aviv University, Tel Aviv •Title of Thesis: " <i>Post-hysterectomy emotional disturbances in women</i> "
1965-67		The Israel Psychoanalytic Society, In Psychoanalysis
1969-70		The Israel Psychoanalytic Society, In Supervision
1969-72		Tel Aviv University, Faculty of CME: Psychiatry
1972-75		Tel Aviv University, Faculty of CME: Psychotherapy
1974		Israeli Medical Board - Certified Psychiatrist #4839
1975		Education Commission for Foreign Medical Graduates (ECFMG), Certificate #235-453-8
1976-79	PhD	University of Michigan, Department of Neurosciences, Horace H. Rackham School of Graduate Studies, Ann Arbor, Michigan •Title of Thesis: " <i>Motivated behaviour and the estrous cycle of the rat</i> "
1976-79		University of Michigan, Towsley Center for CME: Psychobiology
1982	FRCPC	The Royal College of Physicians and Surgeons of Canada, Certification in Psychiatry #2760
1992	CPSO	The College of Physicians and Surgeons of Ontario, General Licence #42447

FELLOWSHIPS & AWARDS:

YEAR	INSTITUTION	FELLOWSHIP/AWARD
1968	University of Tel Aviv	M.D. Magna Cum Laude
1971	Research Division, Theraplix Laboratories, Paris, France	Travelling Fellowship to Sweden
1976	American Physicians Fellowship Inc.	Scholarship
1979	University of Michigan	Clinical Research Fellow with Distinction
1987	Canadian Society for Clinical Investigation	Schering Travelling Fellowship

FELLOWSHIPS & AWARDS:

2000	Canadian College of Neuropsychopharmacology	Heinz Lehmann Award
2002	McMaster University	Distinguished Research Career Award
2003	State of Wisconsin, Office of the Governor	A Commendation "Perinatal Mood Disorders"
2003	Motherisk Program, Hospital for Sick Children, Toronto	The Andre Boivin Visiting Professorship Award
2006	NASPOG, Young Investigators Award	Renamed "The Steiner Young Investigators Award"
2011	Canadian College of Neuropsychopharmacology	CCNP Medal

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS:

1976-2006	American Psychiatric Association
1976-	Collegium Internationale Neuro-Psychopharmacologicum
1977-	American Association for the Advancement of Science
1978-	International Society of Psychoneuroendocrinology
1978-	New York Academy of Sciences
1979-	Society of Biological Psychiatry
1981-	Canadian Medical Protective Association
1981-	College of Physicians & Surgeon of Ontario
1981-	Marcé Society
1981-	Society for Neuroscience
1982-	Canadian College of Neuropsychopharmacology
1985-	Canadian Psychiatric Association
1987-	North American Society for Psychosocial Obstetrics and Gynecology
1988-	Society for Research on Biological Rhythms
1994-	American Society of Clinical Psychopharmacology
1997-	World Psychiatric Association, Section on Women's Mental Health
2001-	International Association of Women's Mental Health (Founding Co-Director)
2004-	Canadian Network for Mood and Anxiety Treatments
2006-	American Psychiatric Association – Life Member
2006-	Organization for the Study of Sex Differences - Founding Member
2006-	Centre for Studies on Human Stress

EMPLOYMENT HISTORY:

YEARS	INSTITUTION	POSITION
1967-68	Hasharon Hospital, Tel Aviv University	Rotating Internship
1968-69	Department of Internal Medicine, Ashkelon Medical Center	Resident
1969-71	The Gehah Psychiatric Hospital, Tel Aviv University	1st-3rd Year Resident
1971-72	The W.S. Schwartz Institute for Psychiatric Treatment and Research (Basic Sciences), Tel Aviv University	Research Fellow

EMPLOYMENT HISTORY:

1971-72	School of Nursing Beilinson Medical Center Psychiatry	Lecturer in Psychiatry
1971-75	Sackler School of Medicine, Tel Aviv University	Instructor in Psychiatry
1972	Department of Neurology, Beilinson Medical Center, Tel Aviv University	Intern
1973-74	Shalvata Psychiatric Centre, Tel Aviv University	4th Year Resident
1974-75	Shalvata Psychiatric Centre, Tel Aviv University	Senior Staff
1975-79	Department of Psychiatry, University of Michigan	Research Fellow
1976-79	W.J. Maxey's Boy's Training School, Department of Social Services, State of Michigan	Consultant
1977-79	Mental Health Research Institute, University of Michigan	Postdoctoral Scholar
1979-80	Child & Adolescence Psychiatric Services, Shalvata Psychiatric Centre, Tel Aviv University	Consultant
1980-81	Consultation-Liaison Services, Shalvata Psychiatric Centre & the "Meir" General Hospital, Tel Aviv University	Senior Consultant
1981-	St. Joseph's Hospital (SJH), Hamilton, Ontario	Active Staff
1981-84	Department of Psychiatry, McMaster University	Associate Professor
1981-84	Department of Neurosciences, McMaster University	Associate Professor
1982-92	Clinical Studies Program, McMaster Psychiatric Unit, SJH	Head & Research Coordinator
1983-92	Affective Disorders Clinic, McMaster Psychiatric Unit, SJH	Director
1984-	Department of Psychiatry, McMaster University	Tenured
1985-98	Department of Psychiatry, McMaster University	Professor
1985-88	Department of Neurosciences, McMaster University	Professor
1987, Jan-Jul	Department of Psychiatry, Hillcrest Hospital, University of Adelaide, South Australia	Visiting Professor (Sabbatical)
1988-98	Department of Biomedical Sciences, McMaster University	Professor
1988-2005	Women's Health Concerns Clinic, SJH	Director
1992-	Father Sean O'Sullivan Research Centre	Founding Member
1992-96	Inpatient Services, Department of Psychiatry, SJH	Director
1992-96	Department of Psychiatry, SJH	Chief & Clinical Director

EMPLOYMENT HISTORY:

1997-2005	Department of Psychiatry, SJH	Director of Research
1998-	Department of Psychiatry and Behavioural Neurosciences	Professor
1999-	Institute of Medical Sciences, University of Toronto	Professor
2000-	Department of Obstetrics & Gynecology, McMaster University	Professor
2001-	Centre for Evaluation of Medicines, Father Sean O'Sullivan Research Centre	Professor
2001-	McMaster Brain Body Institute, SJH	Founding Member
2003-	The Hospital for Sick Children	Adjunct Scientist
2005-	Women's Health Concerns Clinic	Founding Director
2006-	Department of Psychiatry, University of Toronto	Professor

SCHOLARLY AND PROFESSIONAL ACTIVITIES:**EDITORIAL BOARDS:**

1996-	Journal of Psychiatry in Clinical Practice, North American Advisor
1998-99	Archives of Women's Mental Health
2000-01	Archives of Women's Mental Health, Co-Editor in Chief (for the Americas)
2000-	Inst of Physicians Postgraduate Press, Inc., CME External Advisory Board, The Journal of Clinical Psychiatry/ The Primary Care Companion
2001-	Journal of Affective Disorders
2002-	Archives of Women's Mental Health, Editor-in-Chief
2002-	Mental Fitness
2003-10	Bibliotheca Psychiatrica, Editor
2003-	International Journal of Methods in Psychiatric Research
2004-	Women's Health
2008-10	Journal of Psychiatry and Neuroscience, Associate Editor
2009-	Biology of Sex Differences
2011-	Gender Medicine

EXECUTIVE POSITIONS:

1987-93	DSM-IV Task Force, International Advisor
1996-98	NASPOG Executive Board, Member-at-Large
1998-	Association of Professors of Gynecology & Obstetrics, Advisory Board
1998-99	NASPOG, Vice President
1999-00	NASPOG, President Elect
2000-01	NASPOG, President
2001-03	NASPOG Executive Board, Immediate Past President and Development Officer
2001-02	Executive Committee, 2 nd Worldwide Pfizer Neuroscience Consultants Forum
2001-	The Executive of the Marce Society, Member
2002-08	Society for Women's Health Research: The Isis Fund Network on Sex, Gender, Drugs, and the Brain, Member
2003-04	CCNP, Councillor (Clinical)
2004-06	CCNP, President Elect

Dr. Meir Steiner

2006-08 CCNP, President
 2006-10 Organization for the Study of Sex Differences (OSSD), Councillor
 2008-10 CCNP, Past President
 2008-11 DSM-V Subworkgroup on PMDD, Advisor
 2009- Society for Women's Health Research: The Isis Fund Network on Sex Differences in Cardiovascular Disease, Member

JOURNAL REFEREE:

1985- Canadian Journal of Psychiatry
 1987- Hospital & Community Psychiatry
 1988- Psychoneuroendocrinology
 1990- Canadian Journal of Obstetrics & Gynecology
 1991- Psychiatry Research
 1991- Journal of Psychiatry & Neuroscience
 1992- American Journal of Obstetrics & Gynecology
 1993- Biological Psychiatry
 1994- Journal of Psychosomatic Obstetrics & Gynecology
 1996- New England Journal of Medicine
 1996- Life Sciences
 1996- Psychosomatic Medicine
 1998- Journal of the American Medical Women's Association
 1998- Trends in Pharmacological Sciences
 1999- Journal of Affective Disorders
 1999- Harvard Review of Psychiatry
 1999- American Journal of Psychiatry
 1999- Obstetrics & Gynecology
 2000- Lancet
 2001- International Journal of Neuropsychopharmacology
 2002- Fertility and Sterility
 2004- Archives of General Psychiatry
 2006- Journal of Women's Health
 2010- Journal of Psychiatric Research
 2010- British Medical Journal
 2010- Clinical Endocrinology
 2010- Sexual & Reproductive Healthcare
 2010- Neuropsychopharmacology
 2010- General Hospital Psychiatry
 2010- Journal of Occupational and Environmental Medicine
 2011- Journal of Child Psychology and Psychiatry
 2011- Environmental Health Perspectives
 2011- Journal of Abnormal Psychology

EXTERNAL GRANT REVIEWS:

1982- Medical Research Council of Canada/ Canadian Institute of Health Research
 1983- Alberta Mental Health Advisory Council
 1985- National Institute of Mental Health
 1986- Ontario Mental Health Foundation
 1987- Canadian Psychiatric Research Foundation
 1987- Ontario Ministry of Health
 1991- The Physicians' Services Incorporated Foundation
 2001 National Institute of Health Study Section
 2004- College of Reviewers for the Canada Research Chairs, CIHR
 2007- CIHR Behavioural Sciences, B Peer Review Committee

2008- CIHR Centres for Research Development in Gender, Mental Health and Addictions Peer Review Committee
 2010- Institute of Medical Science Laidlaw Manuscript Competition
 2010- Wellbeing of Women/RCOG Research, London, UK

SPEAKERS BUREAU:

1995- Eli Lilly, Inc.
 1996- Pfizer International
 1999- Novartis Canada
 2000- SmithKline Beecham/ GlaxoSmithKline
 2001- Lundbeck, Canada
 2002-10 Wyeth Pharmaceuticals
 2001- Astra-Zeneca
 2009- Servier Canada

MEDICAL CONSULTANT/ADVISORY BOARD MEMBER:

1995- Eli Lilly, Inc.
 1996- Pfizer International and Canada
 1999- GlaxoSmithKline
 2001-03 Barr Laboratories
 2001- Lundbeck, International (Copenhagen & Canada)
 2002-04 Proctor and Gamble (Cincinnati)
 2002-07 Ortho-McNeil Pharmaceutical
 2003-05 Warner Chilcott
 2003-10 Wyeth Pharmaceuticals
 2004- Azevan Pharmaceuticals
 2006-07 Ferring Research Institute
 2007- Bayer-Shering Pharmaceuticals
 2008- Diagnostic Assessment and Clinical Research Association (DAACRO)
 2009- Servier Canada
 2009- Bayer Inc. Canada: External Medical Expert – Yaz PMDD

RESEARCH FUNDING:

YEARS	SOURCE	TITLE	ROLE
1971-72	Research Division, Theraplix Lab, Paris, France	Trifluoperazine in schizophrenia	Principal Investigator
1977-78	Sandoz Inc.	Bromocriptine in premenstrual tension syndrome	Coordinator
1977-79	National Institute of Mental Health	Neuroendocrine regulation in depression	Co-Investigator
1977-78	CRC, University of Michigan	Psychobiology of premenstrual tension	Chief Investigator
1977-79	CRC, University of Michigan	Pharmacology of neuroendocrine control	Co-Investigator
1982-85	Health and Welfare Canada	Cognitive mapping of depression	Co-Investigator

RESEARCH FUNDING:

1983-87	Ontario Mental Health Foundation (OMHF)	Studies in borderline patients: establishment of valid subgroups	Co-Investigator
1983-86	St. Joseph's Hospital (SJH) Health Care Foundation	Measuring platelet MAO activity in psychiatric patients	Principal Investigator
1984-86	Social Sciences & Humanities Research Council, Canada	Bonding in depressed mothers	Principal Co-Investigator
1984-85	SJH Health Care Foundation	Depression in the elderly	Co-Principal Investigator
1984-86	Dow Pharmaceuticals	Noradrenergic regulation in melancholia	Principal Investigator
1984-86	SJH Health Care Foundation	Mother and baby psychiatric intensive care unit	Principal Investigator
1986-88	Ontario Ministry of Health	Coping with depression in the elderly	Principal Investigator
1986-89	SJH Health Care Foundation	The neuroanatomy/neurochemistry of the circadian system	Research Scholarship
1986-88	OMHF	How does ECT work?	Principal Investigator
1986-88	Ontario Ministry of Health	RCT in borderline patients	Co-Principal Investigator
1987-88	Canadian Psychiatric Research Foundation	Retinal sensitivity to light and depression	Principal Investigator
1987-88	SJH Health Care Foundation	The effects of ECT on lymphocyte –receptors	Principal Investigator
1987-88	SJH Health Care Foundation	Cognitive functions in the elderly	Co-Investigator
1988	Medical Research Council of Canada (through CSD)	Equipment grant (Dark Adaptometer)	Co-Investigator
1988-90	OMHF	Adrenergic receptor responsiveness in depression	Principal Investigator
1988-90	Medical Research Council of Canada	Maternal response to infant cues during the puerperium and relation to hormones	Co-Investigator
1988-present	FHS, McMaster University / Positive Incentive Plan	Women's health concerns	Principal Investigator
1989-94	Eli Lilly Canada Inc.	The fenfluramine challenge test in women with LLPDD	Principal Investigator
1989-91	SJH Health Care Foundation	Cholinergic supersensitivity: an animal model for depression	Principal Investigator

RESEARCH FUNDING:

1989-94	Eli Lilly Canada Inc.	Fluoxetine vs placebo in the treatment of LLPDD (Canadian Multicentre Study)	Principal Investigator and Study Coordinator
1991-93	Duphar B.V., The Netherlands	Flesinoxan in depression (Canadian Multicentre Study)	Co-Investigator
1991-93	OMHF	Depression and sensitivity to light	Principal Investigator
1991-93	Social Sciences & Humanities Research Council, Canada	Parental responses to infant odour cues in early postpartum period	Co-Investigator
1991-93	Ontario Ministry of Health	Phenelzine in the treatment of adolescent depression	Co-Investigator
1991-93	Eli Lilly Canada Inc.	Fluoxetine in the treatment of seasonal affective disorder (Canadian Multicentre Study)	Co-Investigator
1993-95	Parke-Davis/Warner-Lambert Canada Inc.	Quinapril for the treatment of premenstrual syndrome (Canadian Multicentre Study)	Co-Investigator
1993-96	Social Sciences & Humanities Research Council, Canada	Parental responses to infant odours and their relation to hormones	Co-Investigator
1994-99	Medical Research Council of Canada / Pharmaceutical Manufacturers Association of Canada & Pfizer Canada Inc.	Sertraline vs IPT alone or in combination for people with dysthymia in primary care	Co-Principal Investigator
1995-97	Pfizer Canada Inc.	Sertraline vs placebo in PMDD (Canadian Multicentre Study)	Co-Investigator
1995-96	SK&B Pharma Inc.	Paroxetine vs placebo in PMDD. (International Multicentre Study)	Principal Investigator
1996-98	SK&B Pharma Inc.	The serotonergic cascade and depression in women	Principal Co-Investigator
1996-99	Medical Research Council of Canada	Parental responses to infant cries and odours and their relation to hormones	Co-Investigator
1997	Pfizer International (N.Y.)	Educational Grant-In-Aid	Principal Investigator
1997	Eli Lilly (U.S.)	Educational Grant-In-Aid	Principal Investigator
1997-99	Ontario Thoracic Society	Stress and bronchial hyperresponsiveness in spontaneously breathing, unrestrained rats	Co-Investigator

RESEARCH FUNDING:

1997-99	SK&B Pharma Inc.	Menopause and beyond	Principal Investigator
1997-99	Pfizer Canada Inc.	Intermittent dosing of sertraline and placebo in PMDD	Co-Investigator
1998-99	Pfizer Canada Inc.	Sildenafil vs placebo in female sexual arousal disorder	Co-Investigator
1998-99	Ontario Thoracic Society	Stress and bronchial hyperresponsiveness in spontaneously breathing, unrestrained rats	Co-Investigator
1998-01	The Smokeless Tobacco Research Council, Inc.	Nicotine, autonomic function and airway hyperresponsiveness	Co-Investigator
1999-00	Eli Lilly (U.S.)	Gender specific measure of irritability	Principal Investigator
1999-00	Glaxo-Wellcome	Paroxetine vs Wellbutrin SR in patients with major depression	Co-Investigator
1999-00	Proctor & Gamble Pharmaceuticals Canada	A validation study of the sexual activity log and the profile of female sexual function in oophorectomized women	Co- Investigator
1999-01	Berlex Canada	Educational Grant-in-Aid	Co-Investigator
1999-01	Eli Lilly (U.S.)	The Burden of Illness of PMDD	Principal Investigator
1999-03	SK&B Pharma Inc.	Intermittent dosing of paroxetine and placebo in PMDD	Principal Investigator (Canadian Multi-centre)
2000-01	Merck Frosst	Stress-induced NK1 receptor endocytosis in a rat model of depression	Principal Investigator
2000-01	Father Sean O'Sullivan Research Centre	Expectations of menopausal women	Principal Investigator
2000-03	CIHR	Behavioural and endocrine responses to infants and infant cues in depressed and non-depressed new mothers	Co-Investigator
2000-03	CIHR Doctoral Research Award (to Ms. L. Born, PhD Cand.)	A gender specific measure of irritability	Supervisor
2001-02	D. C. Russell Award (to Ms. A. Shea, MSc Cand.)	The neurobiology of stress responses in female teens	Supervisor

RESEARCH FUNDING:

2001-02	Pfizer Canada	Sertraline for the acute treatment of DSM-IV generalized anxiety disorder	Co-Investigator (International Multi-Site)
2001-03	GlaxoSmithKline	A prospective comparison of case series of pharmacotherapy (paroxetine), interpersonal psychotherapy (IPT), or a combination of both in the treatment of women with postpartum mood disorders	Principal Investigator
2001-03	Ontario Women's Health Council	Diagnosis & treatment of female specific mood disorders in primary care settings	Principal Investigator
2001-03	Eli Lilly (U.S.)	PMS/PMDD in adolescent girls	Principal Investigator
2001-07	CFI & ORDCF	The biology of brain-body communications	Co-Investigator
2002-03	NIMH	Calcium for the prevention of postpartum depression	Consultant
2002-03	Pfizer Canada	The efficacy, safety and toleration of oral Viagra administered for 12 weeks to women who are receiving hormone replacement therapy and who have female sexual arousal disorder	Co-Investigator
2002-03	OCGS, Ontario Women's Health Scholars Award (to Ms. A. Shea, MSc Cand.)	Hypothalamic-pituitary adrenal axis dysfunction following child maltreatment and its role in the etiology of women's mental illness	Supervisor
2002-04	Father Sean O'Sullivan Research Centre Postdoctoral Research Award (to Dr. L. Ross, PhD)	Perinatal mood & anxiety disorders	Supervisor
2002-05	CIHR (NET)	Health impacts of violence across the lifespan - a multidisciplinary approach	Co-Investigator
2003-04	OGS, Ontario Graduate Scholarship and U of T Open Fellowship Award (to Ms. A. Shea, Phd Cand.)	Maternal allostatic load and infant physiological and temperamental outcomes	Supervisor
2003-04	Thyroid Foundation of Canada	Do thyroid antibodies influence the clinical profile of postpartum depression?	Principal Investigator

RESEARCH FUNDING:

2003-04	TIPPS	Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins (AWARE)	Co-Investigator
2003-05	CIHR Postdoctoral Research Award (to Dr. L. Born, PhD)	Diagnosing mental disorders associated with childbearing: a pocket tool	Co-Supervisor
2003-05	Society for Women's Health Research	Randomized, double blind, placebo-controlled trial of low dose transdermal 17 β -estradiol acceleration of sertraline in major depression with postpartum onset	Principal Investigator
2003-08	CIHR	Maternal adversity, vulnerability and neurodevelopment (MAVAN)	Principal - Co-Investigator
2004-05	OGS, Ontario Graduate Scholarship and U of T Open Fellowship Award (to Ms. A. Shea, PhD Cand.)	Maternal allostatic load and infant physiological and temperamental outcomes	Supervisor
2004-05	CIHR	Mental health in lesbian mothers: a pilot study of preconception through the first postpartum year	Co-Investigator
2004-06	OMHF	Can postpartum depression be prevented? The effects of reducing sleep deprivation during the first week postpartum	Principal Investigator
2004-06	SSHRC	Responsiveness to infant cues in teenage mothers	Co-Investigator
2004-07	OMHF- Research Studentship Award (to Ms. A. Shea, PhD candidate)	Maternal allostatic load and infant physiological and temperamental outcomes	Supervisor
2004-09	CIHR	Maternal responsiveness in new mothers: affective, attentional and endocrine functions	Co-Investigator
2004-05	McMaster University	The resident, the computer and the tutor: e-learning and women's mental health	Co-Investigator
2005-06	Alternate Funding Plan, McMaster University	E-learning for postgraduate training in women's health	Principal Investigator
2005-07	Wyeth Pharmaceuticals	Evaluating an oral contraceptive in a continuous daily regimen in PMDD	Principal Investigator

RESEARCH FUNDING:

2005-07	Pfizer	Pregabalin and Venlafaxine for the acute treatment of DSM-IV generalized anxiety disorder in outpatients	Principal Investigator
2005-	McMaster Gender and Health Initiative	Identifying gender differences in adolescents descriptions of irritable mood	Co-Investigator
2005-06	Brain Body Institute Research Studentship Award (to Ms. M. Peer)	The efficacy of hormone modulation for the management of severe premenstrual asthma: placebo-controlled trial	Supervisor
2006-	Eli Lilly	Semi-intermittent dosing of duloxetine for the treatment of premenstrual exacerbation of depression	Co-Investigator
2006-08	Astra Zeneca Canada	Seroquel SR for the treatment of peri & postmenopausal women: impact on mood sleep and quality of life	Co-Investigator
2007-08	Alternate Funding Plan McMaster University	Menstrual cycle – related changes in mood, anxiety symptoms and stress responses in women with asthma	Principal Investigator
2007-08	CIHR	An evidence-based algorithm to quantify risk-benefit decision-making for use of antidepressant medication during pregnancy and lactation	Co-Investigator
2007-08	HAHSO	Menstrual cycle function in adolescent females with mental health problems: a pilot study	Principal Investigator
2007-09	The Physicians Services Incorporated Foundation	Perimenstrual asthma, stress & inflammation: are hormonal fluctuations relevant?	Principal Investigator
2007-09	Fonds de la recherche en sante Quebec (To Dr. Catherine Lord)	Effect du stress sur l'activation cerebrale de femmes ayant un trouble obsessif-compulsif debutant en periode post-partum	Supervisor
2007-09	Effort Trust	Effect of stress on brain activation patterns in women with postpartum onset of obsessive-compulsive and depressive disorders	Principal Investigator

RESEARCH FUNDING:

2008-09	CHIR/Rx&D Wyeth Pharmaceuticals (Fellowship Award to Dr. Benicio Frey)	An 8 week open trial of desvenlafaxine, a novel serotonin and norepinephrine inhibitor, for the treatment of vasomotor symptoms in perimenopausal women: effects on mood, cognition, brain function, and quality of life	Principal Investigator
2007-10	CIHR	Neural correlates of maternal responsiveness and maternal behaviour in mothers with and without postpartum depression	Co-Investigator
2008-11	SSHRC	Attentional and hormonal correlates of maternal behaviour in teenage mothers	Co-Investigator (A. Fleming PI)
2008-10	Hamilton Community Fdn Community Health, Education and Research Fund (CHER)	Does stress in pregnant immigrant women predispose their infants to allergic disease development	Co-Investigator (C. Soares PI)
2008-10	Lundbeck	A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of major depressive disorder	Principal Investigator
2009-10	Eli Lilly	Duloxetine for the treatment of major depression in midlife women: effects on mood, brain structure and functioning, and quality of life	Co-Investigator (C. Soares PI)
2009-10	Wyeth Pharmaceuticals	Desvenlafaxine succinate in major depressive disorder: effects on structural and functional imaging, cognition, and functional outcomes in midlife women and men	Co-Investigator (C. Soares PI)
2009-14	CIHR	A longitudinal study of food reward and obesity in children: the role of dopamine system genes and maternal adversity	Co-Investigator (R. Levitan PI)
2009-11	MOHLTC	Use of antidepressant medication during pregnancy and lactation: development of an evidence-based decision tool	Co-Investigator (S. Grigoriadis and L. Ross PI's)

RESEARCH FUNDING:

2009-12	CIHR	Maternal adversity, vulnerability and neurodevelopment (MAVAN)	Principle - Co-Investigator
2010-12	OMHF	Neural correlates of maternal responsiveness and maternal behaviour in mothers with postpartum depression	Co-Investigator (A. Fleming PI)
2010-13	CIHR	Identification of GXE determinants of individual differences in maternal care	Co-Investigator (M. Meaney PI)
2010-13	CIHR	Epigenetic effects of maternal depression	Co-Investigator (M. Szyf PI)
2010-15	CIHR	An early developmental model of overeating, obesity and executive dysfunction.	Co-Investigator (R. Levitan PI)
2011-14	CIHR	Neurochemical aspects of depression in women: monoamine oxidase A during perimenopause	Co-Investigator (J. Meyer PI)
2011-12	Alternate Funding Plan – Women's College Hospital	Women's decisions about anti-depressant use in pregnancy	Collaborator (S. Vigod PI)

PENDING:**SUPERVISORY EXPERIENCE:****General**

1971-75 1979-81	Supervision of medical students and residents in Psychiatry, Sackler School of Medicine, Tel Aviv University
1981-	Supervision of MD students, Post-graduates (Residents) in Psychiatry and in Obstetrics-Gynecology, Interns and Midwives, Faculty of Health Sciences, McMaster University
1982-	Supervision of graduate students in Neurosciences, Behavioral Sciences, and Medical Sciences Faculty of Health Sciences, McMaster University
1995-	Supervision of post-doctoral (PhD) fellows, Father Sean O'Sullivan Research Centre, SJH
1999-	Supervision of clinical scholars (MD), in Psychiatry and in Obstetrics-Gynecology, Faculty of Health Sciences, McMaster University
1999-	Supervision of Master's and PhD candidates, Institute of Medical Sciences, University of Toronto
2008-	Supervision of Master's candidates, MINDS Program, McMaster University

Dr. Meir Steiner

Residents – Psychiatry

1983 - J. Clinton
 1985 - M. Korzekwa
 1986 - S. Oztunc
 1986 - R.G. Guscott
 1986 - J. Soni
 1987 - S. Webb
 1988 - D. Irwin
 1988 - J.R. Pelletier
 1989 - H. MacMillan
 1990 - R. VanReekum
 1991 - W. Tam
 1991 - P. Lepage
 1992 - M. Siekierski
 1992 - F. Centorrino
 1992 - J. Johnson
 1993 - H. Bibr
 1993 - D. Ingram
 1994 - L. Yatham
 1995 - D. Schemmer
 1995 - S. McCullagh
 1996 - D. Mercer
 1996 - P. Jeeves
 1999 - B. Chen
 2001 - S. Namburi
 2002 - B. Roy
 2002 - S. Antochi
 2003 - K. Boylan
 2003 - S. Prenger
 2008 - T. Cheng
 2008 - E. Hall
 2008 - S. Duff
 2010 - R. Anglin
 2010 - S. Duff
 2010 - I. Gafni
 2010 - E. Hall

Past Trainees

1984 - S. Goldman (Research Nurse)
 1985 - V.N. Anderson (PhD)
 1985 - S.E. Auffarth (Masters)
 1985 - G. Bean (Masters)
 1985 - G.L. Flett (PhD)
 1986 - J. Lamont (Masters)
 1987 - T.G. Burns (Masters)
 1989 - D. Bird (PhD)
 1989 - M. D. Miceli (Post Doc)
 1989 - G. Orpen (Post Doc)
 1996 - B. Guran (Midwifery)
 1996 - A. Tran (Masters)
 1997 - M. Glibetic (Postdoctoral Fellow)
 1998 - M. Gleeson (Student Volunteer)
 1998 - K. McClellan (Lab Volunteer)
 1999 - I. Blum (MD, Visiting Professorship)

Residents – Obstetrics and Gynecology

1997 - T. Waschbisch
 1998 - J. Francis
 2001 - S. Causey
 2002 - P. Grewal
 2002 - K. Marrow

Dr. Meir Steiner

1999 - J. Hong (4th Year Thesis)
 2000 - C. Sundblad (PhD)
 2000 - A. Dragomir (Masters)
 2000 - V. Djuric (Postdoctoral Fellow)
 2001 - A. Cullimore (MD, Clinical Research Fellow)
 2003 - D. Bentz (Research Internship)
 2003 - D. Zinga (PhD)
 2003 - K.M. Krpan (Masters)
 2003 - S. Gunasekera (MD, Clinical Research Fellow)
 2003 - L. Born (PhD)
 2003 - A. Shea (Masters)
 2004 - D. Zinga (Postdoctoral Fellow)
 2004 - S.I. Rees (Masters)
 2004 - L. Ross (Postdoctoral Fellow)
 2004 - N. Mulpuru (RA)
 2005 - K. Ker (4th Year Thesis)
 2005 - E. Palova (MD, Visiting Professorship)
 2006 - J. Abraham (4th Year Thesis)
 2006 - M. Jung (RA)
 2006 - L. Born (Postdoctoral Fellow)
 2006 - S.D. Phillips (Masters)
 2006 - A. Khan (Grad Student Course in Psychology)
 2006 - N. Hsaio, (MD, Visiting Clinical Research Fellow)
 2006 - L. Matsos (Clinical Clerk)
 2006 - R. Mossman (Clinical Clerk)
 2007 - A. Sooknanan (Clinical Clerk)
 2007 - A. Nguyen (Clinical Clerk)
 2007 - M. Lazinski (4th Year Thesis)
 2007 - A. Shea (PhD)
 2007 - M. Peer (MSc)
 2007 - A. Lomanowska (PhD)
 2007 - L. Bennett (Masters)
 2008 - D. Kumaranayake (Clinical Clerk)
 2008 - S. Barkley (Clinical Clerk)
 2008 - D. Sum (Clinical Clerk)
 2008 - E. Hall (Clinical Clerk)
 2008 - A. Amini (4th year thesis)
 2008 - C. Carew (4th year thesis)
 2008 - A. Krol (3QQ3 Independent Study)
 2008 - E. Haber (Masters in Counselling Student)
 2008 - B. Frey (Postdoctoral Fellow)
 2009 - G. Parr (Clinical Clerk)
 2009 - L. Wright (Clinical Clerk)
 2008 - C. Lord (Postdoctoral Fellow)
 2009 - B. Nicholls (4th Year Thesis)
 2009 - M. Horniachek (Clinical Clerk)
 2010 - C. King (Clinical Clerk)
 2010 - S. Lokuge (MSc)
 2010 - M. Tam (Clinical Clerk)
 2011 - D. Boughan (Clinical Clerk)
 2011 - A. Rostas (Clinical Clerk)

Current Trainees (2010)

M. Peer (IMS, PhD)
 Y. Dowlati (IMS, PhD)

Dr. Meir Steiner
 B. Wendland (IMS PhD)
 W. Simpson (MINDS, MSc)

ADMINISTRATIVE RESPONSIBILITIES:

YEARS	ORGANIZATION	ROLE
1979-81	Committee for Comprehensive Examinations, Postgraduate Studies – Psychiatry; Israel Medical Association - Scientific Council	Member
1981-89	Research and Ethics Committee, SJH	Member
1982-91	Chairman's Advisory Research Committee, Dept of Psychiatry, McMaster University	Member
1983-86	Chairman's Advisory Committee, Department of Neurosciences, McMaster University	Member
1984-86	Departmental T&P Committee, Dept of Psychiatry, McMaster University	Member
1984-90	Task Force on Depression in the Elderly, SJH Foundation	Chair
1984-90	Task Force on Research, SJH Foundation	Member
1984-90	Task Force on Mother and Baby Psychiatric Intensive Care Unit, SJH Foundation	Chair
1987-89	Pharmacy and Therapeutics Committee, SJH	Member
1987-90	Education Coordinating Committee, Dept of Psychiatry, McMaster University	Member
1987-90	CME Advisory Committee, McMaster University	Member
1987-96	Clinical Investigator Training Program Committee, Dept of Psychiatry, McMaster University	Member
1988-91	Planning and Advisory Committee, Dept of Psychiatry, McMaster University	Member
1988-89	Affective Disorders Network, Dept of Psychiatry, McMaster University	Coordinator
1988-97	Recruitment Committee, The R. Samuel McLaughlin Centre for Gerontological Health Research	Member
1989	Senate Ad Hoc Selection Committee for Chairman, Department of Psychiatry, McMaster University	Member
1989-93	Priorities Committee, SJH Foundation	Member
1989-91	Chief's Executive Committee, Dept of Psychiatry, SJH	Member
1990-92	CCNP Finance Committee	Member
1989-90	Organizing Committee, XXI Congress of the ISPNE	Coordinator

ADMINISTRATIVE RESPONSIBILITIES:

1990-91	Organizing Committee, CCNP Annual Meeting, 1991	Member
1990-91	Psychology Review Committee, SJH	Member
1990-92	Finance Committee, Dept of Psychiatry, McMaster University	Member
1992-93	Utilization Committee, SJH	Member
1992-96	Executive Committee, Dept of Psychiatry, McMaster University	Member
1992-96	Clinical Directors Committee, Dept of Psychiatry, McMaster University	Member
1992-96	Psychiatry Task Force Committee, Dept of Psychiatry, McMaster University	Member
1992-96	Medical Advisory Committee, SJH	Member
1992-96	Credentials Committee, SJH	Member
1993-94	Membership Committee, CCNP	Member
1994-97	Chairman's Advisory Group on Finances & Quality Assurance, Dept of Psychiatry, McMaster University	Member
1994-99	System-Linked Research Unit on Health & Social Service Utilization, McMaster University	Advisor
1994 -01	Father Sean O'Sullivan Research Centre, St. Joseph's Hospital	Senior Management
1995-97	T&P Committee, Dept of Psychiatry, McMaster University	Member
1996-00	Research & Education Committee of the Board of SJH	Member
1996-	Research Committee, Department of Psychiatry, McMaster University	Member
2001	Organizing Committee, 1 st World Congress on Women's Mental Health, Berlin, Germany	Member
2002-	T & P Committee, Department of Psychiatry & Behavioural Neurosciences, McMaster University	Member
2002-	Scientific Advisory Committee, World Psychiatric Association	Member
2002-04	Organizing Committee, 2 nd World Congress on Women's Mental Health, Washington, DC	Member
2006-	OSSD Nominating and Membership Committees	Member
2009-11	Organizing Committee, 4 th World Congress on Women's Mental Health, Madrid, Spain	Member

LIFETIME PUBLICATIONS:**(i) BOOK CHAPTERS:****(a) Published:**

1. **Steiner M**, Blum I, Wijsenbeek H, Atsmon A. Results of the treatment of psychoses with propranolol. The implication on the biochemical mechanisms of psychotic disorders. *Kupat Holim Yearbook* 2:201-209, 1972.
2. Elizur A, Graff E, **Steiner M**, Davidson S. Intra-extra red blood cell lithium and electrolyte distributions as correlates of neurotoxic reactions during lithium therapy. In: ES Gershon, RH Belmaker, M Rosenbaum, SS Kety (eds): *The Impact of Biology on Modern Psychiatry*, pp. 55-64, 1977.
3. **Steiner M**: Psychiatric diagnosis for the 1980's. In: M Neumann (ed): *Selected Topics in Mental Health, The Family Physician, (Special Edition) Volume 10*, pp. 144-149, 1981.
4. Radwan M, **Steiner M**, Radwan H. Psychiatric "misdiagnosis" of organic brain syndromes. In: M Neumann (ed): *Selected Topics in Mental Health, The Family Physician, (Special Edition) Volume 10*, pp. 227-231, 1981.
5. **Steiner M**, Kutz I. Recent developments in biological psychiatry. In: M Neumann (ed): *Selected Topics in Mental Health, The Family Physician, (Special Edition) Volume 10*, pp. 323-329, 1981.
6. **Steiner M**. Psychoneuroendocrinology - major advances during the past decade. In: M Neumann (ed): *Selected Topics in Mental Health, The Family Physician, (Special Edition), Volume 10*, pp. 330-336, 1981.
7. **Steiner M**, Neumann M. War neuroses and social support. In: CD Spielberger, IG Sarason, NA Milgram (eds): *Stress and Anxiety, Volume 8: Psychological Stress and Adjustment in Times of War and Peace: The Israeli Experience*, pp. 139-142, 1982.
8. **Steiner M**. Psychobiological aspects of the menopausal syndrome. In: HJ Buchsbaum (ed): *The Menopause*, pp. 151-160, 1983.
9. **Steiner M**, Brown GM. Melatonin/cortisol ratio and the dexamethasone suppression test in newly admitted psychiatric inpatients. In: GM Brown, SD Wainwright (eds): *Advances in the Biosciences, Volume 53: The Pineal Gland - Endocrine Aspects*, pp. 347-353, 1985.
10. **Steiner M**, Haskett RF. The psychobiology of premenstrual syndromes: The Michigan studies. In: BE Ginsburg, BF Carter (eds): *Premenstrual Syndrome: Ethical & Legal Implications in a Biomedical Perspective*, Plenum Press, pp. 369-385, 1986.
11. **Steiner M**. The prevalence, identification and treatment of depression in the elderly. In: EB Ryan, K Kinanen, E Gerszon (eds): *Community and the Elderly*, pp. 39-43, 1986.
12. **Steiner M**. Treatments for premenstrual syndromes. In: C Shagass et al (eds): *Biological Psychiatry-1985*, Elsevier, pp. 135-137, 1986.
13. **Steiner M**, Fleming AS, Anderson VN, Monkhouse E, Boulter GE. A psychoneuroendocrine profile for postpartum blues? In: L Dennerstein, I Fraser (eds): *Hormones and Behaviour, Excerpta Medica: Amsterdam*, pp. 327-335, 1986.
14. Werstiuk ES, **Steiner M**. Anti-Psychotics. II. Butyrophenones. In: FN Johnson (ed): *Lithium Therapy Monographs, Volume 1*, pp. 84-104, 1987.

15. Brown GM, **Steiner M**, Grof P. Neuroendocrinology of affective disorders. In: R Collu, GM Brown, GR VanLoon (eds): Clinical Neuroendocrinology, Blackwell Scientific Publications, Inc., Chapter 19, pp. 461-474, 1988.
16. Vriend J, **Steiner M**. Melatonin and thyroid function. In: Miles et al (eds): Melatonin: Clinical Perspectives, Oxford University Press, pp. 92-117, 1988.
17. **Steiner M**. The myth of menopausal depression. In: B Lerer, S Gershon (eds): New Directions in Affective Disorders, Springer-Verlag Publishers, pp. 393-396, 1989.
18. Links PS, Boiago I, Huxley G, **Steiner M**, Mitton JE. Sexual abuse and biparental failure as etiologic models in borderline personality disorder. In: PS Links (ed): Family Environment and Borderline Personality Disorder, American Psychiatric Press, Inc., pp. 105-120, 1990.
19. Lepage P, **Steiner M**. Gender and serotonergic dysregulation: implications for late luteal phase dysphoric disorder. In: GB Cassano, HS Akiskal (eds): Serotonin-Related Psychiatric Syndromes: Clinical and Therapeutic Links, International Congress and Symposium Series Number 165, Royal Society of Medicine Services Limited, London, pp. 131-143, 1991.
20. Fleming AS, Corter C, **Steiner M**. Sensory and hormonal control of maternal behavior in rat and human mothers. In: CR Pryce, RD Martin, D Skuse (eds): Motherhood in Human and Nonhuman Primates. 3rd Schultz-Biegert Symposium, Kartause Ittingen, Basel, Karger, pp. 106-114, 1995.
21. **Steiner M**. Treatment of psychiatric disorders during pregnancy and postpartum. In: U Halbreich (ed): Baillière's Clinical Psychiatry Series "Psychiatric Issues in Women", Baillière Tindall Limited, London, pp. 687-701, 1996.
22. **Steiner M**, Ingram D. The chronobiology of mood related disorders. In: LT Young, RT Joffe (eds): Bipolar Disorder: Biological Models and their Clinical Application, Marcel Dekker Inc, New York, pp. 127-160, 1997.
23. Severino SK, Abernathy T, Frank E, Freeman E, Gise LH, Hurt SW, Paddison PL, Parry B, Ana Rivera-Tovar, Schnurr PP, Steege J F, **Steiner M**, Stout AL. Late luteal phase dysphoric disorder data reanalysis. In: TA Widiger, AJ Frances, HA Pincus, R Ross, MB First, W Davis, M Kline (eds): DSM-IV Sourcebook, American Psychiatric Association, Washington DC, pp. 193-206, 1998.
24. **Steiner M**. Premenstrual syndromes. In: MP Hopkins (ed): Glass' Office Gynecology, Fifth Edition Revised, Williams & Wilkins, Baltimore, MD, pp. 285-310, 1999.
25. **Steiner M**, Tam W. Postpartum depression in relation to other psychiatric disorders. In: LJ Miller (ed): Postpartum Mood Disorders, American Psychiatric Press, New York, pp. 47-63, 1999.
26. Dunn E, **Steiner M**. The functional neurochemistry of mood disorders in women. In: M Steiner, KA Yonkers, E Eriksson (eds): Mood Disorders in Women, Martin Dunitz Ltd, London, pp. 71-82, 2000.
27. **Steiner M**, Born L, Marton P. Menarche and mood disorders in adolescence. In: M Steiner, KA Yonkers, E Eriksson (eds): Mood Disorders in Women, Martin Dunitz Ltd, London, pp. 247-268, 2000.
28. Eriksson E, Sundblad C, Yonkers KA, **Steiner M**. Premenstrual dysphoria and related conditions. In: M Steiner, KA Yonkers, E Eriksson (eds): Mood Disorders in Women, Martin Dunitz Ltd, London, pp. 269-294, 2000.
29. Eriksson E, Sundblad C, Landen M, **Steiner M**. Behavioural effects of androgens in women. In: M Steiner, KA Yonkers, E Eriksson (eds): Mood Disorders in Women, Martin Dunitz Ltd, London, pp. 233-246, 2000.
30. **Steiner M**, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. In: K Palmer (ed): Managing Depressive Disorders, Adis International Limited, pp. 139-157, 2000.

31. **Steiner M.** Premenstrual dysphoric disorder. In: C Barclay (ed): Insight 2001. Women's Health: Important Developments in Primary Care. APS Publishing, Wiltshire, UK, pp. 1-16, 2001.
32. **Steiner M,** Klemme A, Rohde A. Das Klimakterium aus psychiatrischer Sicht: hormone, affekt und kognitive Funktionen. In: A Rohde, A Riecher-Rössler (eds): Psychische Erkrankungen bei Frauen. Psychiatrie und Psychosomatik in der Gynäkologie, Roderer-Verlag, Regensburg, pp. 147-54, 2001.
33. **Steiner M,** Born L. Anxiety and panic disorders. In: JP Pregler and AH DeCherney (eds): Women's Health: Principles and Clinical Practice, BC Decker, Toronto, pp. 661-674, 2002.
34. **Steiner M,** Born L. Psychiatric aspects of the menstrual cycle. In: SG Kornstein, AH Clayton (eds): Women's Mental Health, Guilford Publications Inc, New York, pp. 48-69, 2002.
35. **Steiner M,** Born L. Premenstrual syndromes. In: F Lewis-Hall, TS Williams, JA Panetta, JM Herrera, (eds): Psychiatric Illness in Women, Emerging Treatments and Research, American Psychiatric Press, Inc. Washington, DC, pp. 157-188, 2002.
36. **Steiner M,** Macdougall M, Born L. Recent advances in the treatment of PMDD. In: K Pearson, S. Sonawalla, J Rosenbaum (eds): Women's Health and Psychiatry, Williams & Wilkins, Baltimore, MD, pp. 95-105, 2002.
37. **Steiner M,** Dunn ET, Born L. Female specific mood disorders. In: HAH D'haenen, JA den Boer, P Willner (eds): Biological Psychiatry, J. Wiley & Sons, Ltd. London, pp. 849-859, 2002.
38. Born L, Palova E, **Steiner M.** Premenstrual syndromes: guidelines for treatment. In: P Gaszner, U Halbreich (eds): Women's Mental Health: an Eastern European Perspective, The Section of Interdisciplinary Collaboration of the World Psychiatric Association (WPA), Budapest, pp. 56-72, 2002.
39. **Steiner M.** Premenstrual dysphoria. In: RE Rakel, ET Bope (eds): Conn's Current Therapy, WB Saunders Company, Philadelphia, PA, pp. 1142-1146, 2003.
40. Born L, **Steiner M.** Anxiolytic drugs. In M Steiner, G Koren (eds): Handbook of Female Psychopharmacology, Martin Dunitz, Taylor & Francis, London, pp. 33-52, 2003.
41. Pearlstein T, **Steiner M.** Treatment of premenstrual dysphoric disorder. In: M Steiner, G Koren (eds): Handbook of Female Psychopharmacology, Martin Dunitz, Taylor & Francis, London, pp. 77-90, 2003.
42. Ross L, Koren G, **Steiner M.** Alcohol, nicotine and drug abuse in women. In: M Steiner, G Koren (eds): Handbook of Female Psychopharmacology, Martin Dunitz, Taylor & Francis, London, pp. 149-170, 2003.
43. Born L, **Steiner M.** Estrogen and other hormones in the treatment of premenstrual syndromes. In: N Bergemann, A Riecher-Rössler (eds): Estrogen Effects in Psychiatric Disorders, Springer, Vienna, pp. 175-189, 2005.
44. Soares CN, **Steiner M,** Prouty J. The effects of reproductive hormones and selective estrogen receptor modulators on the central nervous system during menopause. In: D Stewart (ed): Menopause: a Mental Health Practitioner's Guide, American Psychiatric Press Incorporated, pp. 33-56, 2005.
45. Ross L, Gunasekera S, Rowland M, **Steiner M.** Pharmacotherapy for psychiatric disorders in pregnancy. In: A Riecher-Rössler, M Steiner (eds): Perinatal Stress, Mood and Anxiety Disorders: From Bench to Bedside, Bibliotheca Psychiatrica, Karger, pp. 112-136, 2005.
46. **Steiner M.** Premenstrual syndromes. In: MG Curtis, MP Hopkins, S Overholt (eds): Glass Office Gynecology, Sixth Edition, Lippincott Williams & Wilkins, Baltimore, MD, pp. 159-175, 2005.

47. Buist A, Ross, LE, **Steiner M**. Anxiety and mood disorders in pregnancy and the postpartum period. In: J Kulkarni, D Castle (eds): *Mood and Anxiety Disorders in Women*, Cambridge University Press, pp. 136-162, 2006.
48. Macdougall M, Born L, Krasnik CE, **Steiner M**. Premenstrual syndromes: guidelines for assessment & treatment. In: JE Fisher, W O'Donohue (eds): *Practitioner's Guide to Evidence Based Psychotherapy*, Kluwer Academic Publications, pp. 549-553, 2006.
49. **Steiner M**, Soares CN. Psychotropic therapies. In: PMS O'Brien, A Rapkin, PJ Schmidt (eds): *The Premenstrual Syndromes: PMS and PMDD*, Informa Healthcare, pp. 131-139, 2007.
50. **Steiner M**, Young E. Hormones and mood. In: JB Becker, KJ Berkley, N Geary, E Hampson, JP Herman, E Young (eds): *Sex Differences in the Brain: From Genes to Behavior*. Oxford University Press, pp. 405-426, 2007.
51. Ross LE, Koren G, **Steiner M**. Clinical management of substance use during pregnancy. In: G Koren (ed): *Medication Safety in Pregnancy & Breastfeeding*, McGraw Hill, pp. 163-169, 2007.
52. Taylor V, **Steiner M**, Soares CN. Bipolar disorders in women: special issues. In: LM Yatham, V Kusumakar (eds): *Bipolar Disorders, Second Edition*, Rutledge, Taylor & Francis Group, New York, NY, pp. 153-184, 2009.
53. Warren MP, Tichen KE, **Steiner M**. Hormone therapies and menopause: where do we stand in the post-WHI era? In: CN Soares, M Warren (eds): *The Menopausal Transition. Interface between Gynecology and Psychiatry. Key Issues in Mental Health*, Basel, Karger, pp. 127-144, 2009.
54. Frey BN, Macritchie KA, Soares CN, **Steiner M**. Bipolar disorder in women. In: LN Yatham, M Maj (eds): *Bipolar Disorder: Clinical and Neurobiological Foundations*, John Wiley and Sons, Ltd. London, UK, pp. 463-476, 2010.
55. Fabio K, Guillon C, Lu S, Heindel ND, Miller M, Ferris CF, Brownstein MJ, Garripa C, **Steiner M**, Coccaro E, Damiano E, Koppel GA, Simon NG. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. In: Atta-ur-Rahman, MI Choudhary (eds): *Frontiers in CNS Drug Discovery (ebook)*, Bentham Science Publishers, pp. 156-183, 2010.

(b) Accepted for Publication/ In Press:

1. Shea AK, **Steiner M**, Kamath MV. Heart rate variability as a measure of depression and anxiety during pregnancy. 2011.
2. **Steiner M**. Premenstrual syndromes. In: MG Curtis, MP Hopkins, S Overholt (eds): *Glass Office Gynecology, Seventh Edition*, Lippincott Williams & Wilkins, Baltimore, MD. 2011.

(ii) BOOKS:

(a) Published:

1. *Depression in Women*, [pocketbook]. **Steiner M**, Yonkers KA. Martin Dunitz Ltd, London, 1st Edition 1998; 2nd Edition 1999.
2. *Depressionen bei Frauen (German Edition)*, [pocketbook]. **Steiner M**, Yonkers KA. Martin Dunitz Ltd, London, 1999.
3. *Mood Disorders in Women*. **Steiner M**, Yonkers KA, Eriksson E, (eds). Martin Dunitz Ltd, London, 2000. Reviewed in *The New England Journal of Medicine* 2002;346:1593.

4. Depressao em Mulheres (Portuguese Edition), [pocketbook]. Yonkers KA, **Steiner M**, Soares C. Lemos Editorial & Graficos Ltda, Sao Paulo, 2002
5. Mood Disorders in Women. **Steiner M**, Yonkers KA, Eriksson E, (eds). Martin Dunitz Ltd, London, 2001 (Paperback, 2nd edition).
6. Handbook of Female Psychopharmacology. **Steiner M**, Koren G, (eds). Martin Dunitz, Taylor & Francis, London, 2003.
7. Perinatal Stress, Mood and Anxiety Disorders, From Bench to Bedside. Riecher-Rössler A, **Steiner M**, (eds). Bibliotheca Psychiatrica, Karger, Vienna, 2005.

(iii) **OTHER PUBLICATIONS:**

(a) **Published:**

1. **Steiner M**. APGO educational series on women's health issues. Premenstrual syndrome and premenstrual dysphoric disorder: scope, diagnosis and treatment. Pragmaton Office of Medical Education, Chicago, IL, 1998.
2. **Steiner M**. PMS/PMDD monograph. Pragmaton Office of Medical Education, Chicago, IL, 2000.
3. **Steiner M**. SSRIs in the treatment of PMDD: A critical review. Obstetrics & Gynecology News - PMDD Supplement. International Medical News Group, Morristown, NJ, 2000.
4. **Steiner M**. The diagnosis and treatment of premenstrual syndrome (PMS) and premenstrual dysphoric Disorder (PMDD). A one-hour interactive audioconference jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Interactive Network for Continuing Education. 2000.
5. **Steiner M**. New trends in treating premenstrual disorders. Intercom - a newsletter of The Journal of Clinical Psychiatry, July 2000.
6. **Steiner M**. Review of recent PMDD/PMS antidepressant studies, part of a taped lecture presentation "New Trends in Treating Premenstrual Disorders" sponsored by The Journal of Clinical Psychiatry. 2000.
7. **Steiner M**. Premenstrual dysphoric disorder: Fluoxetine as a treatment option. Mind to mind: The Interactive Journal for Psychiatrists 2001;1:2-3.
8. **Steiner M**. Female-specific mood disorders. CNS Spectrums 2001;6:125.
9. Born L, **Steiner M**. The relationship between menarche and depression in adolescence. CNS Spectrums 2001;6:126-138.
10. Eriksson E, Andersch B, Landen M, Sundblad C, Yonkers K, **Steiner M**. Premenstrual dysphoria: An illustrative example of how serotonin modulates sex-steroid-related behavior. CNS Spectrums 2001;6:141-149.
11. **Steiner M**. Donne Sull'Orlo Di Una Crisi Di Ciclo il Disturbo Ora ha un Nome E Una Cura. IDEA Notizie, Periodico Trimestrale Dell'Istituto Per La Ricerca E La Prevenzione, Della Depressione E Dell'Ansia 2001;7:1-8.
12. **Steiner M**. Hormones and mood: from menarche to menopause and beyond, APA Summit on Women and Depression, October 2000. Published as "Proceedings and Recommendations". American Psychological Association, April 2002.

13. **Steiner M**, Yonkers K. Evidence based treatment of mood disorders in women, *Mental Fitness* 2003;2:34-66.
14. **Steiner M**. Getting Well and Staying Well, Slidekit for Lundbeck Canada Inc. 2005.
15. Sawka AM, Huh A, Dolovich L, Papaioannou A, Eva K, Thabane L, Gafni A, Cullimore A, Macdougall M, **Steiner M**, Adachi JD. In response. *J Obstet Gynaecol Can* 2005;27:322.
16. **Steiner M**, Born L. Co-Eds, Soares C. Ed. *Brazilian Journal of Psychiatry; Women's mental health: current issues and controversies* 2005;27:S40.
17. Consensus Working Group of the Sex, Gender, and Pain SIG of the IASP: Studying sex and gender differences in pain and analgesia: a consensus report. *Pain* 2007;132:S26-S45.
18. **Steiner M**. Expert Q & A: Treating depression in pregnant women. *Canadian Psychiatry Aujourd'hui* 2010;6:22.

(iv) **JOURNAL ARTICLES:**

(a) **Published:**

1. **Steiner M**, Aleksandrowicz DR. Psychiatric sequelae to gynecological operations. *Israel Annals of Psychiatry and Related Disciplines* 1970;8:186-192.
2. Atsmon A, Blum I, Maoz B, **Steiner M**, Wijssenbeek H. The effects of adrenergic blocking agents on psychotic patients. *Harefuah* 1970;79:20-21.
3. Harari A, Munitz H, Wijssenbeek H, Levi J, **Steiner M**, Rosenbaum M. Psychological aspects of chronic haemodialysis. *Psychiatria, Neurologia, Neurochirurgia* 1971;74:219-223.
4. Atsmon A, Blum I, Wijssenbeek H, Maoz B, **Steiner M**, Ziegelman G. The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. *Psychiatria, Neurologia, Neurochirurgia* 1971;74:251-258.
5. Atsmon A, Blum I, **Steiner M**, Latz A, Wijssenbeek H. Further studies with propranolol in psychotic patients: Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion. *Psychopharmacologia (Berlin)* 1972;27:249-254.
6. **Steiner M**, Latz A, Blum I, Atsmon A, Wijssenbeek H. Propranolol vs chlorpromazine in the treatment of psychoses associated with childbearing. *Psychiatria, Neurologia, Neurochirurgia (Amsterdam)* 1973;76:421-426.
7. Wijssenbeek H, **Steiner M**, Goldberg SC. Trifluoperazine: A comparison between regular and high doses. *Psychopharmacologia (Berlin)* 1974;36:147-150.
8. Blum I, Atsmon A, **Steiner M**, Wijssenbeek H. Paradoxical rise in blood pressure during propranolol treatment. *British Medical Journal* 1975;4:623.
9. **Steiner M**, Elizur A, Davidson S. Single case study: A psychosomatic triad in a bipolar patient. *The Journal of Nervous and Mental Disease* 1977;164:359-361.
10. Elizur A, Graff E, **Steiner M**, Davidson S. Acute lithium toxicity and its physiological correlates. *Harefuah* 1977;92:248-251.
11. **Steiner M**, Carroll BJ. The psychobiology of premenstrual dysphoria: Review of theories and treatments. *Psychoneuroendocrinology* 1977;2:321-335.

12. **Steiner M**, Radwan M, Elizur A, Blum I, Atsmon A, Davidson S. Failure of L-Triiodothyronine (T₃) to potentiate tricyclic antidepressant response. *Current Therapeutic Research* 1978;23:655-659.
13. Carroll BJ, **Steiner M**. The psychobiology of premenstrual dysphoria: The role of prolactin. *Psychoneuroendocrinology* 1978;3:171-180.
14. **Steiner M**, Neumann M. Traumatic neurosis and social support in the Yom Kippur war returnees. *Military Medicine* 1978;143:866-868.
15. Feinberg M, Carroll BJ, **Steiner M**, Comorato AJ. Misdiagnoses of endogenous depression with research diagnostic criteria [Letter]. *Lancet* 1979;i:267.
16. Feinberg M, **Steiner M**, Carroll BJ. Effects of long-term lithium treatment on serum calcium, magnesium and calcitonin. *Psychopharmacology Bulletin* 1979;15:81-84.
17. **Steiner M**, Radwan M, Elizur A, Blum I, Atsmon A, Davidson S. Urinary MHPG excretion in depression. *The Japanese Journal of Experimental Medicine* 1979;49:95-99.
18. **Steiner M**. Motivated behaviour and the estrous cycle of the rat. PhD dissertation, University of Michigan, University Microfilms, Ann Arbor, MI, 1979.
19. **Steiner M**, Elizur A, Davidson S. Behavioral toxicity: Neuroleptic-induced paradoxical behavioral toxicity in young borderline schizophrenics. *Confinia Psychiatrica* 1979;22:226-233.
20. Elizur A, **Steiner M**, Davidson S. Anti-psychotic drug induced paradoxical behaviour. *Harefuah* 1979;96:562-565.
21. **Steiner M**. Psychobiology of mental disorders associated with childbearing: An overview. *Acta Psychiatrica Scandinavica* 1979;60:449-464.
22. Katz RJ, **Steiner M**. Dream and motivation: A psychobiological approach. *The Journal of Social and Biological Structures* 1979;2:141-154.
23. Haskett RF, **Steiner M**, Osmun JN, Carroll BJ. Severe premenstrual tension: Delineation of the syndrome, *Biological Psychiatry* 1980;15:121-139.
24. **Steiner M**, Haskett RF, Osmun JN, Carroll BJ. Treatment of premenstrual tension with lithium carbonate. A pilot study. *Acta Psychiatrica Scandinavica* 1980;61:96-102.
25. **Steiner M**. Triiodothyronine, imipramine and depression [Letter]. *American Journal of Psychiatry* 1980;137:383-384.
26. **Steiner M**, Welber AS, Archer R, Carroll BJ. Multimodal treatment of a case of obsessive-compulsive neurosis. *The Journal of Nervous and Mental Disease* 1980;168:184-187.
27. Greden JF, Albala AA, Haskett RF, James N, Goodman L, **Steiner M**, Carroll BJ. Normalization of dexamethasone suppression tests: A laboratory index of recovery from endogenous depression. *Biological Psychiatry* 1980;15:449-458.
28. **Steiner M**, Haskett RF, Carroll BJ. Premenstrual tension syndrome. The development of research diagnostic criteria and new rating scales. *Acta Psychiatrica Scandinavica* 1980;62:177-190.
29. Carroll BJ, Feinberg M, Greden JF, Haskett RF, James N, **Steiner M**, Tarika J. Diagnosis of endogenous depression. *Journal of Affective Disorders*, 2:177-194, 1980.

30. Carroll BJ, Greden JF, Feinberg M, James N, Haskett RF, **Steiner M**, Tarika J. Neuroendocrine dysfunction in genetic subtypes of primary unipolar depression. *Psychiatry Research* 1980;2:251-258.
31. **Steiner M**, Katz RJ, Carroll BJ. Behavioral effects of dopamine agonists across the estrous cycle in rats. *Psychopharmacology* 1980;71:147-151.
32. Carroll BJ, Feinberg M, **Steiner M**, Haskett RF, James N, Tarika J. Diagnostic application of the dexamethasone suppression test in depressed outpatients. *Adv. in Biological Psychiatry* 1980;5:107-116.
33. Katz RJ, **Steiner M**. Tail pinch vs cervical probing: Opposite effects upon intracranial reinforcement in female rats. *Physiological Psychology* 1980;8:395-397.
34. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James N, Kronfol Z, Lohr N, **Steiner M**, DeVigne JP, Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation and clinical utility. *Archives of General Psychiatry* 1981;38:15-22. *Citation Classic - Current Contents*, 32(41):14, October 9, 1989.
35. Carroll BJ, Greden JF, Feinberg M, Lohr N, James N, **Steiner M**, Haskett RF, Albala AA, DeVigne JP, Tarika J. Neuroendocrine evaluation of depression in borderline patients. *Psychiatric Clinics of North America* 1981;4:89-99.
36. **Steiner M**, Katz RJ, Baldrihi G, Carroll BJ. Motivated behavior and the estrous cycle in rats. *Psychoneuroendocrinology* 1981;6:81-90.
37. Elizur A, **Steiner M**. Paradoxical behavioral toxicity of anti-psychotic drugs. *Harefuah* 1981;English Supplement:42-45.
38. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, James N, Kronfol Z, Lohr N, **Steiner M**, DeVigne JP, Young E. Standardization of the dexamethasone suppression test for the diagnosis of melancholia. *Advances in Biological Psychiatry* 1981;7:1-13.
39. **Steiner M**, Katz RJ, Carroll BJ. Detailed analysis of estrous-related changes in wheel running and self-stimulation. *Physiology & Behavior* 1982;28:201-204.
40. Feinberg M, Pegeron JP, **Steiner M**. The effect of morphine on symptoms of endogenous depression. *NIDA Res Monogr.* 1983;43:245-250.
41. Osmun JN, **Steiner M**, Haskett RF. Psychosocial aspects of severe premenstrual tension. *The International Journal of Women's Studies* 1983;6:65-70.
42. **Steiner M**, Haskett RF, Osmun JN, Starkman MN, Peterson E, Metski R, Carroll BJ. The treatment of severe premenstrual dysphoria with bromocriptine. *Journal of Psychosomatic Obstetrics and Gynaecology* 1983;2:223-227.
43. Haskett RF, **Steiner M**, Carroll BJ. A psychoendocrine study of premenstrual tension syndrome: A model for endogenous depression? *Journal of Affective Disorders* 1984;6:191-199.
44. **Steiner M**, Martin S, Wallace JE, Goldman S. Distinguishing subtypes within the borderline domain: A combined psychoneuroendocrine approach. *Biological Psychiatry* 1984;19:907-911.
45. **Steiner M**, Haskett RF, Carroll BJ, Hays SE, Rubin RT. Plasma prolactin and severe premenstrual tension. *Psychoneuroendocrinology* 1984;9:29-35.
46. **Steiner M**, Haskett RF, Carroll BJ, Hays SE, Rubin RT. Circadian hormone secretory profiles in women with severe premenstrual tension syndrome. *British Journal of Obstetrics and Gynaecology* 1984;91:466-471.

47. **Steiner M.** Endocrinology of affective disorder. *Annals of the Royal College of Physicians and Surgeons of Canada* 1984;17:599-602.
48. Gupta RN, **Steiner M.** Liquid chromatographic determination of inhibition of monoamine oxidase activity in platelet rich plasma of depressed patients treated with phenelzine. *Clinica Chimica Acta* 1985;152:63-69.
49. Auffarth SE, **Steiner M**, Werstiuk ES. ³H-clonidine binding to membranes of platelets prepared under physiological conditions. *Progress in Neuro-psychopharmacology and Biological Psychiatry* 1985;9:579-583.
50. **Steiner M**, Goldman S, Gupta RN, Boiago IM, Pellettier JR. Specificity of the combined dexamethasone suppression and TRH/TSH tests in melancholia. *Progress in Neuro-psychopharmacology and Biological Psychiatry* 1985;9:655-659.
51. Links PS, **Steiner M**, Offord DR, Eppel A. Stability of the diagnostic interview for borderlines diagnosis [Letter]. *American Journal of Psychiatry* 1985;142:1525.
52. Haskett RF, **Steiner M.** Diagnosing premenstrual tension syndrome. *Hospital and Community Psychiatry* 1986;37:33-36.
53. Oztunc S, Guscott RG, Soni J, **Steiner M.** Psychosis resulting in suicide in a patient with primary hyperparathyroidism. *Canadian Journal of Psychiatry* 1986;31:342-343.
54. Heine D, **Steiner M.** Standardized paintings as a proposed adjunct instrument for longitudinal monitoring of mood states: A preliminary note. *Occupation Therapy in Mental Health* 1986;6:31-37.
55. **Steiner M**, Werstiuk ES, Seggie J. Dysregulation of neuroendocrine crossroads: depression, circadian rhythms, and the retina - a hypothesis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 1987;11:267-278.
56. **Steiner M.** The effects of gonadal hormones on brain & behavior. *Progress in Neuro-psychopharmacology and Biological Psychiatry* 1987;11:115-119.
57. Gupta RN, **Steiner M**, Lew M. Determination of unconjugated 3-methoxy-4-hydroxyphenylglycol by liquid chromatography for monitoring inhibition of monoamine oxidase activity in plasma. *Clinical Chemistry* 1987;33:2078-2080.
58. Fleming AS, **Steiner M**, Anderson V. Hormonal and attitudinal correlates of maternal behavior during the early postpartum period in first time mothers. *Journal of Reproductive and Infant Psychology* 1987;5:193-205.
59. Links PS, **Steiner M**, Offord DR, Eppel A. Characteristics of borderline personality disorder: a Canadian study. *Canadian Journal of Psychiatry* 1988;33:336-340.
60. Links PS, **Steiner M.** Psychopharmacologic management of patients with borderline personality disorder. *Canadian Journal of Psychiatry* 1988;33:355-359.
61. **Steiner M**, Links PS, Korzekwa M. Biological markers in borderline personality disorders: an overview. *Canadian Journal of Psychiatry* 1988;33:350-354.
62. Links PS, **Steiner M**, Huxley G. The occurrence of borderline personality disorder in the families of borderline patients. *Journal of Personality Disorders* 1988;2:14-20.
63. Robillard M, Kennedy S, Allen LC, Kirshenblat D, **Steiner M.** Variations in dexamethasone suppression test results - RIA values exceed CPBA. *Psychiatric Journal of the University of Ottawa* 1988;13:122-123.
64. **Steiner M.** The neurochemistry of mood. *Psychiatric Journal of the University of Ottawa* 1989;14:342-343.

65. Links PS, **Steiner M**, Mitton J. Characteristics of psychosis in borderline personality disorder. *Psychopathology* 1989;22:188-193.
66. Miceli MO, **Steiner M**. Novel localizations of central- and peripheral-type cholecystokinin binding sites in Syrian hamster brain as determined by autoradiography. *European Journal of Pharmacology* 1989;169:215-224.
67. Seggie J, **Steiner M**, Wright N, Orpen G. The effect of lithium on pupillary response to pulses of light in sheep, a useful animal model. *Psychiatry Research* 1989;30:305-311.
68. **Steiner M**. Postpartum psychiatric disorders. *Canadian Journal of Psychiatry* 1990;35:89-98.
69. Werstiuk ES, **Steiner M**, Burns T. Studies on leukocyte β -adrenergic receptors in depression: a critical appraisal. *Life Sciences* 1990;47:85-105.
70. **Steiner M**, Brown GM, Goldman S. Nocturnal melatonin and cortisol secretion in newly admitted psychiatric inpatients: Implications for affective disorders. *European Archives of Psychiatry and Clinical Neuroscience* 1990;240:21-27.
71. MacMillan H, Gibson JC, **Steiner M**. Hyponatremia and depression. *The Journal of Nervous and Mental Disease* 1990;178:720-722.
72. Links PS, Mitton JE, **Steiner M**. Predicting outcome for borderline personality disorder. *Comprehensive Psychiatry* 1990;31:490-498.
73. Links PS, **Steiner M**, Boiago I, Irwin D. Lithium therapy for borderline patients: Preliminary findings. *Journal of Personality Disorders* 1990;4:173-181.
74. Gupta R, **Steiner M**. Determination of fluoxetine and norfluoxetine in serum by LC with fluorescence detection. *Journal of Liquid Chromatography* 1990;13:3785-3797.
75. Korzekwa M, **Steiner M**, Links P, Eppel A. The Dexamethasone Suppression Test in borderlines: is it useful? *Canadian Journal of Psychiatry* 1991;36:26-28.
76. Seggie J, MacMillan H, Griffith L, Shannon HS, Martin J, Simpson J, **Steiner M**. Retinal pigment epithelium response and the use of the EOG and Arden Ratio in depression. *Psychiatry Research* 1991;36:175-185.
77. Guscott R, **Steiner M**. A multidisciplinary treatment approach to postpartum psychoses. *Canadian Journal of Psychiatry* 1991;36:551-556.
78. Stephenson-Cino P, **Steiner M**, Krames L, Ryan EB, Huxley G. Depression in the elderly and its correlates in family practice: a Canadian study. *Psychological Reports* 1992;70:359-368.
79. **Steiner M**. Premenstrual syndrome: An update. *The Canadian Journal of Continuing Medical Education* 1992;4:71-83.
80. Werstiuk ES, Auffarth SE, Coote M, Gupta RN, **Steiner M**. Platelet α_2 -adrenergic receptors in depressed patients and healthy volunteers: The effects of desipramine. *Pharmacopsychiatry* 1992;25:199-206.
81. **Steiner M**. Female specific mood disorders. *Clinical Obstetrics and Gynecology* 1992;35:599-611.
82. Korzekwa M, Links P, **Steiner M**. Biological markers in borderline personality disorder: new perspectives. *Canadian Journal of Psychiatry* 1993;38(S1):S11-S15.

83. Fleming A, Corter C, Franks P, Surbey M, Schneider B, **Steiner M**. Postpartum factors related to mother's attraction to newborn infant odours. *Developmental Psychobiology* 1993;26:115-132.
84. Links PS, Mitton J, **Steiner M**. Stability of borderline personality disorder. *Canadian Journal of Psychiatry* 1993;38:255-259.
85. Yatham L, **Steiner M**. Neuroendocrine probes of serotonergic function - a critical review. *Life Sciences* 1993; 53:447-463.
86. Orpen G, **Steiner M**. Neural connections of the suprachiasmatic nucleus and medial hypothalamus of the Syrian hamster. *Journal of Anatomy* 1994;184:23-33.
87. Anderson VA, Fleming A, **Steiner M**. Mood and the transition to motherhood. *Journal of Reproductive and Infant Psychology* 1994;12:69-77.
88. MacMillan H, **Steiner M**. Atrial natriuretic factor: does it have a role in psychiatry? *Biological Psychiatry* 1994;35:272-277.
89. Yatham L, **Steiner M**. Serotonin as a neuroendocrine modulator. *Journal of Serotonin Research* 1994;1:7-19.
90. Stewart DE, Fairman M, Barbadoro S, Zownir P, **Steiner M**. Follicular and late luteal phase serum fluoxetine levels in women suffering from LLPDD. *Biological Psychiatry* 1994;36:201-202.
91. **Steiner M**, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D. Fluoxetine in the treatment of PMDD. *New England Journal of Medicine* 1995;332:1529-1534. (*Lead Article*)
92. Orpen G, **Steiner M**. The WAGxDA rat: an animal model of cholinergic supersensitivity. *Biological Psychiatry* 1995;37:874-883.
93. **Steiner M**. Fluoxetine for premenstrual dysphoria [Letter]. *New England Journal of Medicine* 1995;333:1152-1153.
94. Lam RW, Gorman CP, Michalon M, **Steiner M**, Levitt AJ, Corral MR, Watson GD, Morehouse RL, Tam W, Joffe RT. Multicentre, placebo-controlled study of fluoxetine in seasonal affective disorder. *American Journal of Psychiatry* 1995;152:1765-1770.
95. Fleming A, Corter C, Surbey M, Franks P, **Steiner M**. Postpartum factors related to mother's recognition of newborn infant odours. *Journal of Reproductive and Infant Psychology* 1995;13:197-210.
96. **Steiner M**, Dunn EJ. The psychobiology of female-specific mood disorders. *Infertility and Reproductive Medicine Clinics of North America* 1996;7:297-313.
97. Korzekwa M, Lamont J, **Steiner M**. Late luteal phase dysphoric disorder and the thyroid axis revisited. *Journal of Clinical Endocrinology and Metabolism* 1996;81:2280-2284.
98. **Steiner M**. Premenstrual dysphoric disorder: an update. *General Hospital Psychiatry* 1996;18:244-250.
99. Kates N, Eaman S, Santone J, Didemus C, **Steiner M**, Craven M. An integrated regional emergency psychiatry service. *General Hospital Psychiatry* 1996;18:251-256.
100. **Steiner M**, Wilkins A. Diagnosis and assessment of premenstrual dysphoria. *Psychiatric Annals* 1996;26:571-575.

101. Werstiuk E, Coote M, Griffith L, Shannon H, **Steiner M**. Effects of electroconvulsive therapy on peripheral adrenoceptors, plasma noradrenaline, MHPG and cortisol in depressed patients. *British Journal of Psychiatry* 1996;169:758-765.
102. **Steiner M**. Premenstrual syndromes. *Annual Review of Medicine* 1997;48:447-455. Abstract: Focus on Depression & Anxiety 1997;8:66-67.
103. **Steiner M**, Lepage P, Dunn E. Serotonin and gender specific psychiatric disorders. *International Journal of Psychiatry in Clinical Practice* 1997;1:3-13. Abstract: The Chronicle Postgraduate Education Supplement 1998; p 21.
104. Korzekwa M, **Steiner M**. Premenstrual syndromes. *Clinical Obstetrics and Gynecology* 1997;40:564-576.
105. Fleming A, **Steiner M**, Corter C. Cortisol, hedonics and maternal responsiveness in human mothers. *Hormones and Behavior* 1997;32:85-98.
106. **Steiner M**. Premenstrual syndromes. *Primary Care Reports* 1997;3:143-152.
107. **Steiner M**, Judge R, Kumar R. Serotonin reuptake inhibitors in the treatment of premenstrual dysphoria: current state of knowledge. *International Journal of Psychiatry in Clinical Practice* 1997;1:241-247.
108. **Steiner M**, Lamont J, Steinberg S, Stewart D, Reid R, Streiner D. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. *Obstetrics & Gynecology* 1997;90:590-595.
109. **Steiner M**, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. *Psychopharmacology Bulletin* 1997;33:771-774.
110. Coote M, Werstiuk E, **Steiner M**. Effects of ECT and desipramine on neuroendocrine responses to the clonidine challenge test. *Journal of Psychiatry & Neuroscience* 1998;23:172-178.
111. **Steiner M**. Perinatal mood disorders. *Psychopharmacology Bulletin* 1998;34:301-306.
112. Djuric V, Cox G, Overstreet D, Smith L, Dragomir A, **Steiner M**. Genetically transmitted cholinergic hyperresponsiveness predisposes to experimental asthma. *Brain, Behavior and Immunity* 1998;12:272-284.
113. Overstreet DH, **Steiner M**. Genetic and environmental models of stress-induced depression in rats. *Stress Medicine* 1998;14:261-268.
114. **Steiner M**, Streiner D, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D. The measurement of premenstrual mood symptoms. *Journal of Affective Disorders* 1999;53:269-27.
115. Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R, Ling F, Parry B, Pearlstein T, Rosenblum J, Rubinow D, Schmidt P, Serverino S, **Steiner M**, Stewart DE, Thys-Jacobs S. Is premenstrual dysphoric disorder a distinct clinical entity? *Journal of Women's Health* 1999;8:663-679.
116. **Steiner M**, Bell B, Browne G, Roberts JG, Byrne C, Dunn E, Chalklin L, Kraemer J, Mills M, Wallik D. Prevalence of dysthymia disorder in primary care. *Journal of Affective Disorders* 1999;54:303-308.
117. Djuric VJ, Dunn E, Overstreet DH, Dragomir A, **Steiner M**. Antidepressant effect of ingested nicotine in female rats of flinders resistant and sensitive lines. *Physiology & Behavior* 1999;67:533-537.
118. **Steiner M**, Yatham L, Coote M, Wilkins A, Lepage P. Serotonergic dysfunction in women with pure PMDD: is the fenfluramine challenge test still relevant? *Psychiatry Research* 1999;87:107-115.
119. Schemmer D, Siekierski M, **Steiner M**. CT of the brain: how useful is it in general psychiatry? [Letter] *Canadian Journal of Psychiatry* 1999;44:929.

120. Born L, **Steiner M**. Irritability: the forgotten dimension of female-specific mood disorders. *Archives of Women's Mental Health* 1999;2:153-167.
121. Korzekwa M, **Steiner M**. Assessment and treatment of premenstrual syndromes: an update. *Prim Care Update Ob/Gyn* 1999;6:153-162.
122. **Steiner M**, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. *CNS Drugs* 2000;13:287-304.
123. **Steiner M**. Recognition of premenstrual dysphoric disorder and its treatment. (Invited Commentary) *Lancet* 2000;356:1126-1127.
124. **Steiner M**, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology & treatment. *Journal of Clinical Psychiatry* 2000;61:17-21.
125. Pearlstein T, **Steiner M**. Non-antidepressant treatment of premenstrual syndrome. *Journal of Clinical Psychiatry* 2000;61:22-27.
126. **Steiner M**, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. *International Clinical Psychopharmacology* 2000;15 Suppl 3:S5-17.
127. **Steiner M**. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. *J Psychiatry Neurosci* 2000;25:459-468.
128. Yatham LN, **Steiner M**, Liddle PF, Shia IS, Lam RW, Zis AP, Coote M. A PET study of brain 5-HT₂ receptors and their correlation with platelet 5-HT₂ receptors in healthy humans. *Psychopharmacology* 2000;151:424-427.
129. MacQueen G, Born L, **Steiner M**. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. *CNS Drug Reviews* 2001;7:1-24.
130. **Steiner M**, Romano SJ, Babcock S, Dillon J, Shuler C, Berger C, Carter D, Reid R, Stewart D, Steinberg S, Judge R. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. *British Journal of Obstetrics & Gynecology* 2001;108:462-468.
131. Stallings J, Fleming AS, Corter C, Worthman C, **Steiner M**. The effect of infant cries on affective, hormonal, and autonomic responses in new mothers and non-parturient women. *Parenting: Science and Practice* 2001;1:71-100.
132. **Steiner M**. Effective treatment of premenstrual dysphoric disorder (PMDD). *Today's Therapeutic Trends* 2001;19:165-78.
133. Born L, **Steiner M**. Current management of premenstrual syndrome and premenstrual dysphoric disorder. *Current Psychiatry Reports* 2001;3:463-469.
134. Browne G, **Steiner M**, Roberts JG, Byrne C, Gafni A, Dunn E, Bell B, Mills M, Chalklin L, Wallik D, Kraemer J. Sertraline and interpersonal psychotherapy, alone and combined, in the treatment of patients with dysthymic disorder in primary care: a 2 year comparison of effectiveness and cost. *Journal of Affective Disorders* 2002;68:317-330. A structured abstract for the NHS Economic Evaluation Database has been published by the University of York, October 2003.
135. **Steiner M**. Postnatal depression: a few simple questions. *Family Practice* 2002;19:469-470.
136. Born L, Shea A, **Steiner M**. The roots of depression in female adolescents: is menarche the key? *Current Psychiatry Reports* 2002;4:449-460.

137. Fleming AS, Corter C, Stallings J, **Steiner M**. Testosterone and prolactin are associated with emotional responses to infant cries in new fathers. *Hormones & Behaviour* 2002;42:399-413.
138. Macdougall M, **Steiner M**. Treatment of premenstrual dysphoria with selective serotonin reuptake inhibitors: focus on safety. *Expert Opinion on Drug Safety* 2003;2:161-166.
139. **Steiner M**, Brown E, Trzepacz P, Dillon J, Berger C, Carter D, Reid R, Stewart D. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. *Archives of Women's Mental Health* 2003;6:71-77.
140. **Steiner M**, Dunn EJ, Born L. Hormones and mood: from menarche to menopause and beyond. *Journal of Affective Disorders* 2003;74:67-83.
141. **Steiner M**, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. *Archives of Women's Mental Health* 2003;6:203-209.
142. Ross L, **Steiner M**. Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: historical perspectives and future directions. *Expert Opinion on Therapeutic Patents* 2003;13:1491-1499.
143. Ross L, **Steiner M**. A biopsychosocial approach to premenstrual dysphoric disorder. *Psychiatric Clinics of North America* 2003;26:529-546.
144. **Steiner M**. Female specific mood disorders. *Psychiatry* 2003;2:18-21.
145. Bell B, Chalklin L, Mills M, Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Wallik D, Kraemer J, Webb M, Jamieson E, Whittaker S, Dunn E. Burden of dysthymia and comorbid illness in adults in a Canadian primary care setting: high rates of psychiatric illness in the offspring. *Journal of Affective Disorders* 2004;78:73-80.
146. Bergant A, Schneider A, Tran T, Hacket E, Lanczik M, **Steiner M**. Diagnostik prämenstrueller Störungen. *Deut Med Wochenschrift* 2004;129:188-192.
147. Born L, Zinga D, **Steiner M**. Challenges in identifying and diagnosing postpartum disorders. *Primary Psychiatry* 2004;11:29-34.
148. Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, **Steiner M**. Paroxetine CR for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. *Psychosomatic Medicine* 2004;66:707-713.
149. Shea A, Walsh C, MacMillan H, **Steiner M**. Child maltreatment, HPA axis dysregulation and psychiatric morbidity in females. *Psychoneuroendocrinology* 2004;30:162-178.
150. Bonari L, Pinto N, Ahn E, Einarson A, Koren G, **Steiner M**. Perinatal risks of untreated depression in pregnancy. *Canadian Journal of Psychiatry* 2004;49:726-735.
151. Sawka AM, Huh A, Dolovich L, Papaioannou A, Eva K, Thabane L, Gafni A, Cullimore A, Macdougall M, **Steiner M**, Adachi JD. Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE study. *Journal of Obstetrics and Gynaecology of Canada* 2004;26:967-973.
152. Soares CN, Joffe H, **Steiner M**. Menopause and mood. *Clinical Obstetrics and Gynecology* 2004;47:576-591.
153. Rees SL, Panesar S, **Steiner M**, Fleming AS. The effects of adrenalectomy and corticosterone replacement on maternal behavior in the postpartum rat. *Hormones and Behavior* 2004;46:411-419.

154. Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, Herman JP, Marts S, Sadee W, **Steiner M**, Taylor J, Young E. Strategies and methods for research on sex differences in brain and behavior. *Endocrinology* 2005;4:1650-1673.
155. Krpan KM, Coombs R, Zinga D, **Steiner M**, Fleming AS. Experiential and Hormonal Correlates of Maternal Behaviour in Teen and Adult Mothers. *Hormones and Behaviour* 2005;47:112-122.
156. **Steiner M**, Allgulander C, Ravindran A, Kosar H, Burt T, C Austin. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. *Human Psychopharmacology: Clinical & Experimental* 2005;20:3-13.
157. **Steiner M**, Streiner DL, Pham B. Validation of a revised visual analogue scale for premenstrual mood symptoms: results from prospective and retrospective trials. *The Canadian Journal of Psychiatry* 2005;50:327-332.
158. Soares C, Prouty J, Born L, **Steiner M**. Treatment of menopause-related mood disturbances. *CNS Spectrums* 2005;10:489-497.
159. Koren G, Matsui D, Einarson A, Knoppert D, **Steiner M**. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? *Canadian Medical Association Journal* 2005;172:1457-1459.
160. Pearlstein T, Bellew KM, Endicott J, **Steiner M**. Paroxetine CR for premenstrual dysphoric disorder: remission analysis following a double-blind, placebo-controlled trial. *The Primary Care Companion to the Journal of Clinical Psychiatry* 2005;7:53-60.
161. **Steiner M**, Macdougall M, Berger C, Carter D, Reid R, Steinberg S, Stewart D. Assessment of sexual drive and desire in women with premenstrual dysphoric disorder who have been treated with fluoxetine. *International Journal of Psychiatry in Clinical Practice* 2005;9:120-123.
162. Ross LE, Murray BJ, **Steiner M**. Sleep and perinatal psychiatric disorders: a critical review. *Journal of Psychiatry and Neuroscience* 2005;30:247-56.
163. **Steiner M**, Hirschberg AL, Bergeron R, Holland F, Gee M, Van Erp E. Luteal phase dosing with paroxetine controlled-release in the treatment of premenstrual dysphoric disorder. *American Journal of Obstetrics and Gynecology* 2005;193:352-360.
164. **Steiner M**. Women's mental health: what don't we know? *Brazilian Journal of Psychiatry* 2005;27 Suppl 2:S41-2.
165. Born L, Phillips SD, **Steiner M**, Soares C. Trauma and the reproductive lifecycle in women. *Brazilian Journal of Psychiatry* 2005;27 Suppl 2:S65-72.
166. **Steiner M**, Pearlstein T, Cohen L, Endicott J, Kornstein S, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and its comorbidities: The role of SSRIs. *Journal of Women's Health* 2006;15:57-69.
167. **Steiner M**, Peer M, Soares CN. Comorbidity and premenstrual syndrome: recognition and treatment approaches. *Gynaecology Forum* 2006;11:13-16.
168. Rees SL, Panesar S, **Steiner M**, Fleming AS. The effects of adrenalectomy and corticosterone replacement on induction of maternal behavior in the virgin female rat. *Hormones and Behaviour* 2006;49:337-45.
169. Graham MD, Rees SL, **Steiner M**, Fleming AS. The effects of adrenalectomy and corticosterone replacement on maternal memory in postpartum rats. *Hormones and Behaviour* 2006;49:353-61.

170. Born L, Soares CN, Phillips SD, Jung M, **Steiner M**. Women and reproductive-related trauma. *Annals of the New York Academy of Sciences* 2006;1071:491-494.
171. Rees SL, **Steiner M**, Fleming AS. Early deprivation, but not maternal separation, attenuates rise in corticosterone levels after exposure to a novel environment in both juvenile and adult female rats. *Behavioural Brain Research* 2006;175:383-391.
172. **Steiner M**. Female specific mood disorders. *Psychiatry* 2006;5:131-134.
173. Halbreich U, Backstrom T, Eriksson E, O'Brien S, Calil H, Ceskova E, Dennerstein L, Douki S, Freeman E, Genazzani A, Heuser I, Kadri N, Rapkin A, **Steiner M**, Wittchen HU, Yonkers K. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. *Gynecological Endocrinology* 2007;23:123-130.
174. Burton C, Chatterjee D, Chatterjee-Chakraborty M, Lovic V, Grella SL, **Steiner M**, Fleming AS. Prenatal stress and motherless rearing disrupt expression of plasticity markers and stress-induced corticosterone release in adult female Sprague-dawley rats. *Brain Research* 2007;1158:28-38.
175. Ravindran LN, Woods SA, **Steiner M**, Ravindran AV. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): A Case Series. *Archives of Women's Mental Health* 2007;10:125-127.
176. Shea AK, Streiner DL, Fleming A, Kamath MV, Broad K, **Steiner M**. The effect of depression, anxiety and early life trauma on the cortisol awakening response during pregnancy: preliminary results. *Psychoneuroendocrinology* 2007;32:1013-1020.
177. Giardino J, Gonzalez A, **Steiner M**, Fleming A. Effects of motherhood on physiological and subjective responses to infant cries in teenage mothers: a comparison with non-mothers and adult mothers. *Hormones and Behaviour* 2008;53:149-58.
178. Rees SL, Akbari E, **Steiner M**, Fleming AS. Effects of early deprivation and maternal separation on pup-directed behavior and HPA axis measures in the juvenile female rat. *Developmental Psychobiology* 2008;50:315-21
179. Shea AK, **Steiner M**. Cigarette smoking during pregnancy. *Nicotine & Tobacco Research* 2008;10:267-278.
180. Peer M, Soares CN, **Steiner M**. Menstrual cyclicality & anxiety disorders: implications for treatment. *Psychiatric Times* 2008;5:31-35.
181. **Steiner M**, Ravindran A, LeMelledo JM, Carter D, Huang J, Anonychuk A, Simpson S. Luteal-phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo controlled trial in Canadian women. *Journal of Clinical Psychiatry* 2008;69:991-998.
182. **Steiner M**. Editorial: Advances in neurobiology, assessment and treatment of female-specific mood disorders, Papers from a symposium presented at the joint congress of the Collegium Internatgionale Neuro-Psychopharmacologicum and the Canadian College of Neuropsychopharmacology, Chicago, July 11, 2006. *Journal of Psychiatry and Neuroscience* 2008;33:289-290.
183. Pearlstein T, **Steiner M**. Premenstrual dysphoric disorder: burden of illness and treatment update. *Journal of Psychiatry and Neuroscience* 2008;33:291-301.
184. Born L, Koren G, Lin E, **Steiner M**. A new female-specific rating scale of irritability. *Journal of Psychiatry and Neuroscience* 2008;33:344-354.
185. **Steiner M**. Psychopharmacology for the clinician: treating depression during pregnancy. *Journal of Psychiatry and Neuroscience* 2008;33:384.

186. Shea AK, Kamath MV, Fleming A, Streiner DL, **Steiner M**. The effect of depression and anxiety on heart rate variability during pregnancy: A naturalistic study. *Clinical Autonomic Research* 2008;18:203-212.
187. Lazinski M, Shea A, **Steiner M**. Effects of maternal prenatal stress and developmental outcomes in the offspring: a review. *Archives of Women's Mental Health* 2008;11:363-375.
188. Gonzalez A, Jenkins JM, **Steiner M**, Fleming AS. The relation between early life adversity, cortisol awakening response and diurnal salivary cortisol levels in postpartum women. *Psychoneuroendocrinology* 2009;34:76-86.
189. **Steiner M**. Female specific mood disorders. *Psychiatry* 2009;8:61-66.
190. MacMillan HL, Georgiades K, Duky EK, Shea A, **Steiner M**, Niec A, Tanaka M, Gensey S, Spree S, Vella E, Walsh C, De Bellis M, Van der Muelen J, Boyle MH, Schmidt L. Cortisol response to stress in female adolescents exposed to childhood maltreatment: results of the Youth Mood Project. *Biological Psychiatry* 2009;66:62-68.
191. Martini J, Wittchen H-U, Soares CN, **Steiner M**. Introducing new women-specific diagnostic modules: the Composite International Diagnostic Interview for Women: (CIDI-VENUS). *Archives of Women's Mental Health* 2009;12:281-289.
192. Bennett L.M. Hall G.B.C. Schmidt L.A. **Steiner M**. MacMillan H.L. How do new mothers who were exposed to child maltreatment parent: a Canadian feasibility study. *International Journal of Child and Family Welfare* 2009;1:36-54.
193. **Steiner M**. Tools for diagnosing premenstrual disorders. *Gynaecology Forum* 2009;3:17-21.
194. Soares CN, **Steiner M**. Perinatal depression: searching for specific tools for a closer look at this window. *Journal of Clinical Psychiatry* 2009;70:1317-1318.
195. Vigod S, Ross LE, **Steiner M**. Understanding and treating premenstrual dysphoric disorder: an update for the women's health practitioner. *Obstetrics and Gynecology Clinics* 2009;36:907-924.
196. Vigod S, Frey B, Soares CN, **Steiner M**. Approach to premenstrual dysphoria for the mental health practitioner. *Psychiatric Clinics of North America* 2010;33:257-272.
197. Grigoriadis S, Barrett J, Pittini R, Herer E, Zaltz A, Bazinet RP, Bradley L, Kennedy S, **Steiner M**, Levitt A. Omega-3 supplements in pregnancy: are we too late to identify the possible benefits? *Journal of Obstetrics and Gynaecology Canada* 2010;32:209-216.
198. Frey BN, Hall G, Attard S, Yucel K, Skelin I, **Steiner M**, Soares CN. Shift in the brain network of emotional regulation in midlife women: is the menopausal transition the turning point? *Menopause* 2010;17:840-845.
199. Lokuge S, Frey BN, Foster JA, Soares, CN, **Steiner M**. The rapid effects of estrogen: a mini review. *Behavioural Pharmacology* 2010;21:465-472.
200. Soares CN, Frey, BN, Haber E, **Steiner M**. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. *Journal of Clinical Psychopharmacology* 2010;30:612-615.
201. Lord C, Hall G, Soares CN, **Steiner M**. Physiological stress response in postpartum women with obsessive-compulsive disorder: a pilot study. *Psychoneuroendocrinology* 2011;36:133-138.

202. O'Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman E, Halbreich U, Ismail KMK, Panay N, Pearlstein T, Rapkin A, Reid R, Schmidt P, **Steiner M**, Studd J, Yonkers K. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. *Archives of Women's Mental Health* 2011;14:13-21.
203. **Steiner M**, Peer M, Palova E, Freeman E, Macdougall M, Soares CN. The premenstrual symptoms screening tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. *Archives of Women's Mental Health* 2011;14:77-81.
204. Mileva-Seitz V, Kennedy J, Atkinson L, **Steiner M**, Levitan R, Matthews SG, Meaney MJ, Sokolowski MB, Fleming AS. Serotonin transporter allelic variation in mothers predicts maternal sensitivity, behaviour, and attitudes toward 6-month-old infants. *Genes, Brain, and Behavior* 2011;10:325-333.
205. Bentz D, **Steiner M**, Meinschmidt G. SIPS – Screening-Instrument für prämenstruelle Symptome: Die deutsche Version des Premenstrual Symptoms Screening Tool zur Erfassung klinisch relevanter Beschwerden. *Der Nervenarzt* 2011 [Epub].
206. **Steiner M**. Serotonin, depression, and cardiovascular disease: sex-specific issues. *Acta Physiologica* 2011 [Epub].
207. Lord C, Rieder A, Hall G, Soares CN, **Steiner M**. Piloting the perinatal obsessive-compulsive scale (POCS): development and validation. *Journal of Anxiety Disorders* 2011 [Epub]. doi: 10.1016/j.janxdis.2011.07.005.
208. Lomanowska AM, Chatterjee-Chakraborty M, **Steiner M**, Kraemer GW. Effects of motherless rearing on basal and stress-induced corticosterone levels in rat pups. *Stress* 2011 [Epub].
209. **Steiner M**, Peer M, Macdougall M, Haskett R. The premenstrual tension syndrome rating scales: an updated version. *Journal of Affective Disorders* 2011 [Epub]. doi: 10.1016/j.jad.2011.06.058.

(b) Accepted for Publication/ In Press:

1. Ross LE, Grigoriadis S, Mamisashvili L, Koren G, **Steiner M**, Dennis C-L, Cheung A, Mousmanis P. Quality assessment of observational studies in psychiatry: an example from perinatal psychiatric research. *International Journal of Methods in Psychiatric Research* 2011.
2. Lord C, **Steiner M**, Soares C, Carew C, Hall G. Stress response in postpartum women with and without obsessive-compulsive symptoms: an fMRI study. *Journal of Psychiatry and Neuroscience* 2011.
3. Barrett J, Wonch KE, Hall G, Gonzalez A, Ali N, **Steiner M**, Fleming AS. Consistency of early care in family of origin influences brain response to infant stimuli in reward and affect brain regions. *Social Neuroscience* 2011.
4. Lokuge S, Frey BN, Foster JA, Soares CN, **Steiner M**. Neurobiological basis of depression in women: new insights into the link between estrogen and serotonin. *Journal of Clinical Psychiatry* 2011.

(c) Submitted for Publication:

1. Ross LE, Grigoriadis S, Mamisashvili L, Dennis C-L, Koren G, **Steiner M**, Mousmanis P, Cheung A. Effects of prenatal antidepressant treatment on pregnancy and delivery outcomes: a systematic review and meta-analysis. *Archives of General Psychiatry* 2011.
2. Shea A, Kamath M, Fleming A, Streiner D, Kamath A, Toth R, **Steiner M**. Maternal depression and its effects on infant heart rate variability. *Journal of Clinical Monitoring and Computing* 2011.

3. Gonzalez A, Jenkins JM, **Steiner M**, Fleming AS. Neuropsychology and physiology: intervening mechanisms between maternal early adversity and parenting. *Biological Psychiatry* 2011.
4. Miller VM, Kaplan J, Schork NJ, Ouyang P, Berga S, Wenger NK, Shaw L, Webb RC, Mallampalli M, **Steiner M**, Taylor DA, Bairey-Merz N, Reckelhoff JF. Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists. *Biology of Sex Differences* 2011.

(v) INVITED PRESENTATIONS AT MEETINGS:

1. **Steiner M**. Propranolol in the treatment of acute psychosis. Visiting speaker, Hassle Pharmaceuticals, Göteborg, Sweden, December 1971.
2. **Steiner M**. New perspectives in premenstrual tension. ACOG Annual Meeting, Dearborn, MI, October 1978.
3. **Steiner M**. Endocrine studies in affective disorders. Visiting speaker, Department of Psychiatry, McMaster University, Hamilton, ON, November 1980.
4. **Steiner M**. Psychobiology of premenstrual tension syndromes. Special Lecture, Department of Psychiatry, Toronto Western Hospital, Toronto, ON, November 1980.
5. **Steiner M**. Overnight dexamethasone suppression test and affective disorders. OPA Annual Meeting, Toronto, ON, January 1982.
6. Brown P, Brown G, **Steiner M**, Grof P, Adam K, Prudo R. Affective disorders: current research methodologies. CPA Annual Meeting, Montreal, PQ, September 1982.
7. **Steiner M**. Endocrinology of affective disorder. Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Calgary, AL, September 1983.
8. **Steiner M**. Current research on PMS and affective disorders. National Science Foundation, Philadelphia, PA, September 1984.
9. **Steiner M**. Psychobiology of the menopause. Nassau, Bahamas, March 1985.
10. **Steiner M**. The prevalence, identification and treatment of depression in the elderly. Hamilton, ON, March 1985.
11. Seggie J, **Steiner M**. Identification of new physiological indicators of depression among the elderly. Geriatric Research in Psychiatry, Hamilton, ON, April 1985.
12. **Steiner M**. Communicating with the lonely, isolated and depressed. McMaster Summer Institute on Gerontology, Hamilton, ON, June 1985.
13. **Steiner M**. Psychoneuroendocrine assessment of borderline patients. McMaster University, Hamilton, ON, December 1985.
14. Links PS, **Steiner M**. Psychopharmacology management of borderline patients. McMaster University, Hamilton, ON, December 1985.
15. **Steiner M**, Links P, Wallace J, Eppel A, Offord D, Mitton J, Martin S, Huxley G, Korzekwa M, Goldman S. Borderline personality disorder - putting research into practice. SA Branch, The Royal Australian & New Zealand College of Psychiatrists, Adelaide, Australia, March 1986.
16. **Steiner M**, Seggie J, Werstiuk E. Dysregulation of neuroendocrine crossroads - rhythms, the retina and depression. Flinders Medical Centre, Flinders University and Hillcrest Hospital, University of Adelaide, Australia, March 1986.

17. **Steiner M.** Reproductive cyclicity and mood disorders in women. Royal Adelaide Hospital and Queen Elizabeth Hospital, University of Adelaide, Australia, March 1986.
18. **Steiner M.** The myth of menopausal depression. International Conference on New Directions in Affective Disorders, Jerusalem, Israel, April 1987.
19. **Steiner M.** The effects of gonadal hormones on brain & behavior. Department of Psychology, Flinders University, Adelaide, Australia, May 1987.
20. **Steiner M.** Borderline personality disorders - putting research into practice. Keynote speaker, Annual Research Day, Dept. of Psychiatry, University of Adelaide, Adelaide, Australia, May 1987.
21. **Steiner M.** Female reproductive cyclicity and mood disorders. Hong Kong Psychiatric Association, Hong Kong, June 1987.
22. **Steiner M.** Affective disorders, circadian rhythms, and neuroendocrine challenge tests. Departments of Psychiatry and Pharmacology, University of Hong Kong, Hong Kong, June 1987.
23. **Steiner M.** Female reproductive cyclicity and mood disorders. Mental Health Services, Northern Territory, Darwin, Australia, July 1987.
24. **Steiner M.** Female reproductive cyclicity and mood disorders. Visiting Professor, Institute of Mental Health, Beijing Medical College, Beijing, China, July 1987.
25. **Steiner M.** The myth of menopausal depression. First Annual Conference on Women's Health Concerns. Pittsburgh, PA, October 1987.
26. **Steiner M.** Neurochemistry and receptor theories in depression. Canadian Consensus Symposium on Depression, Ottawa, ON, September 1988.
27. **Steiner M.** Abuse, addiction and withdrawal of benzodiazepines. North Bay, ON, October 1988.
28. **Steiner M.** Biological markers in treating resistant depression. OPA Annual Meeting, Toronto, ON, January 1989.
29. **Steiner M.** Women's health concerns. CME Day in Psychiatry, Burlington, ON, October 1989.
30. **Steiner M.** Postpartum depression: an update. Hahnemann University, Philadelphia, PA, February 1990.
31. **Steiner M.** The neurochemistry of mood. Cleveland, OH, April 1990.
32. **Steiner M.** Hormonally related mood disorders in women of reproductive age. XXI Congress of ISPNE, Buffalo, NY, August 1990. Abstract: Neuroendocrinology Letters 1990;12:218.
33. **Steiner M.** The chronobiology of gender specific mood disorders. CCNP Annual Meeting, Hamilton, ON, June 1991. Abstract: Symposium #8.
34. **Steiner M.** Prevalence and epidemiology of psychiatric disorders in women and the psychobiology of menopause. Annual Meeting of the Nova Scotia Mental Health Association, Dartmouth, NS, September 1991.
35. **Steiner M.** Retinal supersensitivity, circadian dysregulation and affective disorders - a hypothesis. University of Michigan, Ann Arbor, MI, November 1991.
36. **Steiner M.** New psychiatric drugs - Prozac & Luvox - worth all the hype? Hamilton Academy of Medicine Annual Clinic Day, Hamilton, ON, January 1992.

37. **Steiner M.** PMS - what's new? The Section of Women Physicians of The Hamilton Academy of Medicine Eighth Women and Health Day, Hamilton, ON, April 1992.
38. **Steiner M.** Mood disorders with postpartum onset: a family study. The 8th Annual Postpartum Support International Conference, Toronto, ON, June 1994.
39. Steinberg SI, **Steiner M**, Stewart D, Carter D, Misri S, Reid R, Berger C, Grover D. Fluoxetine: a treatment for LLPDD. XIXth CINP Congress, Washington, DC, June 1994. Abstract: Neuropsychopharmacology 1994;10:712S.
40. **Steiner M.** Sex differences in the brain - are they relevant to treatment response? XIXth CINP Congress, Washington, DC, June 1994. Abstract: Neuropsychopharmacology 1994;S-187-803A.
41. **Steiner M.** Premenstrual dysphoric syndrome. Academy of Psychosomatic Medicine, Phoenix, AZ, November 1994.
42. **Steiner M.** Premenstrual dysphoria and serotonergic dysfunction. XI ISPOG, Basel, Switzerland, May 1995. Journal of Psychosomatic Obstetrics and Gynecology 1995;16:131.
43. **Steiner M.** Mood disorders with postpartum onset. XI ISPOG, Switzerland, May 1995. Journal of Psychosomatic Obstetrics and Gynecology 1995;16:131.
44. **Steiner M.** Towards an understanding of the biology of postpartum mood disorders. International Conference on New Directions in Affective Disorders, Jerusalem, Israel, September 1995. Abstract: p. S39.
45. **Steiner M.** Women specific mood disorders and the serotonergic cascade. CPA Annual Meeting, Victoria, BC, September 1995. Book of Abstract: p. 102.
46. **Steiner M.** Premenstrual mood disorders: clinical experience with serotonergic-based therapies. ECNP Congress, Venice, Italy, October 1995. Abstract: European Neuropsychopharmacology 1995;5:210-211.
47. **Steiner M.** The serotonergic cascade and gender specific mood disorders. International Symposium on Depression, Hamilton, ON, November 1995.
48. **Steiner M.** Premenstrual dysphoric disorder: What's new? International Symposium in Psychiatry, Ameland, The Netherlands, April 1996.
49. **Steiner M.** PMDD and the serotonergic cascade. Grand Rounds, Göteborg University, Göteborg, Sweden, June 1996.
50. **Steiner M**, Dunn E. The psychobiology of female specific mood disorders. CINP Congress, Melbourne, Australia, June 1996. Abstract: European Neuropsychopharmacology 1996;6:88.
51. **Steiner M.** Depression in the postpartum patient. Congress of the AEP, London, England, July 1996. Abstract: European Psychiatry 1996;11:168S.
52. **Steiner M**, Fleming A, Corter C. Maternal behaviour in humans: new perspectives. ISPNE Congress, Cascais, Portugal, August 1996. Abstract: p. 55.
53. **Steiner M.** Hormones and the serotonergic system. ISPNE Congress, Cascais, Portugal, August 1996. Abstract: p. 41.
54. **Steiner M.** Gonadal hormones and serotonin. World Congress of Psychiatry, Madrid, Spain, August 1996.
55. **Steiner M.** Psychiatric morbidity in families of women with postpartum depression: implications for treatment. Marcé Society, London, UK, September 1996.

56. **Steiner M.** Premenstrual dysphoric disorder. Faces of Liaison Psychiatry, Leuven University Hospital, Leuven, Belgium, September 1996.
57. Fleming A, **Steiner M**, Corter C. Psychological aspects of maternal behaviour in humans. APA Women's Health Conference, Washington, DC, September 1996. Abstract: p. 22.
58. **Steiner M**, Fairman M. Psychiatric disorders associated with childbearing: prediction, prophylaxis, diagnosis and treatment. Brantford General Hospital, Brantford, ON, October 1996.
59. **Steiner M.** Premenstrual dysphoria: biology and treatment. International Psycho-Gynecology Symposium, Antwerp, Belgium, November 1996.
60. **Steiner, M.** Premenstrual dysphoria: current research and applications for treatment. Grand Rounds, Department of Psychiatry, University of Iowa, Iowa City, IA, December 1996.
61. **Steiner, M.** Dysthymia in primary care. Department of Psychiatry, University of Iowa, Iowa City, IA, December 1996.
62. Fleming A, **Steiner M**, Corter C. Psychological aspects of maternal behaviour in humans. NASPOG Annual Meeting, Chicago, IL, February 1997.
63. **Steiner M.** Serotonin reuptake inhibitors in the treatment of premenstrual dysphoria. World Congress of Biological Psychiatry, Nice, France, June 1997. Abstract: Biological Psychiatry 1997:42:5S-6S.
64. **Steiner M.** Mood disorders with postpartum onset: a family study. World Congress of Biological Psychiatry, Nice, France, June 1997. Abstract: Biological Psychiatry 1997:42:129S.
65. **Steiner M.** Gonadal hormones, serotonin and mood. Congress of the International Psychogeriatric Association, Jerusalem, Israel, August 1997. Abstract: p. 87.
66. **Steiner M.** SSRIs in the treatment of premenstrual dysphoria. ECNP Congress, Vienna, Austria, September 1997.
67. **Steiner M.** Mood disorders during the childbearing years: advances in pharmacotherapy. WPA, Regional Meeting, Beijing, China, October 1997.
68. **Steiner M.** SSRIs in the treatment of premenstrual dysphoria. Brazilian Psychiatric Association Annual Meeting, Brasilia, Brazil, October 1997.
69. **Steiner M.** Serotonin and gender-specific psychiatric disorders. Israel Diabetes Association, Tel Aviv, Israel, November 1997.
70. **Steiner M.** Postpartum depression with psychotic features. "Zoloft - A Decade of Discovery" Meeting, Berlin, Germany, March 1998.
71. **Steiner M.** Depression and other serotonin related disorders. Global Medical Conference. Indianapolis, May 1998.
72. **Steiner M.** SSRIs in the treatment of PMDD: an Update. ACOG Annual Meeting, New Orleans, May 1998.
73. **Steiner M.** Biopsychosocial aspects of female specific mood disorders. Marcè Society, Iowa City, June 1998. Abstract: Archives of Women's Mental Health 1999;2:130.
74. **Steiner M.** New developments in PMDD and PMS. CINP Congress, Glasgow, Scotland, July 1998. Abstract: The International Journal of Neuropsychopharmacology 1999;2:S71.

75. **Steiner M.** SSRIs in the treatment of PMDD. Psychiatric Latin America Regional Neuroscience Conference. Indianapolis, August 1998.
76. **Steiner M.** SSRIs in the treatment of PMDD: an update. Biennial Congress of the Society of Psychiatrist of South Africa and the Association of Psychiatrists in Africa. September 1998.
77. **Steiner M.** SSRIs in the treatment of PMDD: an update. AEP, Copenhagen, Denmark, September 1998. Abstract: European Psychiatry 1998;13:222s.
78. **Steiner M.** Depression across the life cycle of women. AOA, New Orleans, October 1998.
79. **Steiner M.**, SSRIs in the treatment of PMDD. Regional Neuroscience Conference, Paris, France, October 29-30, 1998. Abstract: European Neuropsychopharmacology 1998;8:S202.
80. **Steiner M.** Emerging trends in the treatment of PMDD. Congress Psychiatric Diseases in Women, Vienna, Austria, November 1998.
81. **Steiner M.** Progress in treating PMS and PMDD. Annual U.S. Psychiatric & Mental Health Congress, San Francisco, CA, November 1998.
82. **Steiner M.** SSRIs in the treatment of PMS. Asia/Pacific Regional Neuroscience Conference, Penang, Malaysia, February 1999.
83. **Steiner M.** Treatment of PMDD. (Symposium) World Federation of Societies of the Biological Psychiatry, Florence, Italy, April 1999.
84. **Steiner M.** Treatment considerations in women's health. Pfizer Worldwide Consultants' Forum – The CNS Challenge, Barcelona, Spain, April 1999.
85. **Steiner M.** Women's health at the turn of the millennium: gender, sex, the brain and behaviour. Professional Women's Series luncheon, Hamilton, ON, April 1999.
86. **Steiner M.** Depression and psychosis: improving outcomes in the new millennium. Houston, TX, April 1999.
87. **Steiner M.** Depression and psychosis: improving outcomes in the new millennium. Seattle, Washington, April 1999.
88. **Steiner M.** New approaches in the treatment of PMDD. Regional Neuroscience Conference, Prague, Czech Republic, April 1999.
89. **Steiner, M.** Estrogens, memory, mood and cognition. Goderich, Ontario, May 1999.
90. **Steiner, M.** New approaches in the treatment of PMDD. Grand Rounds Jackson, Mississippi, June 1999.
91. **Steiner M.** Managing PMS/PMDD: burden of illness and clinical strategies. Annual Congress on Women's Health & Gender-Based Medicine, Hilton Head Island, South Carolina, June 1999.
92. **Steiner M.** Premenstrual syndromes: an update. CCNP Annual Meeting, Halifax, NS, June 1999.
93. **Steiner, M.** Plenary lecture, women's health at the turn of the millennium: gender, sex, the brain and behaviour. Annual Meeting of the Royal College of Psychiatrists in Birmingham, England, June 1999.
94. **Steiner, M.** Depression and psychosis: improving outcomes in the new millennium. Denver, CO, July 1999.
95. **Steiner, M.** Depression and psychosis: improving outcomes in the new millennium. Raleigh, NC, August 1999.

96. **Steiner, M.** Interactive video and internet symposium "Women's Health Initiative: PMDD", by psychLINK, Dallas, TX, September 1999.
97. **Steiner, M.** PMS versus PMDD: diagnosis and classification. ECNP Congress, London, UK, September 1999. Abstract: European Neuropsychopharmacology 1999;9 (suppl 5):S145.
98. **Steiner M.** Dysthymia. ECNP Congress, London, UK, September 1999.
99. **Steiner, M.** Treatment of mood disorders during pregnancy and postpartum. Pacific Rim Regional Neuroscience Conference, Gold Coast, Australia, September 1999.
100. **Steiner, M.** New treatments for PMDD. Pacific Rim Regional Neuroscience Conference, Gold Coast, Australia, September 1999.
101. **Steiner, M.** New treatments for PMDD. Annual meeting of the American Society for Reproductive Medicine, Toronto, ON, September 1999.
102. **Steiner M.** Hormones, serotonin & female-specific mood disorder. American Psychiatric Association Institute on Psychiatric Services, New Orleans, LA, October 1999.
103. **Steiner M.** Serotonin and mood disorders in women. Congress "Psychiatric Disorders in Women", Basel, Switzerland, November 1999.
104. **Steiner M.** PMS/PMDD: an update. OBS/GYN Grand Rounds, University of Minnesota, January 2000.
105. **Steiner M.** Mood disorders and the menstrual cycle: managing PMDD. San Diego, CA, February 2000.
106. **Steiner M.** Special Address. Women's mental health in the new millennium. NASPOG Annual Meeting, St. Petersburg, FL, March 2000.
107. **Steiner M.** PMDD: diagnosis and treatment. Grand Rounds, Mass. General, Boston MA, March 2000.
108. **Steiner M.** Depression throughout the woman's lifecycle: PMDD, pregnancy and lactation. Middle East Regional Neuroscience Conference, Interlaken, Switzerland, March 2000.
109. **Steiner M.** Depression throughout the woman's lifecycle: PMDD, pregnancy and lactation. European Regional Neuroscience Conference, Stresa, Italy, March 2000.
110. **Steiner M.** Diagnosis and treatment of PMS/PMDD: an update. CCNP Annual Meeting, Marrakesh, Morocco, April 2000.
111. **Steiner M.** Gender specific mood disorders: from basic research to clinical practice. CCNP Annual Meeting, Marrakesh, Morocco, April 2000.
112. **Steiner M.** PMDD: new research. Austrian Psychiatry Congress OEGNP, Gmunden, Austria, May 2000.
113. **Steiner M.** A psychological approach to managing PMDD. Global Medical Conference. Indianapolis, IN, May 2000.
114. **Steiner M.** PMDD: new research. APA Annual Meeting, Chicago, IL, May 2000.
115. **Steiner M.** The pathophysiology of PMDD and review of recent studies. ACOG, San Francisco, CA, May 2000.
116. **Steiner M.** A physiological approach to managing PMDD. Houston, TX, May 2000.

117. **Steiner M.** Perimenopause, menopause and beyond: hormones, mood and cognitive functioning. Society of Obstetricians and Gynaecologists of Canada, Montreal, Quebec, June 2000.
118. **Steiner M.** Advances in treatment of PMS and PMDD. CINP Annual Meeting, Brussels, July 2000.
119. **Steiner M.** Perimenopause, menopause and beyond: the estrogen-serotonin link. International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, July 2000.
120. **Steiner M.** Diagnosis and treatment of PMS/PMDD: an update. International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, July 2000.
121. **Steiner M.** A physiological approach to managing PMDD, San Diego, CA, July 2000.
122. **Steiner M.** Mood disorders in women and children: unique treatment needs and solutions. ECNP, Munich, Germany, September 2000.
123. **Steiner M.** PMS/PMDD. Women's Mental Health Congress, Sao Paulo, Brazil, September 2000.
124. **Steiner M.** PMS/PMDD. Rio de Janeiro and Belo Horizonte, Brazil, September 2000.
125. **Steiner M.** Perimenopause, menopause and beyond: the estrogen-serotonin link. CPA Annual Meeting. Victoria, BC, October 2000.
126. **Steiner M.** Hormones and mood: from menarche to menopause and beyond. APA Summit on Women and Depression, Wye River Conference Centre, Queenstown, Maryland, October 2000. Published as "Proceedings and Recommendations" by the American Psychological Association, April 2002
127. **Steiner M.** A physiological approach to managing PMDD. New York, NY, October 2000.
128. **Steiner M.** PMS & PMDD: diagnosis & treatment. AEP Congress, Prague, Czech Republic, October 2000.
129. **Steiner M.** The use and Safety of psychotropic drugs in pregnancy & lactation. Brantford, Ontario, November 2000.
130. **Steiner M.** Perimenopause/menopause: diagnosis and treatment. Flushing, MI, November 2000.
131. **Steiner M.** Premenstrual dysphoria: pathophysiology and treatment. Women's Health, CME Series in Psychiatry. Ann Arbor, MI, November 2000.
132. **Steiner M.** Perimenopause, menopause and beyond: hormones, mood and cognitive functioning. Congress of Psychiatric Disorders in Women. Bonn, Germany, November 2000.
133. **Steiner M.** Diagnosis and assessment of PMS/ PMDD. International Forum on Mood and Anxiety Disorders, Monte Carlo, November 2000.
134. **Steiner M.** SSRIs in the treatment of PMDD: a critical review. Nebraska Ob/Gyn Society Meeting, Las Vegas, Nevada, December 2000.
135. **Steiner M.** Clinical trials methodology: study design and outcome measure. International Consensus Meeting on PMDD, Courchevel, France, January 2001.
136. **Steiner M.** PMDD: new research. Austrian Launch Event for PMDD, Austria, Vienna, January 2001.
137. **Steiner M.** Managing postpartum depression. Low Birth Risk Conference, Burlington, Ontario, February 2001.

138. **Steiner M.** Diagnosis and treatment of PMS/PMDD: an update. Pfizer CNS Summit, Antalya, Turkey, February 2001.
139. **Steiner M.** Intimacy and health: the mind-body connection. NASPOG Annual Meeting, Waikoloa, HI, February 2001.
140. **Steiner M.** Diagnosis and treatment of PMS/PMDD: an update. 5th Psychopharmacology Course, Stanford University. Stanford, CA, March 2001.
141. **Steiner M.** Mood disorders and dimorphism in neurotransmitter systems. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001.
142. **Steiner M.** Gender, serotonin and mood. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001.
143. **Steiner M.** Menarche and mood disorders in adolescents: the forgotten dimension. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001.
144. **Steiner M.** Dysthymia in women. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001.
145. **Steiner M.** PMDD: improving function and quality of life. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001.
146. **Steiner M.** Intimacy and health: the mind-body connection. Annual Meeting of the American College of Psychoanalysts, Chicago, IL, May 2001.
147. **Steiner M.** Diagnosis and treatment of PMDD: an update. Regional ISPNE Congress, St. Petersburg, Russia, June 2001.
148. **Steiner M.** Postpartum depression: Into the new millennium. Parenting workshop. University of Toronto, Mississauga, Ontario, July 2001.
149. **Steiner M.** Dysthymia in primary care: the role of IPT. World Assembly for Mental Health, Vancouver, BC, July 2001.
150. **Steiner M.** Female Mood Disorders: Premenstrual dysphoria as an illustrative example of how SSRI's work. CINP, Hiroshima, Japan, October 2001.
151. **Steiner M.** Depression in Women: Management Considerations. Athens & Thessaloniki, Greece, March 2002
152. **Steiner M.** Gender Issues in Mood and Anxiety Disorders. The 2nd Worldwide Pfizer Neuroscience Consultants Forum, Lisbon, Portugal, April 2002
153. **Steiner M.** Diagnosis and Treatment of Perinatal Mood Disorders. Day in Perinatology, Hamilton Convention Centre, Hamilton, Ontario, May 2002
154. **Steiner M.** The Neuropsychobiology of Perinatal Mood Disorders. NIMH Conference on Perinatal Mood Disorders, Bethesda, Maryland, July 2002
155. **Steiner M.** PMDD: Improving Function and Quality of Life and Treatment of Depression in Menopause. Taipei, Taiwan, August 2002.
156. **Steiner M.** Mood Disorders in Women - Across the Lifecycle. Eli Lilly Australia, September 2002.

157. **Steiner M.** Mood disorders and sexual dimorphism in neurotransmitter systems. 15th ECNP Congress, Barcelona, Spain, October 2002.
158. **Steiner M.** Female specific mood disorders. CME Conference, Birch Run, Michigan, November 2002.
159. **Steiner M.** Mood Disorders during Pregnancy and Lactation: How safe are Psychotropics. Kongress Psychische Erkrankungen Von Frauen, Munster, Germany, November 2002.
160. **Steiner M.** Female Specific Mood Disorders. Neuroscience Grand Rounds, Novartis, Basel, November 2002.
161. **Steiner M.** Estrogen, reproductive cyclicity and mood in women. Yale Conference on the Impact of Estrogen on Mood and Memory in Women, New Haven, CT, March 2003.
162. **Steiner M.** Hormones and the brain. (Symposium) APA Annual Meeting, San Francisco, CA, May 2003.
163. **Steiner M.** The neurobiology of perinatal mood and anxiety disorders. (Symposium) Perinatal Mood Disorders, Madison, Wisconsin, June 2003.
164. **Steiner M.** Hormones and mood: from menarche to menopause and beyond. (Symposium) American Psychological Association Annual Meeting, Toronto, August 2003.
165. **Steiner M.** Perinatal Mood Disorders. (Symposium) American Society for Reproductive Medicine, San Antonio, Texas, October 2003.
166. **Steiner M.** Treatment of PMS and PMDD: State of the art. Kongress der Gesellschaft für die psychische Gesundheit von Frauen, Innsbruck, October 2003.
167. **Steiner M.** Postpartum Depression - when a happy time turns dangerous. Bovine Visiting Professorship, Motherisk Update 2003, Hospital for Sick Children, Toronto, November 2003.
168. **Steiner M.** Diagnosis and treatment of perinatal mood disorders. Paediatric Grand Rounds, Hospital for Sick Children, Toronto, November 2003.
169. **Steiner M.** Hormones and mood: from menarche to menopause and beyond. James W. Wiggins Lectureship in Obstetrics and Gynecology, Presbyterian Women's Program, Albuquerque, NM, November 2003.
170. **Steiner M.** Treating mood disorders across the lifespan of women. SOGC 22nd Ontario CME Program, Toronto, December 2003.
171. **Steiner M.** Macdougall M, Born L. Diagnosis and measurement of PMS/PMDD: any shortcuts? (Symposium) International Congress of Biological Psychiatry, Sydney, Australia, February 2004.
172. **Steiner M.** Hormones and the Brain. (Symposium) 2nd World Congress on Women's Mental Health, Washington, March 2004.
173. **Steiner M.** Reproductive Age. (Plenary) 2nd World Congress on Women's Mental Health, Washington, March 2004.
174. **Steiner M.** Gonadal steroids and the brain: implications in aging women. (Symposium) APA Annual Meeting, New York, May 2004.
175. **Steiner M.** The neuropsychobiology of perinatal mood disorders: are hormonal changes relevant? APA Annual Meeting, New York, May 2004.

176. **Steiner M.** PMS/PMDD - diagnosis and treatment: any shortcuts? (Symposium) CCNP Annual Meeting, Kingston, May 2004.
177. **Steiner M.** Premenstrual disorders: state of the art. Psychiatry Grand Rounds, Worcester, Massachusetts, June 2004.
178. **Steiner M.** Markowitz J. "Ask the experts" session: Dysthymic Disorder. 1st International IPT Symposium, Pennsylvania, June 2004.
179. **Steiner M.** Female specific mood disorders: beyond depression & Anxiety. 2004 WFSBP Asia-Pacific Congress, Seoul, Korea, July 2004.
180. **Steiner M.** Antidepressants and the neonatal withdrawal (discontinuation) syndrome: fact or fiction? The Toronto-Hamilton Chapter of the North American Society for Psychosocial Obstetrics & Gynecology, Toronto, October 2004.
181. Schmidt LA, MacMillan HL, Bennett L, Parkin C, **Steiner M**, Boyle MH, Niec A, Gensey S, Spree S. Patterns of resting and reactive frontal brain electrical activity (EEG) and salivary cortisol in adolescent females exposed to extreme child maltreatment: stability and relation to psychopathology. CIHR NET Violence, Gender, and Health Workshop, York University, Toronto, November 2004.
182. **Steiner M.** Sex differences in mood disorders. (Symposium) Society for Neurosciences Meeting, San Diego, CA, October 2004.
183. **Steiner M.** Treatment options for bipolar women in the reproductive years. (Symposium) World Congress of Biological Psychiatry, Vienna, Austria, June 2005. Abstract The World Journal of Biological Psychiatry, 6:93, 2005.
184. **Steiner M.** Perinatal psychiatry: what obstetricians should know. American College of Obstetricians and Gynecologists, Toronto, October 2005.
185. **Steiner M.** SSRI's during pregnancy: do they really hurt the babies? (Symposium) Kongress der Gesellschaft für die psychische Gesundheit von Frauen (GPGF), Heidelberg, Germany, October 2005.
186. **Steiner M.** Stress, hormones and maternal behavior. (Symposium) 18th ECNP Congress, Amsterdam, The Netherlands, October 2005.
187. **Steiner M.** Treatment options for bipolar women in the reproductive years. (Workshop) Australasian Society for Bipolar Disorders, Melbourne, February 2006.
188. Born L, **Steiner M.** Irritability and the spectrum of female specific mood disorders. (Symposium) AEP 14th European Congress of Psychiatry, Nice, France March 2006. Abstract: European Psychiatry 2006;21 Suppl 1:S6.
189. Born L, **Steiner M.** Irritability and the spectrum of female specific mood disorders. Hot Issues in Psychiatry, Pisa, Italy, March 2006. Abstract: Clinical Neuropsychiatry 2006;3:43.
190. **Steiner M.** Depression in primary care: a gender-specific clinical challenge. 14th Annual Congress on Women's Health, Hilton Head, SC, June 2006. Abstract: Journal of Women's Health 2006;15:454.
191. **Steiner M.** Diagnosis and treatment of perinatal mood and anxiety disorders: state of the art. Women's Mental Health Symposium on Anxiety Management, Taiwan, June 2006.
192. **Steiner M.** Depression in primary care: a gender-specific clinical challenge. Women's Mental Health Symposium on Anxiety Management, Taiwan, June 2006.

193. **Steiner M.** PMDD: State of the art. Women's Mental Health Symposium on Anxiety Management, Taiwan, June 2006.
194. **Steiner M.** Stress, hormones and maternal behaviour. (Symposium) Society of Behavioral Neuroendocrinology, Pittsburgh, June 2006.
195. **Steiner M,** Born L. Irritability and the spectrum of female-specific mood disorders. (Symposium) CINP Congress, Chicago, July 2006. Abstract: The International Journal of Neuropsychopharmacology 2006;9 Suppl 1:S38.
196. Shea A, Streiner D, Fleming A, Kamath M, **Steiner M.** Birth outcomes and physiological correlates of depression and anxiety during pregnancy. (Symposium) CINP Congress, Chicago, July 2006. Abstract: The International Journal of Neuropsychopharmacology 2006;9 Suppl 1:S130.
197. **Steiner M.** The use of SSRI's in pregnancy: The North American Experience. Marce Society International Biennial Scientific Meeting, Keele, UK, September, 2006.
198. **Steiner M.** Methodologic approaches to perinatal treatment outcome research. Marce Society International Biennial Scientific Meeting, Keele, UK, September 2006.
199. Shea A, Streiner D, Fleming A, Kamath M, **Steiner M.** Physiologic correlates of adversity in mother-baby diads. 19th ECNP Congress, Paris, September 2006.
200. **Steiner M.** Antidepressants in pregnancy. Ben Lotimer Clinical Update Day 2006. Hamilton. October 2006.
201. **Steiner M.** Stress, depression and anxiety during pregnancy and adverse infant outcomes. University of California Research Day, Irvine School of Medicine, California, November 2006.
202. **Steiner M.** The use of SSRI's in pregnancy, The North American experience. A Day in Low Risk Obstetrics, Hamilton, ON, February 2007.
203. **Steiner M.** Treatment of depression in women. (Symposium) The XV International Congress of ISPOG, Kyoto, Japan, May 2007. Abstract: Journal of Psychosomatic Obstetrics & Gynecology 2007;28 Suppl 1:S6-3.
204. **Steiner M.,** Soares C. Reproductive age, stress and trauma. (Symposium) The XV International Congress of ISPOG, Kyoto, Japan, May 2007. Abstract: Journal of Psychosomatic Obstetrics & Gynecology 2007;28 Suppl 1:S17-2.
205. **Steiner M.** Women and depression: the role of reproductive age, stress, and trauma. The 15th Annual Congress on Women's Health, June 2007.
206. **Steiner M.** Premenstrual disorders: state of the art. 63rd Annual Clinical Meeting, The Society of Obstetricians and gynaecologists of Canada. Ottawa, June 2007.
207. **Steiner M.** Perinatal mood and anxiety disorders: diagnosis and treatment. 1st Sesam Summer School, Basel, August 2007.
208. **Steiner M.** Women and Depression: The role of reproductive age, stress and trauma. Grand Rounds, University of Illinois at Chicago, Chicago, October 2007.
209. **Steiner M.** Between Scylla and Charybdis: antidepressant treatment during pregnancy. Psychiatry Academic Day, Mount Sinai, Toronto, November 2007.
210. **Steiner M.** Antidepressant treatment during pregnancy – serious concern or much ado about little. SWHR Mood Disorders & Hormonal Transitions Media Luncheon, New York, November 2007.

211. **Steiner M.** Premenstrual disorders: state of the art. The American College of Psychiatrists 2008 Annual Meeting. Kauai, Hawaii, February 2008.
212. **Steiner M.** Keynote Speaker. Depression in primary care: a gender-specific clinical challenge. 3rd International Congress on Women's Mental Health, Melbourne, Australia, March 2008.
213. **Steiner M.** Women's Mental Health: depression. Omnia Education, Chicago, May 2008.
214. **Steiner M.** Women's Mental Health: depression. Omnia Education, Long Island NY, May 2008.
215. **Steiner M.** Hormones & Mood: from menarche to menopause and beyond. Queen's University Department of Psychiatry Research Conference. Kingston, ON, May 2008.
216. **Steiner M.** Perinatal depression: an update on risk factors and clinical management. The Future of Crisis Intervention, Hamilton, ON, June 2008.
217. **Steiner M.** Women's Mental Health: Depression. Omnia Education, Richmond, VA, June 2008.
218. **Steiner M.** The risk: benefit ratio of using antidepressants during pregnancy. (Symposium) 21st ECNP Congress, Barcelona, August 2008.
219. **Steiner M.** Women's Mental Health: postpartum Depression. Omnia Education, Detroit, MI, September 2008.
220. **Steiner M.** What a difference an X makes. Society for Women's Health Research Conference. Washington, DC, October 2008.
221. **Steiner M.** Women's Mental Health: Postpartum Depression. Omnia Education, Pasadena, CA, November 2008.
222. **Steiner M.** Diagnosing depression in women of child-bearing years. Omnia Education, Bahamas, November 2008.
223. **Steiner M.** Treating depression in women of child-bearing years. Omnia Education, Bahamas, November 2008.
224. **Steiner M.** Managing depression during pregnancy and postpartum. Omnia Education, Bahamas, November 2008.
225. **Steiner M.** The risk of using antidepressants during pregnancy: serious concern or much ado about little? Ontario Psychiatric Association 89th Annual Conference, Toronto, ON, February 2009.
226. **Steiner M.** The burden of female-specific mood disorders. First scientific day of the Chair on sex, gender and mental health from the CIHR Institute of gender and health. Montreal, QC, March 2009.
227. **Steiner M.** Antidepressant treatment during pregnancy and postpartum: serious concerns or much ado about little? Moods and Cycles: diagnosis Meeting, Muskoka Seminars, Blue Mountain, ON, July 2009.
228. **Steiner M.** Antidepressant treatment during pregnancy and postpartum: serious concerns or much ado about little? University of Michigan Depression Center Colloquium Series, Ann Arbor, MI, September 2009.
229. **Steiner M.** Antidepressant treatment during pregnancy and postpartum: serious concern or much ado about little? University of Toronto Centre for Research in Parenting, Toronto, ON, October, 2009.
230. **Steiner M.** Depression and cardiovascular disease: does sex matter? 4th Congress of the International Society of Gender Medicine, Sex and Gender in Medicine, Berlin, Germany, November 2009.

231. **Steiner M.** Perinatal psychiatric illness: early detection, treatment, and prevention. Lincoln County Academy of Medicine Annual Educational Day, Lincoln County, April 2010.
232. **Steiner M.** New diagnostic tools to assess psychiatric disorders across the female life cycle. (Symposium) 2010 Canadian Neuroscience Meeting Jointly presented by CAN and CCNP, Ottawa, ON, May 2010.
233. **Steiner M.** Implications of animal models and human studies of smoking in pregnancy. (Trainee Breakfast Session) 2010 Canadian Neuroscience Meeting Jointly presented by CAN and CCNP, Ottawa, ON, May 2010.
234. **Steiner M.** Perinatal stress, anxiety and depression are associated with adverse infant outcomes – can they be prevented? The Brazilian Congress of Brain, Behavior and Emotions, Gramado, Brazil, June 2010.
235. **Steiner M.** Perinatal stress, anxiety and depression are associated with adverse infant outcomes – can they be prevented? Grand Rounds, Foothills Medical Centre, Calgary, AB, June 2010.
236. **Steiner M.** Serotonin, depression, and cardiovascular disease: sex-specific issues. 12th International Symposium on Vascular Neuroeffector Mechanisms, Odense, Denmark, July 2010.
237. **Steiner M.** Perinatal psychiatric illness: early detection, treatment and prevention. Ground Rounds, Brampton Civic Hospital, Brampton, ON, October 2010.
238. **Steiner M.** Perinatal OCD. Tackling Depression and Anxiety Day, Hamilton, ON, October 2010.
239. **Steiner M.** The measurement of premenstrual symptoms: prospective vs retrospective scales. (Symposium) Premenstrual disorders: an update. 16th International Congress of the International Society of Psychosomatic Obstetrics and Gynecology, Venice, Italy, October 2010.
240. **Steiner M.** Perinatal psychiatric illness: early detection, treatment, and prevention. Oakville, ON, November 2010.
241. **Steiner M.** Women's mental health research: where are we going next? (Symposium) Biological correlates and new paradigms in women's mental health research. 4th World Congress on Women's Mental Health, Madrid, Spain, March 2011.
242. **Steiner M.** Selective serotonin reuptake inhibitors. International Society for Premenstrual Disorders Consensus Meeting, London, UK, March 2011.
243. **Steiner M.** Tools for diagnosing premenstrual disorders. (Symposium) Premenstrual disorders. 1st World Congress of Obstetrics, Gynaecology and Andrology, London, UK, March 2011.
244. **Steiner M.** (Symposium) Premenstrual disorders: an update. 10th World Congress of Biological Psychiatry, Prague, Czech Republic, May 2011.
245. **Steiner M.** New advances and diagnostic tools to assess psychiatric disorders in midlife women: the CIDI-VENUS. (Symposium) From scan to bedside: innovative approaches to women's mental health research and menopause. 13th World Congress on Menopause, Rome, Italy, June 2011.
246. Bisceglia R, Fleming A, Meaney M, **Steiner M.** Exploring mother-infant cortisol synchrony: who is leading and when. Elizabeth Young Memorial Symposium. 41st Annual Conference of the International Society of Neuropsychoneuroendocrinology, Berlin, Germany, August 2011.

(a) **Accepted:**

1. **Steiner M.** Sex differences in depression and CVD. American Physiological Society Conference, Jackson, MS, October 2011.

(b) Submitted:

1. **Steiner M.** Tools for diagnosing premenstrual disorders. (Symposium) Premenstrual disorders: an update. 28th World Congress of the International College of Neuropsychopharmacology, Stockholm, Sweden, June 2012.

(vi) CONTRIBUTED ORAL OR POSTER PRESENTATIONS:

1. Atsmon A, Blum I, Wijssenbeek H, **Steiner M.** A therapeutic trial with propranolol. Fifth World Congress of Psychiatry, Mexico. Abstract: La Prensa Medica Mexicana, 1971, p. 189.
2. Atsmon A, Blum I, **Steiner M,** Wijssenbeek H. Propranolol therapy helps some patients with mental disorders. AMA First International Health Conference, Tel Aviv. Abstract: JAMA 1973;24:173-174.
3. Elizur A, Graff M, **Steiner M,** Davidson S. Intra-extra RBC lithium distribution as predictor of lithium neurotoxicity. International Symposium on the Impact of Biology on Modern Psychiatry, Jerusalem, Israel, December 1975.
4. Carroll BJ, Feinberg MP, **Steiner M,** Commorato A, James N. Neuroendocrine identification of endogenous depression. Annual Meeting of the American Psychosomatic Society, Atlanta, GA, March 1977. Abstract: Psychosomatic Medicine 1977;39:54-55.
5. **Steiner M.** Premenstrual dysphoria syndromes. Neuroscience Seminars, University of Michigan, Ann Arbor, MI, April 1977.
6. Carroll BJ, Feinberg MP, **Steiner M,** James N. Neuroendocrine identification of depression. Annual Meeting of the American Psychiatric Association, Toronto, ON, May 1977. Abstract: p. 86.
7. Heine D, **Steiner M.** Use of painting as a diagnostic and communication media in the treatment of affective disorders. Annual State of Michigan Activities Training Conference, Kalamazoo, MI, August 1977.
8. **Steiner M,** Carroll BJ. The psychobiology of premenstrual dysphoria. Free Communication. Sixth World Congress of Psychiatry, Honolulu, HI, September 1977.
9. **Steiner M,** Carroll BJ, Starkman M. Endocrine studies in premenstrual dysphoria. Fourth Congress of the International College of Psychosomatic Medicine, Kyoto, Japan, September 1977. Abstract: pp. 162-163.
10. Heine D, **Steiner M.** Diagnostic use of patients with affective disorders. Annual Conference of the American Occupational Therapy Association, San Juan, Puerto Rico, October 1977.
11. **Steiner M.** Theoretical and practical issues in adolescent sexuality. Department of Social Services, State of Michigan, Whitmore Lake, MI, May 1978.
12. Feinberg M, **Steiner M,** Carroll BJ. Effects of long-term lithium treatment on serum calcium, magnesium and calcitonin. Annual NCDEU Meeting, Key Biscayne, FL, May 1978.
13. **Steiner M,** Neumann M. Traumatic neurosis and social support in the Yom Kippur war returnees. International Congress of Psychological Stress and Adjustment in Times of War and Peace, Jerusalem, Israel, June 1978. Abstract: p. 232.
14. **Steiner M,** Haskett RF, Starkman M, Osmun J, Peterson E, Carroll BJ. Classification and treatment of premenstrual tension syndromes, 11th CINP Congress, Vienna, Austria, July 1978.
15. **Steiner M.** On aggression and violence. Department of Social Services, State of Michigan, Whitmore Lake, MI, October 1978.

16. Elizur A, **Steiner M**, Davidson S. Anti-psychotic drug-induced paradoxical behavioral toxicity. The 3rd Israel Psychiatric Association Meeting, Acre, Israel, January 1979.
17. **Steiner M**. The family-to-group transition in delinquent youth. Department of Social Services, State of Michigan, Whitmore Lake, MI, March 1979.
18. **Steiner M**, Haskett RF, Osmun J, Rubin R, Carroll BJ. Premenstrual tension syndrome - psychoendocrine evaluation and treatment outcome. American Psychosomatic Society Annual Meeting, Dallas, TX, March 1979. Abstract: Psychosomatic Medicine 1979;41:73, 1979. Reviewed in: Clinical Psychiatry News, May 1979.
19. Greden JF, Albala AA, Haskett RF, James N, Goodman L, **Steiner M**, Carroll BJ. Normalization of dexamethasone suppression tests: A probable index of recovery among endogenous depressives. Annual Meeting of the Society of Biological Psychiatry, Chicago, IL, May 1979. Abstract: #25. Reviewed in Clinical Psychiatry News, August 1979.
20. Feinberg M, Carroll BJ, Smouse P, Rawson S, Haskett RF, **Steiner M**, Albala AA, Zelnick T. Comparison of physician and self-ratings of depression. Annual Meeting of the Society of Biological Psychiatry, Chicago, IL, May 1979. Abstract: #80.
21. Haskett RF, **Steiner M**, Osmun J, Carroll BJ. Severe premenstrual tension: delineation of the syndrome. Annual Meeting of the Society of Biological Psychiatry, Chicago, IL, May 1979. Abstract: #78.
22. **Steiner M**, Haskett RF, Osmun J, Carroll BJ. Treatment of premenstrual tension with lithium carbonate: A pilot study. Annual Meeting of the Society of Biological Psychiatry, Chicago, IL, May 1979. Abstract: #79.
23. Feinberg M, **Steiner M**, Carroll BJ, Commorato A. The RDC and endogenous depression. Annual Meeting of the American Psychiatric Association, Chicago, IL, May 1979. Abstract: p. 81.
24. **Steiner M**, Haskett RF, Carroll BJ, Hays SE, Rubin RT. Is there a role for prolactin in the psychobiology of premenstrual dysphoria? ISPNE Congress, Park City, UT, August 1979. Abstract: p. 10.
25. **Steiner M**, Katz RJ, Baldrighi G, Carroll BJ. Hedonic behavior and the estrous cycle of the rat: Evidence from self-stimulation and wheel-running. ISPNE Congress, Park City, UT, August 1979. Abstract: p. 44.
26. **Steiner M**, Haskett RF, Carroll BJ, Osmun JN, Hays SE, Rubin RT. Hypothalamic-pituitary function in premenstrual tension syndrome. Fifth Congress of the International College of Psychosomatic Medicine, Jerusalem, Israel, September 1979. Abstract: p. 314.
27. Stier S, Gaoni B, Calev J, **Steiner M**. The therapeutic and prognostic value of intensive sexual and family education in young psychotic patients. National Conference on Family Planning, Ramat-Gan, Israel, January 1980, Abstract: p. 52.
28. Carroll BJ, Greden JF, Feinberg M, Lohr N, James N, **Steiner M**, Haskett RF, Albala AA, deVigne JP, Tarika J. Evaluation of depression in borderline patients. APA Annual Meeting, San Francisco, CA, May 1980.
29. Carroll BJ, Feinberg M, Greden JF, Haskett RF, James N, **Steiner M**, Tarika J. Biologic validation of diagnoses of depression. APA Annual Meeting, San Francisco, CA, May 1980.
30. Carroll BJ, Feinberg M, Greden JF, Haskett RF, James N, **Steiner M**, Tarika J. Biologic validation of diagnoses of depression. Annual Meeting of the Psychiatric Research Society, Boston, MA, September 1980. Abstract: Journal of Psychiatric Research 1981;16:130-131.
31. **Steiner M**, Radwan M. Psychosocial aspects of mastectomy: A cross-cultural study. Conference on Breast Cancer, Tel Aviv, Israel, October 1980. Abstract: #89.

32. Radwan M, **Steiner M**. The influence of emotional factors on the course of breast cancer. Conference on Breast Cancer, Tel Aviv, Israel, October 1980. Abstract: #30.
33. Radwan M, **Steiner M**. Cross-cultural coping styles associated with mastectomy. Sixth World Congress of the International College of Psychosomatic Medicine, Montreal, PQ, September 1981. Abstract: #137.
34. Radwan M, **Steiner M**. Psychological adaptation to jejunoileal bypass for morbid obesity: A cross-cultural study. Sixth World Congress of the International College of Psychosomatic Medicine, Montreal, PQ, September 1981. Abstract: #684.
35. **Steiner M**, Katz RJ. The intrinsic pattern of motivated behaviour and the estrous cycle of the rat. The Fifth European Neuroscience Congress, Liege, Belgium, September 1981. Communication Workshop on Steroids and Behaviour. Abstract: Neuroscience Letters 1981;Suppl 7:15.
36. Radwan M, **Steiner M**. Psychological aspect of mastectomy. A cross-cultural study. Israel Psychiatric Association Meeting, Jerusalem, Israel, November 1981. Abstract: p. 31.
37. Haskett RF, **Steiner M**, Carroll BJ, Rubin RT. Neuroendocrine studies of premenstrual syndrome. Annual Meeting of the American College of Neuropsychopharmacology, San Diego, CA, December 1981.
38. Feinberg M, **Steiner M**, Pegeron J-P. The effect of morphine on the symptoms of endogenous depression. Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Toronto, ON, June 1982.
39. **Steiner M**, Martin S, Wallace JE, Goldman S, Keane PM. Distinguishing subtypes within the borderline domain: A combined psycho-neuroendocrine approach. Annual Meeting of the Society of Biological Psychiatry, New York, NY, April 1983. Abstract: #151.
40. **Steiner M**. Psychobiology of borderline syndromes - new subtyping. Annual Meeting of the VII World Congress of Psychiatry, Vienna, Austria, July 1983. Abstract: #P272.
41. Martin S, Wallace JE, Goldman S, **Steiner M**. Psychobiology of borderline syndromes: New subtyping. CPA Annual Meeting, Ottawa, ON, September 1983.
42. **Steiner M**, Brown GM, Williams PA, Gupta RN. Melatonin/cortisol (M/C) ratio and the DST in newly admitted psychiatric inpatients. Annual Meeting of the Society of Biological Psychiatry, Los Angeles, CA, May 1984. Abstract: #87.
43. **Steiner M**, Brown GM. Melatonin/cortisol ratio: a biological marker? APA Annual Meeting, Los Angeles, CA, May 1984. Abstract: #NR53.
44. **Steiner M**, Brown GM. Pineal-hypothalamic-pituitary function in newly admitted psychiatric patients. CINF Congress, Florence, Italy, June 1984. Abstract: F-299.
45. **Steiner M**, Brown GM. Melatonin/cortisol (M/C) ratio and the DST in newly admitted psychiatric inpatients. International Congress of Endocrinology, Digby, NS, July 1984. Abstract: #D50.
46. Robillard M, Kennedy S, **Steiner M**. Dexamethasone suppression test: a comparative laboratory study. CPA Annual Meeting, Banff, AL, October 1984.
47. **Steiner M**, Goldman S, Gupta RN. Specificity of the DST and TRH test. Annual Meeting of the Society of Biological Psychiatry, Dallas, TX, May 1985. Abstract: #163.
48. Links PS, **Steiner M**, Offord DR, Eppel AB, Mitton J, Hendershot A, Korzekwa M. Validity of affective borderline subtypes. APA Annual Meeting, Dallas, TX, May 1985. Abstract: #NR159.
49. Auffarth SE, Werstiuk ES, **Steiner M**. ³H-Clonidine binding to membranes of platelets prepared under physiological conditions. CCNP Annual Meeting, London, ON, May 1985. Abstract: #21.

50. **Steiner M**, Goldman S, Gupta RN, Boiago IM. Specificity of the combined dexamethasone suppression and RH/TSH tests in melancholia. CCNP Annual Meeting, London, ON, May 1985. Abstract: #47.
51. Links PS, **Steiner M**. The validity of the borderline personality disorder diagnosis, and the interface with affective disorders. WPA, Montreal, PQ, June 1985.
52. **Steiner M**. Treatment of premenstrual changes. Society of Biological Psychiatry, Philadelphia, PA, September 1985. Abstract: #117.5.
53. **Steiner M**, Werstiuk ES, Auffarth SE, Bean G. ³H-Clonidine binding to membranes of platelets of depressed patients before and after treatment. Society of Biological Psychiatry, Philadelphia, PA, September 1985. Abstract: #134.12.
54. **Steiner M**, Goldman S, Scordino K, Guscott RG, Fairman M. The identity of postpartum disorders. Society of Biological Psychiatry, Philadelphia, PA, September 1985. Abstract: #235.3.
55. **Steiner M**, Fleming AS, Borovich D, Anderson VN, Boulter GE. Is there a neuroendocrine profile for maternity blues? Society of Biological Psychiatry, Philadelphia, PA, September 1985. Abstract: #235.4.
56. Flett GL, Krames L, **Steiner M**. The comparability of depressive disorders in children and adults: A review of the literature. Society of Biological Psychiatry, Philadelphia, PA, September 1985. Abstract: #143.4.
57. Korzekwa M, Links P, **Steiner M**, Mitton J. The dexamethasone suppression test in affective borderline personality subtype. Society of Biological Psychiatry, Philadelphia, PA, September 1985. Abstract: #131.4.
58. **Steiner M**. Treatments for Premenstrual Syndrome. Society of Biological Psychiatry, Philadelphia, PA, September 1985. In: Shagass, Josiassen, Bridger, Weiss, Stoff, Simpson (eds). Biological Psychiatry, Proceedings of the 14th World Congress of Biological Psychiatry 1985;135-37.
59. Auffarth SE, Werstiuk ES, **Steiner M**. In vitro treatment of human platelets with desmethylimipramine alters binding properties of the alpha-2-adrenoceptor. Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Vancouver, BC, September 1985. Abstract: #733.
60. Bean G, Werstiuk ES, **Steiner M**. The effect of electroconvulsive therapy on alpha-2-receptors in platelets from depressed patients. Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Vancouver, BC, September 1985. Abstract: #R-723.
61. Werstiuk ES, Auffarth SE, **Steiner M**. Platelet alpha-2-adrenergic receptors: The effect of in vitro desipramine treatment on ³H-clonidine binding. Annual Meeting of the Society for Neurosciences, Dallas, TX, October 1985. Abstract: #305.3.
62. **Steiner M**, Seggie J, Werstiuk ES. Biological rhythms, melatonin and depression. International Congress on Melatonin in Humans, Vienna, Austria, November 1985. Abstract: Journal of Neural Transmission 1986;21 Suppl:488-489.
63. **Steiner M**, Werstiuk ES, Auffarth SE, Bean G. The effects of ECT vs DMI treatment on ³H-clonidine binding to membranes of platelets of depressed inpatients. ACNP Annual Meeting, Maui, HI, December, 1985. Abstract: p. 109.
64. Seggie J, **Steiner M**. New physiological indices of depression in the elderly. Health Sciences Gerontology Research Group, Newsletter 1985;3:2.

65. **Steiner M**, Fleming AS, Anderson VN, Boulter GE. A psychoneuroendocrine profile for postpartum blues? 8th International Congress of Psychosomatic Obstetrics and Gynaecology, Melbourne, Australia, March 1986. Abstract: p. 83.
66. **Steiner M**, Guscott RG. A treatment model for postpartum psychoses. 8th International Congress of Psychosomatic Obstetrics and Gynaecology, Melbourne, Australia, March 1986. Abstract: p. 83-84.
67. **Steiner M**, Seggie J, Werstiuk ES. Biological rhythms, melatonin and depression. Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May, 1986. Abstract: #13.
68. **Steiner M**, Werstiuk ES, Auffarth SE, Bean G. ³H-clonidine binding to membranes of platelets of depressed patients. Annual Meeting Society of Biological Psychiatry, Washington, DC, May 1986. Abstract: #244.
69. Guscott RG, **Steiner M**. A treatment model for postpartum psychoses. APA Annual Meeting, Washington, DC, May 1986. Abstract: #93.
70. **Steiner M**, Seggie J, Werstiuk ES. Biological rhythms, melatonin and depression. CCNP Annual Meeting, Vancouver, BC, May 1986. Abstract: #63.
71. **Steiner M**. Psychobiologic aspects of the menopausal syndrome. CCNP Annual Meeting, Vancouver, BC, May 1986. Abstract: #64.
72. **Steiner M**, Goldman S, Kirshenblat D, Brown GM. Serum melatonin: Implications for affective disorders? CCNP Annual Meeting, Vancouver, BC, May 1986. Abstract: #65.
73. **Steiner M**. The effects of gonadal hormones on brain & behavior. CCNP Annual Meeting, Vancouver, BC, May 1986. Abstract: #66.
74. Werstiuk ES, Auffarth SE, **Steiner M**. Platelet alpha-2-adrenergic receptors in depressed patients. CCNP Annual Meeting, Vancouver, BC, May 1986. Abstract: #71.
75. Werstiuk ES, Auffarth SE, Bean G, **Steiner M**. Treatment effects on ³H-clonidine binding to platelet membranes in depressed patients. Annual Meeting of the Canadian Society for Clinical Investigation, Toronto ON, September 1986. Abstract: #C-718.
76. Links PS, **Steiner M**, Wallace J, Munroe-Blum H. Borderline personality disorder: current research and implications for practice symposium. CPA Annual Meeting, Vancouver, BC, September 1986.
77. **Steiner M**. Psychoneuroendocrine assessment of borderline patients. CPA Annual Meeting, Vancouver, BC, September 1986.
78. **Steiner M**. Melatonin and the dexamethasone suppression test. Canadian Pineal Workshop, Lake Simcoe, ON, October 1986.
79. Werstiuk ES, **Steiner M**, Auffarth SE, Bean G. Platelet alpha-2-adrenergic receptors in depressed patients: The effect of desipramine and ECT. Annual Meeting of the Society for Neuroscience, Washington, DC, November 1986. Abstract: #340.2.
80. **Steiner M**. Predictors and correlates of changes in postpartum mood. ACNP Annual Meeting, Washington, DC, December 1986. Abstract: #54.
81. **Steiner M**. Treatment of premenstrual dysphoria. APA Annual Meeting, Chicago, IL, May 1987.

82. Burns TG, Werstiuk ES, **Steiner M**. Evaluation of studies on lymphocyte beta-adrenoceptors in depressive illness. CCNP Annual Meeting, Ottawa, ON, May 1987. Abstract: #W14.
83. Werstiuk ES, Auffarth SE, **Steiner M**. ³H-clonidine binding to intact human platelets and platelet membranes. CCNP Annual Meeting, Ottawa, ON, May 1987. Abstract: #W25.
84. Links PS, **Steiner M**, Mitton J. Confirmation of psychosis in borderlines. APA Annual Meeting, Chicago, IL, May 1987.
85. Fleming AS, **Steiner M**, Anderson VN. Hormonal and attitudinal correlations in maternal behavior during the early postpartum period in first-time mothers. Marcé Society, Stockholm, Sweden, September 1987.
86. Anderson VN, Fleming AS, **Steiner M**. Pregnancy and postpartum mood. Marcé Society, Stockholm, Sweden, September 1987.
87. Seggie J, **Steiner M**. Biological rhythms and affective disorders. CPA Annual Meeting, London, ON, September 1987. Abstract: p. 14.
88. Fleming AS, **Steiner M**, Anderson VN. Hormonal and mood correlates of maternal behavior in first-time mothers. Annual meeting of the American Psychosomatic Society, Toronto, ON, March 1988.
89. **Steiner M**, Pellettier JR, Gupta RN, Werstiuk ES. ECT and the neuroendocrine window. CCNP Annual meeting, Montreal, QC, May 1988. Abstract: #Th-65.
90. Werstiuk ES, Gupta RN, Fairman M, Coote M, **Steiner M**. Effects of ECT on leukocyte monoamine receptors in depressed patients. CCNP Annual meeting, Montreal, QC, May 1988. Abstract: #Th-63.
91. Links PS, **Steiner M**, Boiago I, Irwin D. Desipramine, lithium vs placebo in borderline patients. CCNP Annual, Montreal, QC, May 1988. Abstract: #Th-57.
92. Links PS, **Steiner M**, Huxley G. Familial occurrence of borderline personality. APA Annual meeting, Montreal, QC, May 1988. Abstract: #26B.
93. **Steiner M**, Werstiuk ES, Burns TG. The effects of ECT on lymphocyte beta-adrenergic receptors. Annual meeting of the Society of Biological Psychiatry, Montreal, QC, May 1988. Abstract: #293.
94. James N, Van Den Bos JL, **Steiner M**. L-tryptophan: A clinical overview. Annual meeting of the Society of Biological Psychiatry, Montreal, QC, May 1988. Abstract: #331.
95. Seggie J, **Steiner M**, Orpen G. Sheep and circadian rhythm regulation. 1st Annual Meeting of the Society for Research on Biological Rhythms, Charleston, SC, May 1988. Abstract: #50A.
96. Orpen G, **Steiner M**, Miceli MO. A horseradish peroxidase-wheat germ agglutinin (HRP-WGA) study of the efferent connections of the hamster SCN and adjacent regions of the medial hypothalamus. 1st Annual meeting of the SRBR, Charleston, SC, May 1988. Abstract: #38A.
97. **Steiner M**, Pellettier JR, Gupta RN, Werstiuk ES. ECT and the neuroendocrine window. 16th CINP, Munich, West Germany, August 1988. Abstract: Psychopharmacology 1988;96 Suppl:395.
98. **Steiner M**, Fleming AS, Anderson VN. Psychoneuroendocrinology of pregnancy and postpartum mood. ISPNE Congress, Groningen, The Netherlands, August 1988. Abstract: p. 279.
99. **Steiner M**, Werstiuk ES. Neuroendocrine and neurobiochemical responses as a probe into the mechanisms of action of ECT. ISPNE Congress, Groningen, The Netherlands, August, 1988. Abstract: p. 280.

100. Links PS, **Steiner M**. Significance of borderline personality disorder plus major depressive disorder. World Psychiatric Association Regional Symposium, Washington, DC, October 1988.
101. Miceli MO, **Steiner M**. Distribution of cholecystokinin (CCK) binding sites in Syrian hamster brain. Annual Meeting of the Society for Neuroscience, Toronto, ON, November 1988. Abstract: #145.8.
102. Seggie J, **Steiner M**, Martin S, Fawcett S, Fairman M, Simpson J. Retinal changes in depression. Annual Meeting of the Society for Neuroscience, Toronto, ON, November 1988. Abstract: #156.19.
103. Werstiuk ES, **Steiner M**. Adrenergic receptor function in depression. Annual Meeting of the Society for Neuroscience, Toronto, ON, November 1988. Abstract: #374.12.
104. **Steiner M**, Seggie J, Martin J, Fairman M, Simpson J. ECT reduces sensitivity to light. ACNP Annual meeting, San Juan, Puerto Rico, December 1988. Abstract: #24.
105. **Steiner M**, Links PS, Korzekwa M. Biological markers of depression in personality disorders. World Federation of Societies of Biological Psychiatry, Jerusalem, Israel April 1989. Abstract: p. 72.
106. Links PS, **Steiner M**, Boiago I, Irwin D. Management of depression in borderline personality disorder. World Federation of Societies of Biological Psychiatry, Jerusalem, Israel, April 1989. Abstract: p. 73.
107. **Steiner M**. LLPDD - Methodological issues: Have we learned from past mistakes? World Federation of Societies of Biological Psychiatry, Jerusalem, Israel, April 1989. Abstract: p. 78.
108. Links PS, Boiago I, **Steiner M**. Usefulness of lithium for borderline patients. Society of Biological Psychiatry Annual Meeting, San Francisco, CA, May 1989. Abstract: #177.
109. Huxley G, Stephenson-Cino P, Krames L, Ryan E, **Steiner M**. Coping with depression in the elderly: An educational model. Annual McMaster Workshop on Gerontological Research, Hamilton, ON, May 1989.
110. Links PS, Mitton J, **Steiner M**. Predicting outcome for borderline patients. APA Annual Meeting, San Francisco, CA, May 1989.
111. Links PS, **Steiner M**, Huxley G. Subtyping borderlines by family history. APA Annual Meeting, San Francisco, CA, May 1989.
112. Krames L, Ryan E, **Steiner M**, Stephenson-Cino P, Huxley G. Depression and wellness in a physically healthy community sample of the elderly. XIV International Congress of Gerontology, Acapulco, Mexico, June 1989. Abstract: p. 449.
113. **Steiner M**. Norepinephrine and behaviour. CPA Annual Meeting, St. John's, NF, September 1989.
114. Seggie J, **Steiner M**. Retinal changes in depression. Second Canadian Pineal Conference, Jackson's Point, ON, October 1989. Abstract: Clinical and Investigative Medicine 1990;13:A5.
115. Orpen G, **Steiner M**. Lack of direct hypothalamic projections to the pineal gland in the Syrian Hamster. Second Canadian Pineal Conference, Jackson's Point, ON, October 1989. Abstract: Clinical and Investigative Medicine 1990;13:A5.
116. **Steiner M**, Orpen G. The cholinergic supersensitive pigmented genetic rat as a potential animal model for studies of depression and disturbed circadian rhythms. Second Canadian Pineal Conference, Jackson's Point, ON, October 1989. Abstract: Clinical and Investigative Medicine 1990;13:A5.

117. Stephenson-Cino P, **Steiner M**, Ryan EB, Krames L, Huxley G. Depression in the elderly and its correlates in family practice. Canadian Association on Gerontology Annual Meeting, Ottawa, ON, October 1989.
118. Krames L, Stephenson-Cino P, Huxley G, Ryan EB, **Steiner M**. Group treatment benefits for depressed seniors. Canadian Association on Gerontology, Ottawa, ON, October 1989.
119. **Steiner M**, Ryan E, Huxley G, Stephenson-Cino P, Krames L. Health correlates of depressive symptoms in community elders. Annual Scientific Meeting of the Gerontological Society of America, Minneapolis, MN, November 1989. Abstract: #289.
120. **Steiner M**, Sota T, Orpen BG. Increased sensitivity to cholinergic agonists: a genetic trait. Annual Meeting of the Society for Neuroscience, 1989. Abstract: p. 96.
121. Orpen BG, Woskowska Z, **Steiner M**. Neural connections of the suprachiasmatic nucleus with midline thalamic nuclei. Annual Meeting of the Society for Neuroscience 1989. Abstract: p. 290.
122. Seggie J, **Steiner M**, Grof P, Mai F. Retinal changes in depression. Research Day, Royal Ottawa Hospital, Ottawa, ON, November 1989.
123. Lepage P, **Steiner M**. The fenfluramine challenge in women with LLPDD. Serotonin-System-Related Syndromes Meeting, Venice, Italy, March 1990. Abstract: #9.
124. **Steiner M**, MacMillan H, Seggie J. Depression, electrooculograms (EOG), and Arden ratios: Differential response to light and dark. Annual Meeting of the Society of Biological Psychiatry, New York, NY, May 1990. Abstract: Biological Psychiatry 1990;27:154A.
125. Orpen G, **Steiner M**. A genetic animal model for studies of depression and disturbed circadian rhythms. Meeting of the SRBR, Jacksonville, FL, May 1990. Abstract: p. 23.
126. **Steiner M**, Orpen G. A genetic animal model for studies of depression and disturbed circadian rhythms. Annual Meeting of the Society for Light Treatment and Biological Rhythms, New York, NY, May 1990. Abstract: p. 40.
127. Seggie J, MacMillan H, Griffith L, Shannon HS, **Steiner M**. Responses of the retinal pigmented epithelium to light and dark in depression. Annual Meeting of the Society for Light Treatment and Biological Rhythms, New York, NY, May 1990. Abstract: p. 11.
128. MacMillan H, **Steiner M**, Seggie J. Supersensitivity to light in depression. APA Annual Meeting, New York, NY, May 1990. Abstract: NR18.
129. Orpen G, **Steiner M**. A genetic animal model for studies of depression and disturbed circadian rhythms. CCNP Annual Meeting, Banff, AB, June 1990. Abstract: p. 71.
130. Seggie J, MacMillan H, Griffith L, Shannon HS, **Steiner M**. Responses of the retinal pigmented epithelium to light and dark in depression. CCNP Annual Meeting, Banff, AB, June 1990. Abstract: p. 74.
131. Werstiuk ES, Coote M, **Steiner M**. Platelet and leukocyte adrenergic receptors in depressed patients. CCNP Annual Meeting, Banff, AB, June 1990. Abstract: p. 77.
132. Korzekwa M, Huxley G, Lamont J, Milner R, **Steiner M**. LLPDD and thyroid function. ISPNE Congress, Buffalo, NY, August 1990. Abstract: Neuroendocrinology Letters 1990;12:308A.

133. Lepage P, Huxley G, Korzekwa M, Scordino K, Coote M, Lamont J, Milner R, **Steiner M**. The fenfluramine challenge in women with LLPDD. ISPNE Congres, Buffalo, NY, August 1990. Abstract: Neuroendocrinology Letters 1990;12:308B.
134. **Steiner M**. LLPDD - Methodological issues: Have we learned from past mistakes? CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #45.
135. **Steiner M**, MacMillan HL, Seggie J. Supersensitivity to light in depression. CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #116.
136. Korzekwa M, Huxley G, Lamont J, Milner R, **Steiner M**. TSH response to TRH in LLPDD. CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #115.
137. Lepage P, Huxley G, Korzekwa M, Scordino K, Coote M, Lamont J, Milner R, **Steiner M**. The fenfluramine challenge in women with LLPDD. CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #113.
138. Huxley G, Korzekwa M, Lepage P, Milner R, Lamont J, Scordino K, **Steiner M**. LLPDD and multi-axial diagnostic systems. CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #112.
139. Doyle W, Brodie P, Fairman M, Scordino K, **Steiner M**. Postpartum obsessive compulsive disorders. CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #114.
140. Links PS, **Steiner M**, Boiago I, Irwin D. Randomized trial of desipramine, lithium carbonate and placebo in borderline personality disorder. CPA Annual Meeting, Toronto, ON, September 1990. Abstract: #18.
141. Gupta RN, **Steiner M**. Determination of fluoxetine and norfluoxetine in serum by liquid chromatography with fluorescence detection. International Conference of Therapeutic Drug Monitoring and Toxicology, Barcelona, Spain, October 1990. Abstract: Química Clínica 1990;9:325.
142. Werstiuk ES, Coote M, **Steiner M**. Peripheral adrenergic receptor function in depressed patients. Annual Meeting of the Society for Neuroscience, St. Louis, MI, October 1990. Abstract: #164.15.
143. Ryan EB, **Steiner M**, Krames L, Stephenson-Cino P, Huxley G. Well-being among elders residing in the community: Application of the Self Evaluation of Life Function (SELF) Scale. Canadian Association on Gerontology, Victoria, BC, October 1990.
144. **Steiner M**, Ryan EB, Huxley G, Stephenson-Cino P, Krames L. Correlates of degree of depression among community elders with depressive symptoms. Annual Scientific Meeting of the Gerontological Society of America, Boston, MA, November 1990. Abstract: p. 226A.
145. Korzekwa M, Huxley G, Scordino K, Lepage P, Lamont J, Milner R, **Steiner M**. PMS and the thyroid axis. NASPOG Annual Meeting, Houston, TX, February 1991. Abstract: p. 41.
146. Huxley G, Korzekwa M, Lamont J, Milner R, Scordino K, **Steiner M**. LLPDD and multi-axial diagnostic systems. NASPOG Annual Meeting, Houston, TX, February 1991. Abstract: p. 13.
147. Fairman M, Scordino K, Doyle W, **Steiner M**. Postpartum psychiatric disorders: A family study. NASPOG Annual Meeting, Houston, TX, February, 1991. Abstract: p. 42.
148. Doyle W, Fairman M, Scordino K, Brodie P, **Steiner M**. Postpartum obsessive compulsive disorders. NASPOG Annual Meeting, Houston, TX, February 1991. Abstract: p. 43.

149. Lepage P, **Steiner M**. Serotonin and gender specific psychiatric disorders: An ethological hypothesis. Annual Meeting of the Society of Biological Psychiatry, New Orleans, LA, May 1991. Abstract: Biological Psychiatry, 1991;29:112A.
150. MacMillan H, Seggie J, **Steiner M**. Altered retinal function in depression. CCNP Annual Meeting, Hamilton, ON, June 1991. Abstract: #6.
151. Orpen G, DeHaan M, **Steiner M**. Circadian rhythm, sex and strain influences on muscarinic receptor binding in the CNS. CIMP Annual Meeting, Hamilton, ON, June 1991. Abstract: #T-11, p. 31.
152. Links P, **Steiner M**, Boiago I, Irwin D. Randomized trial of lithium, desipramine and placebo in borderline personality disorder. CIMP Annual Meeting, Hamilton, ON, June 1991. Abstract: #T-7, p. 27.
153. **Steiner M**, Orpen G. Muscarinic receptor binding in CNS: Strain, gender and circadian effects. International Conference on Chronobiology, Tel Aviv, Israel, June 1991. Abstract: p. 8.9.
154. **Steiner M**, MacMillan H, Seggie J. Supersensitivity to light in depression. International Conference on Chronobiology, Tel Aviv, Israel, June 1991. Abstract: p. 17.6.
155. Orpen G, **Steiner M**. Muscarinic receptor binding in CNS: Strain, gender and circadian effects. Annual Meeting of the IBRO World Congress of Neuroscience, Montreal, PQ, August 1991. Abstract: P54.38.
156. MacMillan H, Seggie J, **Steiner M**. Electroretinography in depression. Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May 1992. Abstract: Biological Psychiatry 1992;31:74A.
157. Orpen G, **Steiner M**. The cholinergic supersensitive *pigmented* rat - Is it a better animal model for depression? Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May 1992. Abstract: Biological Psychiatry 1992;31:222A.
158. Werstiuk ES, Coote M, **Steiner M**. Effects of ECT on plasma noradrenaline, MHPG and peripheral adrenergic receptor function in depressed patients. CCNP Annual Meeting, Saskatoon, SA, June 1992.
159. Fleming A, Corter C, Franks P, Surbey M, Schneider B, **Steiner M**. Postpartum factors related to mother's attraction to newborn infant odours. ISPOG Congress, Stockholm, June 1992. Abstract: Journal Psychosomatic Obstetrics and Gynaecology 1992;13 Suppl 1:205.
160. **Steiner M**. The chronobiology of female specific mood disorders. ISPOG Congress, Stockholm, June 1992. Abstract: Journal Psychosomatic Obstetrics and Gynaecology 1992;13 Suppl 1:206.
161. Werstiuk ES, Coote M, **Steiner M**. Plasma catecholamines and adrenergic receptor function in depressed patients. International Catecholamine Symposium. Amsterdam, June 1992. Abstract: p. 346.
162. Lepage P, **Steiner M**. Serotonin and gender specific psychiatric disorders. CIMP Congress, Nice, France, June 1992. Abstract: Clinical Neuropharmacology 1992;15 Suppl 1:37B.
163. **Steiner M**. The chronobiology of female specific mood disorders. CIMP Congress, Nice, France, June 1992. Abstract: Clinical Neuropharmacology 1992;15 Suppl 1:46B.
164. **Steiner M**, MacMillan H, Griffith L, Martin J, Shannon H, Seggie J. Supersensitivity to light in depression. CIMP Congress, Nice, France, June 1992. Abstract: Clinical Neuropharmacology 1992;15 Suppl 1:48B.
165. **Steiner M**, Orpen G. The cholinergic supersensitive *pigmented* rat - Is it a better animal model for depression? CIMP Congress, Nice, France, June 1992. Abstract: Clinical Neuropharmacology 1992;15: Suppl 1:69B.

166. Fairman M, Brodie P, Doyle W, Scordino K, **Steiner M**. Postpartum disorders: A family study. International Conference of the Marcé Society, Edinburgh, UK, September 1992. Abstract: p. 50.
167. Doyle W, Fairman M, Scordino K, Brodie P, **Steiner M**. Postpartum obsessive compulsive disorders. International Conference of the Marcé Society, Edinburgh, UK, September 1992. Abstract: p. 49.
168. Brodie P, Fairman M, Doyle W, **Steiner M**. Postpartum depression and primary narcissism. International Conference of the Marcé Society, Edinburgh, UK, September 1992. Abstract: p. 44.
169. **Steiner M**, Coote M, Griffith L, Shannon H, Werstiuk E. Plasma catecholamines and adrenergic receptor function in depressed patients. CPA Annual Meeting, Montreal, QC, September 1992. Abstract: p. 67.
170. **Steiner M**, MacMillan H, Seggie J. Electroretinography in depression. CPA Annual Meeting, Montreal, QC, September 1992. Abstract: p. 5.
171. **Steiner M**, Fairman M, Korzekwa M, Lepage P, Tam W. LLPDD: Should it be included as a separate diagnosis in the DSM-IV? CPA Annual Meeting, Montreal, QC, September 1992. Abstract: p. 29.
172. MacMillan H, Trojan W, Seggie J, **Steiner M**. The dark adaptation threshold as a biological marker in adolescent mood disorders. Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 1993. Abstract: Biological Psychiatry 1993;33:77A.
173. **Steiner M**. Light therapy - how does it work? World Congress of Psychiatry, Rio De Janeiro, Brazil, June 1993. Abstract: Session 010.
174. **Steiner M**, MacMillan H, Griffith L, Shannon H, Seggie J. ERG studies in depression - is it relevant? World Congress of Psychiatry, Rio De Janeiro, Brazil, June 1993. Abstract: Session 046.
175. **Steiner M**. Serotonin and gender specific psychiatric disorders: an ethological hypothesis. Annual Meeting Atlantic Provinces Psychiatric Association, Baddeck, NS, June 1993.
176. Fleming J, Sanford M, **Steiner M**, Streiner D. Phenelzine in adolescent depression: preliminary findings from a controlled trial. 40th Annual Meeting American Academy of Child & Adolescent Psychiatry, San Antonio, TX, October 1993.
177. **Steiner M**. Sex differences in serotonergic regulation: treatment implications in depression. National Institute of Mental Health (NIMH), Bethesda, MD, November 1993.
178. **Steiner M**. Fluoxetine in the treatment of LLPDD: a multicentre, placebo-controlled, double-blind trial. ACNP Annual Meeting, Honolulu, HI, December 1993. Abstract: p. 256.
179. **Steiner M**. Severe premenstrual dysphoria, affective disorders and the DSM-IV. 22nd Annual Meeting of NASPOG, San Diego, CA, February 1994.
180. **Steiner M**. Mood disorders with postpartum onset: A family study. 22nd Annual Meeting of NASPOG, San Diego, CA, February 1994.
181. **Steiner M**, Fairman M, Coote M, Lepage P, Tam W. Serotonergic dysregulation in LLPDD. 22nd Annual Meeting of NASPOG, San Diego, CA, February 1994.
182. **Steiner M**. The treatment of mood disorders with postpartum onset: a prospective study. CINP Regional Workshop on Critical Issues in the Treatment of Affective Disorders, Paris, France, March 1994.

183. **Steiner M**, Fairman M, Korzekwa M, Lamont J. Severe PMDD, affective disorders and the DSM-IV. Women's Health: A National Multidisciplinary Conference. McMaster University, Hamilton, ON, April 1994.
184. **Steiner M**. Fluoxetine in the treatment of LLPDD: A multicentre, placebo-controlled double-blind trial. Women's Health: A National Multidisciplinary Conference. McMaster University, Hamilton, ON, April 1994.
185. Coote M, Fairman M, Trojan W, Yatham L, Lepage P, Tam W, **Steiner M**. Serotonergic function in LLPDD. Women's Health: A National Multidisciplinary Conference. McMaster University, Hamilton, ON, April 1994.
186. Tam W, Brodie P, Fairman M, Doyle W, **Steiner M**. Admitting mothers with their babies. Women's Health: A National Multidisciplinary Conference. McMaster University, Hamilton, ON, April 1994.
187. **Steiner M**, Fairman M, Doyle W. Mood disorders with postpartum onset: A family study. Society of Biological Psychiatry Annual Meeting, Philadelphia, PA, May 1994. Abstract: Biological Psychiatry 1994;35:729.
188. **Steiner M**, Fairman M, Korzekwa M, Lamont J. Severe premenstrual dysphoria, affective disorders and the DSM-IV. Society of Biological Psychiatry Annual Meeting, Philadelphia, PA, May 1994. Abstract: Biological Psychiatry 1994;35:650.
189. Tam W, **Steiner M**. The treatment of mood disorders with postpartum onset: A prospective study. First International Conference on Bipolar Disorder, University of Pittsburgh, Pittsburgh, PA, June 1994.
190. **Steiner M**, Tam W, Fairman M. A multidisciplinary team approach to the treatment of postpartum psychiatric disorders: Admitting mothers and babies to an inpatient psychiatric service. The 8th Annual Postpartum Support International Conference, Toronto, ON, June 1994.
191. Lam RW, Gorman C, Michalon M, **Steiner M**, Levitt AJ. A Canadian multicentre, placebo-controlled study of fluoxetine in seasonal affective disorder. SLTBR Annual Meeting, Washington, DC, June 1994. Abstract: p.6.
192. **Steiner M**. Fluoxetine in the treatment of LLPDD: A multicentre, placebo-controlled, double-blind trial. CINP Congress, Washington, DC, June 1994. Abstract: Neuropsychopharmacology 1994;10:100S.
193. **Steiner M**, Fairman M, Doyle W. Mood disorders with postpartum onset: A family study. CINP Congress, Washington, DC, June 1994. Abstract: Neuropsychopharmacology 1994;10:176S.
194. **Steiner M**. Fluoxetine in the treatment of LLPDD: A multicentre, placebo-controlled, double-blind trial. XIV FIGO World Congress, Montreal, PQ, September 1994. Abstract: International Journal Gynecology & Obstetrics 1994;46 Suppl 2:122.
195. **Steiner M**, Coote M, Fairman M, Trojan W, Yatham L, Lepage P, Tam W. Serotonergic dysfunction in PMDD. ECNP Annual Congress, Jerusalem, Israel, October 1994.
196. **Steiner M**. Fluoxetine in the treatment of LLPDD. ECNP Annual Congress, Jerusalem, Israel, October 1994.
197. Fairman M, Trojan W, Wilkins A, **Steiner M**. The effect of SSRIs on menstrual cycle length: Results of a prospective study of fluoxetine in the treatment of LLPDD. NASPOG Annual Meeting, Washington, DC, February 1995.
198. **Steiner M**, Lamont J. The effect of fluoxetine on the menstrual cycle. XI ISPOG Congress, Basel, Switzerland, May 1995. Journal of Psychosomatic Obstetrics & Gynecology 1995;16:132.

199. **Steiner M**, Fleming A, Corter C, Coote M, Lawrence J. Cortisol and maternal attraction to infant odour. XI ISPOG Congress, Basel, Switzerland, May 1995. *Journal of Psychosomatic Obstetrics and Gynecology* 1995;16:132.
200. **Steiner M**. The prospective measurement of premenstrual dysphoria. XI ISPOG Basel, Switzerland, May 1995. *Journal of Psychosomatic Obstetrics and Gynecology* 1995;16:133.
201. **Steiner M**. Measuring efficacy of treatment in premenstrual dysphoria: Overcoming the challenge. 2nd International Conference on New Directions in Affective Disorders, Jerusalem, Israel, September 1995. Abstract: p. P94.
202. **Steiner M**, Lamont J. The effect of fluoxetine on menstrual cycle length: Is it significant? 2nd International Conference on New Directions in Affective Disorders, Jerusalem, Israel, September 1995. Abstract: p. P95.
203. Pulver M, Fairman M, **Steiner M**. Three educational approaches for peri-menopausal women: A pilot study. NASPOG, Sante Fe, NM, February 1996.
204. Dunn E, Coote M, Browne G, **Steiner M**. Biological "markers" in dysthymia. Society of Biological Psychiatry Annual Meeting, New York, NY, May 1996. Abstract: #92. *Biological Psychiatry* 1996;39:526.
205. Djuric VJ, Overstreet DH, Bienenstock J, **Steiner M**, Perdue MH. Cholinergic hypersensitivity in intestinal allergy and depression. Society of Biological Psychiatry Annual Meeting, New York, NY, May 1996. Abstract: #93. *Biological Psychiatry* 1996;39:527.
206. **Steiner M**, Coote M, Tran A, Corter C, Fleming A. Cortisol and maternal attraction to infant odour. Society of Biological Psychiatry Annual Meeting, New York, NY, May 1996. Abstract: #94. *Biological Psychiatry* 1996;39:527.
207. **Steiner M**, Coote M, Tran A, Corter C, Fleming A. Cortisol and maternal attraction to infant odour. CINP Congress, Melbourne, Australia, June 1996. Abstract: #P-6-8. *European Neuropsychopharmacology* 1996;6:58.
208. **Steiner M**, Dunn E, Coote M, Browne G. Serotonergic dysregulation in dysthymia. CINP Congress, Melbourne, Australia, June 1996. Abstract: #P-4-21. *European Neuropsychopharmacology* 1996;6:50.
209. **Steiner M**, Dunn E, Coote M, Browne G. Dysthymia and the serotonergic cascade. World Congress of Psychiatry, Madrid, Spain, August 1996. Abstract: p. 110.
210. Fairman M, Tam W, **Steiner M**. Antepartum prophylaxis for pregnant women with a history of major depression. Marcé Society, London, UK, September 1996.
211. Cooper N, Fairman M, Pulver M, **Steiner M**. Depression with postpartum onset: Focus groups as a model for improving care. APA Women's Health Conference, Washington, DC, September 1996. Abstracts: p. 148.
212. Dunn E, Coote M, Browne G, **Steiner M**. Hormonal and serotonergic measurements in patients with dysthymia. CPA Annual Meeting, Quebec, PQ, October 1996. Abstracts: P13.
213. Djuric V, Radford K, Achong M, Cox G, Dunn E, **Steiner M**. Naloxone ameliorates bronchoconstriction during pulmonary immediate hypersensitivity. Proceedings of the 3rd International Congress of the International Society for Neuroimmunomodulation, Bethesda, MD, November 1996. Abstract: p. 108.

214. Djuric V, Overstreet DH, Crosthwaite D, Dunn E, **Steiner M**. Continuous access to sucrose induces depressive-like behaviour in the rat. Society for Neuroscience Annual Meeting, Washington, DC, November 1996. Abstract: Book of Abstracts 22:1334.
215. Djuric V, Cox G, Smith L, Dunn E, **Steiner M**. Protective effect of acute stress on allergen-induced bronchoconstriction in the rat. American Academy of Allergy, Asthma, and Immunology Annual Meeting. San Francisco, CA, February 1997. Abstract: Journal of Allergy and Clinical Immunology 1997; 99:S416.
216. Cooper N, Fairman M, Macdougall M, Tam W, **Steiner M**. Depression with postpartum onset - is childhood sexual abuse a risk factor in its development? NASPOG Annual Meeting, Chicago, IL, February 1997.
217. Fairman M, Macdougall M, Cooper N, Tam W, **Steiner M**. Depression with postpartum onset: Focus groups as a model for improving care. NASPOG Annual Meeting, Chicago, IL, February 1997.
218. Dunn E, Helpard B, **Steiner M**. Sertraline and cytochrome P450 3A4 in dysthymia. Society of Biological Psychiatry Annual Meeting, San Diego, CA, May 1997. Biological Psychiatry 1997;41:34S.
219. Dunn E, Coote M, Browne G, **Steiner M**. Hormonal and serotonergic measurements in patients with dysthymia. Society of Biological Psychiatry Annual Meeting, San Diego, CA, May 1997. Biological Psychiatry 1997;41:34S.
220. Djuric V, Crosthwaite D, Gurunlian L, Dragomir A, Dunn E, **Steiner M**. Continuous access to sucrose and serotonergic sensitivity in the rat. Society of Biological Psychiatry Annual Meeting, San Diego, CA, May 1997. Biological Psychiatry 1997;41:44S.
221. **Steiner M**, Coote M, Wilkins A, Dunn E. Gonadal hormones and serotonergic function in women with premenstrual dysphoria. Society of Biological Psychiatry Annual Meeting, San Diego, CA, May 1997. Biological Psychiatry 1997;41:120S.
222. **Steiner M**, Browne G, Roberts JG, Dunn E, Bell B, Jamieson E. Prevalence of dysthymia in primary care. APA Annual Meeting, San Diego, CA, May 1997.
223. **Steiner M**, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with PMDD. NCDEU Annual Meeting, Boca Raton, FL, May 1997. Abstract #91.
224. Djuric V, Roberts S, Overstreet DH, Chen Y, Wang L, **Steiner M**, Tougas G. Autonomic balance and intestinal anaphylaxis in the rat. American Gastroenterology Association, Washington, DC, May 1997.
225. **Steiner M**, Coote M, Wilkins A, Dunn E. Gonadal hormones and serotonergic function in women with premenstrual dysphoria. 6th World Congress of Biological Psychiatry, Nice, France, June 1997. Biological Psychiatry 1997;42:105S.
226. Djuric V, Crosthwaite D, Gurunlian L, Dragomir A, Dunn E, **Steiner M**. Continuous access to sucrose and serotonergic sensitivity in the rat. 6th World Congress of Biological Psychiatry, Nice, France, June 1997. Biological Psychiatry 1997;42:105S.
227. Dunn E, Helpard B, **Steiner M**. Sertraline and cytochrome P450 3A4 in dysthymia. World Congress of Biological Psychiatry, Nice, France, June 1997. Biological Psychiatry 1997;42:112S.
228. Dunn E, Coote M, Browne G, **Steiner M**. Hormonal and serotonergic measurements in patients with dysthymia. World Congress of Biological Psychiatry, Nice, France, June 1997. Biological Psychiatry 1997;42:112S.

229. **Steiner M**, Browne G, Roberts JG, Dunn E, Bell B, Jamieson E. Prevalence of dysthymia in primary care. World Congress of Biological Psychiatry, Nice, France, June 1997. *Biological Psychiatry* 1997;42:260S.
230. **Steiner M**, Coote M, Wilkins A, Dunn E. Biological correlates of irritability in women with premenstrual dysphoria. ECNP Congress, Vienna, Austria, September 1997. Abstract: *Eur Neuropsychopharmacol* 1997;7 Suppl 2:S172.
231. Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Bell B, Webb M, Jamieson E. A randomized trial of the effectiveness of sertraline vs interpersonal therapy (IPT) alone or in combination, for people with dysthymia. ECNP Congress, Vienna, Austria, September 1997.
232. Djuric V, Overstreet DH, Dragomir A, **Steiner M**. Carbohydrate-rich diet in experimental models of depression. ECNP Congress, Vienna, Austria, September 1997.
233. Dunn E, Coote M, Browne G, **Steiner M**. Interactions of steroid hormones and the serotonergic cascade in patients with dysthymia. ECNP Congress, Vienna, Austria, September 1997.
234. Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Bell B, Dunn E. Sertraline vs interpersonal psychotherapy (IPT) alone or in combination for people with dysthymia in primary care (a randomized clinical trial, 6 month follow-up). CPA Annual Meeting, Calgary, AB, September 1997.
235. Djuric V, Overstreet DH, Cox G, Smith L, Dragomir A, **Steiner M**. Airway hyperresponsiveness in an animal model of cholinergic sensitivity. Society for Neuroscience Annual Meeting, New Orleans, LA, October 1997. Abstract: p 998.
236. Bell B, Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Chalklin L, Mills M, Webb M, Jamieson E, Dunn E. The prevalence, co-morbidity and costs of dysthymia in primary care: under recognition of the mix of problems. WPA Conference, Jerusalem, Israel, November 1997. Abstract: p. 23.
237. **Steiner M**, Dunn E, Coote M, Helpard B, Browne G, Bell B. Biological markers in dysthymia. WPA Conference, Jerusalem, Israel, November 1997. Abstract p. 24.
238. Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Bell B, Webb M, Jamieson E, Dunn E. A randomized trial of the effectiveness of sertraline vs interpersonal therapy (IPT) alone or in combination, for people with dysthymia. WPA Conference, Jerusalem, Israel, November 1997. Abstract: p. 24.
239. **Steiner M**. Sertraline and IPT in dysthymia: a randomized clinical trial. ACNP Annual Meeting, Kamuela, HI, December 1997.
240. Wang L, Chen Y, Djuric V, **Steiner M**, Overstreet DH, Tougas G. Stress alters the autonomic response to gastric distention in rats. CAG Annual Meeting, Banff, AB, March 1998.
241. Cox G, Djuric V, Overstreet DH, Smith L, Dragomir A, **Steiner M**. Role of the cholinergic system in aggravating allergen-induced airway responses. ALS/ATS International Conference, Chicago, IL, April 1998.
242. Bell B, Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Dunn E. The prevalence of dysthymia in primary care. APA Annual Meeting, Toronto, ON, May 1998.
243. Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Bell B, Dunn E. IPT & sertraline in dysthymia (6 month follow-up). APA Annual Meeting, Toronto, ON, May 1998.
244. Djuric V, Overstreet DH, Dragomir A, Smith L, Cox G, **Steiner M**. Experimental asthma in a genetic animal model of depression. Society of Biological Psychiatry Annual Meeting, Toronto, ON, May 1998.

245. Dragomir A, Djuric V, **Steiner M**. Dual effect of glucocorticoids on 5-HT1A receptor sensitivity. Society of Biological Psychiatry Annual Meeting, Toronto, ON, May 1998.
246. Dunn E, Coote M, Helpard B, Jones M, Roberts JG, Browne G, Bell B, **Steiner M**. Surrogate markers in the treatment of dysthymia. Society of Biological Psychiatry Annual Meeting, Toronto, ON, May 1998.
247. **Steiner M**, Fleming A, Stallings J, Corter C, Worthman C. Cortisol and testosterone correlates of affective responses to infant cry and odour stimuli in new parents. Society of Biological Psychiatry Annual Meeting, Toronto, ON, May 1998.
248. Wang L, Chen Y, Djuric V, **Steiner M**, Overstreet DH, Tougas G. Acute stress increases the vagal response to gastric distention (GD) in a rat model of cholinergic hypersensitivity. American Gastroenterological Association and American Association for the Study of Liver Diseases Annual Meeting, New Orleans, LA. May 1998.
249. Wang L, Djuric V, Blennerhassett PA, **Steiner M**, Overstreet DH, Collins SM, Tougas G. Increased worm expulsion and vagal response to gastric distention (GD) following *T. Spiralis* infection in a rat model of cholinergic hyper-responsiveness. American Gastroenterological Association and American Association for the Study of Liver Diseases Annual Meeting, New Orleans, LA, May 1998.
250. **Steiner M**, Born L, Fairman M, Glavac Petric, Tam W. Subclinical hypothyroidism in postpartum depression. ISPOG Annual Meeting, Washington, DC, June 1998. Abstract: #15.
251. Fairman M, Glavac Petric I, Tam W, **Steiner M**. Antepartum prophylaxis for pregnant women with a history of major depression. ISPOG Annual Meeting, Washington, DC, June, 1998. Abstract: #21.
252. Glavac Petric I, Cooper N, **Steiner M**. Depression with postpartum onset: how effective is the support group model? ISPOG Annual Meeting, Washington, DC, June 1998. Abstract: #29.
253. **Steiner M**. SSRIs in the treatment of premenstrual dysphoria. ISPOG Annual Meeting, Washington, DC, June 1998. Abstract: #12.
254. Dunn E, **Steiner M**, Browne G, Bell B, Roberts JG. Is there an optimal dose of sertraline in the treatment of dysthymia? NCDEU Annual Meeting, Boca Raton, FL, June 1998.
255. **Steiner M**, Browne G, Roberts JG, Gafni A, Byrne C, Bell B, Dunn E. Sertraline and IPT in dysthymia: one year follow-up. NCDEU, Boca Raton, FL, June 1998.
256. Fairman M, Glavac Petric I, Tam W, **Steiner M**. Depression, past or present: an antepartum prophylaxis. Marcè Society, Iowa City, IA, June 1998. Abstract: Archives of Women's Mental Health 1999;2:120.
257. **Steiner M**, Born L, Fairman M, Glavac Petric I, Tam W. Subclinical hypothyroidism in postpartum depression. Marcè Society, Iowa City, IA, June 1998. Abstract: Archives of Women's Mental Health 1999;2:137.
258. Glavac Petric I, Cooper N, **Steiner M**. Depression with postpartum onset: how effective is the support group model? Marcè Society, Iowa City, IA, June 1998. Abstract: Archives of Women's Mental Health 1999;2:129.
259. Browne G, **Steiner M**, Gafni RJ, Byrne C, Bell B, Dunn E. Sertraline and IPT in dysthymia: one year follow-up. CINP, Glasgow, Scotland, July 1998. Abstract: The International Journal of Neuropsychopharmacology 1999;2:S71.
260. Dragomir A, Djuric V, **Steiner M**. Glucocorticoid-dependent modulation of 5-HT1A receptor function. ISPNE Congress, Trier, Germany, August 1998.

261. **Steiner M**, Gwirtsman HE, Bell B, Ravindran AV, Browne G, Dunn E. Dysthymia: the forgotten depression. CPA Annual Meeting, Halifax, NS, September 1998. Abstract: #S8.
262. Bell B, Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Dunn E. The prevalence of dysthymia in primary care. CPA Annual Meeting, Halifax, NS, September 1998. Abstract: #S8b.
263. Browne G, **Steiner M**, Roberts JG, Gafni A, Byrne C, Dunn E. Sertraline and IPT in dysthymia: one year follow-up. CPA Annual Meeting, Halifax, NS, September 1998. Abstract: #S8d.
264. Dunn E, **Steiner M**, Browne G, Roberts JG, Bell B. Is there an optimal dose of sertraline in the treatment of dysthymia? CPA Annual Meeting, Halifax, NS, September 1998. Abstract: #S8e.
265. **Steiner M**. Menopause and the brain. CPA Annual Meeting, Halifax, NS, September 1998. Abstract: #S5.
266. **Steiner M**. Stress and gender specificity of the serotonergic cascade. 2nd World Congress on Stress, Melbourne, Australia, October 1998.
267. Djuric VJ, Overstreet DH, Tougas G, **Steiner M**. The flinders sensitive line rat as a model in psychosomatic medicine; 2nd World Congress on Stress, Melbourne, Australia, October 1998.
268. **Steiner M**, Browne G, Roberts JG, Gafni A, Byrne C, Bell B, Dunn E. Sertraline and IPT in dysthymia: one-year follow-up. ECNP Annual Meeting. Paris, France, October 1998. Abstract: European Neuropsychopharmacology 1998;8:S202.
269. **Steiner M**, Romano S, Babcock S, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Shuler C. Fluoxetine's efficacy in improving physical symptoms associated with PMDD. NASPOG Annual Meeting, Maui, HI, February 1999. Abstract: p. 34.
270. Dunn E, **Steiner M**. PMDD: Is severity of symptoms associated with polymorphism in the promoter region of the serotonin transporter gene? NASPOG Annual Meeting, Maui, HI, February 1999. Abstract: p. 35.
271. Boulter M, Macdougall M, **Steiner M**. Characteristics of women recruited for a randomized controlled trial of paroxetine and estrogen in treatment of depression at menopause. NASPOG Annual Meeting, Maui, HI, February 1999. Abstract: p. 40.
272. Brown E, Romano SJ, Pearlstein T, Schmidt PJ, **Steiner M**. Comparing fluoxetine's efficacy in improving mood, physical, and social impairment symptoms associated with PMDD across three randomized placebo-controlled clinical trials. NASPOG Annual Meeting, Maui, HI, February 1999. Abstract: p. 46.
273. Born L, **Steiner M**. A gender-specific measure of irritability. NASPOG Annual Meeting, Maui, Hawaii, February 1999. Abstract: p. 66.
274. Cox G, Djuric V, Hu X-A, Tam T, Wang M, Kamath M, **Steiner M**, Tougas G. Allergic airways responses are associated with enhanced parasympathetic tone. ALA/ATS International Conference, San Diego, April 1999. Abstract: American Journal of Respiratory and Critical Care Medicine 1999;159:A535.
275. Dunn E, **Steiner M**. Premenstrual dysphoric disorder (PMDD): is severity of symptoms associated with polymorphism in the promoter region of the serotonin transporter gene? 43rd Annual CSCC-CAMB Conference, Winnipeg, Manitoba, May 1999. Clinical Biochemistry 1999;32;306.
276. **Steiner M**, Romano S, Babcock S. Fluoxetine's efficacy in improving physical symptoms associated with PMDD. Society for Biological Psychiatry's Annual Meeting, Washington, DC, May 1999.

277. **Steiner M**, Steinberg S, Stewart D et al. Fluoxetine's efficacy in improving physical symptoms associated with PMDD: results from a multi-site, randomized, placebo-controlled trial. APA Annual Meeting, Washington, DC, May 1999. Abstract: p. 18.
278. Wang L, Djuric VJ, Blennerhassett, PA, **Steiner M**, Overstreet DH, Collins SM, Tougas G. Cholinergic modulation of intestinal inflammation. Annual Meeting of American Gastroenterological Association and American Association for the Study of Liver Diseases, Orlando, FL, May 1999.
279. Brown E, Romano SJ, Pearlstein T, **Steiner M**. Comparing fluoxetine's efficacy in improving mood, physical and social impairment symptoms associated with PMDD across three randomized, placebo-controlled clinical trials. NCDEU, Boca Raton, FL, June 1999. Abstract: #54.
280. **Steiner M**, Romano SJ, Dillon J. Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD. 7th Annual Congress on Women's Health & Gender-Based Medicine, Hilton Head, South Carolina, June 1999. Abstract: Journal of Women's Mental Health & Gender-Based Medicine 1999;8:713.
281. Fleming A, Stallings J, **Steiner M**. Glucocorticoids and maternal responsiveness in human mothers. Annual Meeting of the Society for Behavioral Neuroendocrinology, Charlottesville, VA, June 1999.
282. **Steiner M**, Romano SJ, Babcock S, McCray S, Dillon J. Fluoxetine's efficacy in PMDD: additional analysis. World Congress of Psychiatry, Hamburg, Germany, August 1999.
283. **Steiner M**, Romano SJ, Babcock S. Fluoxetine improves physical symptoms associated with PMDD. World Congress of Psychiatry, Hamburg, Germany, August 1999.
284. **Steiner M**, Romano SJ, Babcock S, McCray S, Dillon JA. Efficacy of fluoxetine in improving mood symptoms, physical symptoms, and social impairment in patients with PMDD. ECNP Congress, London, UK, September 1999. Abstract: European Neuropsychopharmacology 1999;9:S208.
285. **Steiner M**, Romano SJ, Babcock S. Fluoxetine's efficacy in improving physical symptoms associated with PMDD. ECNP Congress, London, UK, September 1999. Abstract: European Neuropsychopharmacology 1999;9:S208.
286. Browne G, **Steiner M**, Roberts JG, Gafni A, et al. The two-year effects and expense of sertraline versus interpersonal psychotherapy (IPT) alone or combined for people with dysthymia in primary care. 2nd Thematic Conference, Geneva, Switzerland, October 1999.
287. Gafni A, Roberts JG, Browne G, **Steiner M**, et al. Economic consequences of combining pharmacotherapy with psychotherapy for dysthymia in primary care. 2nd Thematic Conference, Geneva, Switzerland, October 1999.
288. **Steiner M**, Romano SJ, Babcock S, McCray S, Dillon J. Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD: results from a multi-site, randomized, double-blind, placebo-controlled trial. International Congress on Women's Health Issues, San Francisco, CA, January 2000.
289. Fairman M, **Steiner M**. Antepartum prevention in women at high risk for postpartum depression. NASPOG Annual Meeting, St. Petersburg, FL, March 2000.
290. **Steiner M**, Macdougall M. Sexual functioning in women treated with specific serotonin reuptake inhibitors for premenstrual dysphoric disorder. NASPOG Annual Meeting, St. Petersburg, FL, March 2000.

291. **Steiner M**, Judge R, Babcock S, McCray S, Dillon J. Efficacy of fluoxetine in improving mood symptoms, physical symptoms, and social impairment in patients with PMDD. NASPOG Annual Meeting, St. Petersburg, FL, March 2000.
292. Born L, **Steiner M**. Gender differences in a self-report survey on irritability. NASPOG Annual Meeting, St. Petersburg, FL, March 2000.
293. **Steiner M**, Browne G, Roberts JG, Gafni A, Byrne C, Bell B, Dunn E. Treating dysthymia in primary care: sertraline vs IPT (a two-year followup). Society of Biological Psychiatry, Chicago, IL, May 2000. Abstract: Biological Psychiatry 2000;47:91S.
294. **Steiner M**, Browne G, Roberts JG, Gafni A, Byrne C, Bell B, Dunn E. Treating dysthymia in primary care: sertraline vs IPT. APA Annual Meeting, Chicago, IL, May 2000. Abstract: #92B.
295. Yatham LN, **Steiner M**, Liddle PF, Shiah I-S, Lam RW, Zis AP, Coote M. A PET study of brain 5-HT₂ receptors and their correlation with platelet 5-HT₂ receptors. Society of Biological Psychiatry, Chicago, IL, May 2000. Abstract: Biological Psychiatry 2000;47:95S.
296. Djuric VJ, Kamath VM, Overstreet DH, **Steiner M**. Parasympathetic rebound following stress in four rat strains. Society of Biological Psychiatry, Chicago, IL, May 2000. Abstract: Biological Psychiatry 2000;47:147S.
297. **Steiner M**, Judge R, Brown E, Dillon J, Johnson R. Fluoxetine improves social functioning in women with PMDD. APA Annual Meeting, Chicago, IL, May 2000.
298. **Steiner M**, Judge R, Brown E, Dillon J, Johnson R. Fluoxetine improves social functioning in women with PMDD. NCDEU Annual Meeting, Boca Raton, FL, May 2000.
299. **Steiner M**, Judge R, Brown E, Dillon J, Johnson R. Fluoxetine improves social functioning in women with PMDD. Congress on Women's Mental Health, Hilton Head, SC, June 2000. Abstract: Journal of Women's Health & Gender-Based Medicine 2000;9:452.
300. **Steiner M**, Judge R, Brown E, Dillon J. Fluoxetine improves social functioning in women with PMDD. CINP Annual Meeting, Brussels, Belgium, July 2000.
301. **Steiner M**, Judge R, Brown E, Dillon J. Fluoxetine's effect on food cravings during the luteal phase in women with PMDD. CINP Annual Meeting, Brussels, Belgium, July 2000.
302. Brown E, Judge R, Pearlstein T, **Steiner M**. Fluoxetine's efficacy in PMDD: effect size analysis. CINP Annual Meeting, Brussels, Belgium, July 2000.
303. **Steiner M**, Judge R, Babcock S. Fluoxetine's efficacy in improving physical symptoms associated with PMDD. CINP Annual Meeting, Brussels, Belgium, July 2000.
304. **Steiner M**, Judge R, Brown E, Dillon J. Fluoxetine improves social functioning in women with PMDD. BAP Annual Meeting, Cambridge, England, July 2000.
305. Born L, **Steiner M**. Depression with postpartum onset: the course of treatment in euthyroid, antibody positive and antibody negative women. Marcé Biennial International Conference, Manchester, England, September 2000. Abstract: Archives of Women's Mental Health 2000;3:125.
306. **Steiner M**, Judge R, Brown E, Dillon J. Fluoxetine improves social functioning in women with PMDD. FIGO World Congress of Gynecology and Obstetrics, Washington, D.C. September 2000. Abstract: International Journal of Gynecology and Obstetrics 2000;70 Suppl 3:99.

307. **Steiner M**, Judge R, Brown E, Dillon J. Fluoxetine's effect on food cravings during the luteal phase in women with premenstrual dysphoric disorder (PMDD). FIGO World Congress of Gynecology and Obstetrics, Washington, D.C. September 2000. Abstract: International Journal of Gynecology and Obstetrics 2000; 70 Suppl 4:147.
308. **Steiner M**, Trzepacz P, Brown E. Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial. ECNP Congress, Munich, Germany, September, 2000. Abstract: European Neuropsychopharmacology 2000;10 Suppl 3:226.
309. **Steiner M**, Trzepacz P, Brown E. Fluoxetine improves work efficiency in women with PMDD. Annual Academy of Psychosomatic Medicine Meeting, Palm Springs, CA, November 2000.
310. **Steiner M**, Judge R, Babcock S, Dillon J. Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD. Annual Academy of Psychosomatic Medicine Meeting, Palm Springs, CA, November 2000.
311. **Steiner M**, Trzepacz, Brown E. PMDD and work efficiency: response to fluoxetine in a randomized clinical trial. 1st International Forum on Mood and Anxiety Disorders, Monte Carlo, Monaco, November 2000.
312. **Steiner M**, Trzepacz P, Brown E, Dillon J. Fluoxetine treatment improves social functioning in women with PMDD. NASPOG Annual Meeting, Waikoloa, HI, February 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 1:11.
313. Dunn E, Macdougall M, Coote M, **Steiner M**. Biochemical correlates of symptoms associated with premenstrual dysphoric disorder. NASPOG Annual Meeting, Waikoloa, HI, February 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 1:18.
314. Cullimore A, Boulter M, Macdougall M, Muggah H, Gold I, **Steiner M**. Health care expectations of perimenopausal women. NASPOG Annual Meeting, Waikoloa, HI, February 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 1:19.
315. Causey S, Fairman M, Nicholson D, **Steiner M**. Can postpartum depression be prevented? NASPOG Annual Meeting, Waikoloa, HI, February 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 1:24.
316. Born L, Nicholson D, **Steiner M**. Do thyroid antibodies influence the clinical profile of postpartum depression? NASPOG Annual Meeting, Waikoloa, HI, February 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 1:27.
317. Dunn E, Macdougall M, Coote M, **Steiner M**. Biochemical correlates of symptoms associated with premenstrual dysphoric disorder. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:1.
318. **Steiner M**. Treatment of depression in menopause. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:3.
319. Cullimore A, Boulter M, Macdougall M, Muggah H, Gold I, **Steiner M**. Health care expectations of perimenopausal women. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:4.
320. Causey S, Fairman M, Nicholson D, **Steiner M**. Can postpartum depression be prevented? 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:12.

321. Born L, Nicholson D, **Steiner M**. Do thyroid antibodies influence the clinical profile of postpartum depression? 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:14.
322. **Steiner M**. Dysthymia in women. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:19.
323. **Steiner M**. Gender, serotonin and mood. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:38.
324. **Steiner M**, Trzepacz P, Brown E, Dillon J. PMDD and work efficiency: response to fluoxetine in a randomized clinical trial. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:78.
325. **Steiner M**, Trzepacz P, Brown E, Dillon J. Fluoxetine treatment improves social functioning in women with PMDD. 1st World Congress of Women's Mental Health, Berlin, Germany, March 2001. Abstract: Archives of Women's Mental Health 2001;3 Suppl 2:78.
326. **Steiner M**, Brown E, Dillon J. Fluoxetine reduces food cravings during the luteal phase in women with PMDD. APA Annual Meeting, New Orleans, LA, May 2001.
327. **Steiner M**, Trzepacz P, Brown E, Dillon J. PMDD and work efficiency: response to fluoxetine in a randomized clinical trial. Society of Biological Psychiatry Annual Meeting, New Orleans, LA, May 2001. Abstract: Biological Psychiatry 2001, 49:116S.
328. **Steiner M**, Trzepacz P, Brown E, Dillon J. Fluoxetine treatment improves social functioning in women with PMDD. Society of Biological Psychiatry Annual Meeting, New Orleans, LA, May 2001. Abstract: Biological Psychiatry 2001;49:50S.
329. Dunn E, Macdougall M, Coote M, **Steiner M**. Polymorphism in the serotonin (5-HT) transporter gene and free testosterone levels may influence the severity of symptoms associated with PMDD. ACNP Annual Meeting, Waikoloa, HI, December 2001.
330. **Steiner M**, Nicholson D, Macdougall M. The burden of illness of premenstrual symptoms, NASPOG, 30th Annual Meeting, Cancun, Mexico, February, 2002.
331. Born L, Arthur H, Cullimore A, Muggah H, Tanser P, Allega R, Streiner D, **Steiner M**. The happy heart: a psychosocial program for depressed mature women at risk for coronary heart disease. NASPOG, 30th Annual Meeting, Cancun, Mexico, February, 2002.
332. Macdougall M, Nicholson D, Mailing S, Bell B, **Steiner M**. Diagnosis and treatment of female specific mood disorders: a new program for primary care physicians. NASPOG, 30th Annual Meeting, Cancun, Mexico, February, 2002.
333. Born, L, **Steiner M**, Koren G. Irritability: the burden of illness. NASPOG, 30th Annual Meeting, Cancun, Mexico, February, 2002.
334. **Steiner M**, Dunn E, Macdougall M, Coote M. Serotonin (5-HT) transporter gene polymorphism, free testosterone, and symptoms associated with PMDD. Society of Biological Psychiatry Annual Meeting, Philadelphia, PA, May, 2002.
335. **Steiner M**, Brown E, Macdougall M. The burden of illness of premenstrual symptoms. Tenth Annual Congress on Women's Health & Gender Based Medicine, Hilton Head, South Carolina, May 2002

336. **Steiner M**, Brown E, Macdougall M. The burden of illness of premenstrual symptoms. 42nd Annual NCDEU Meeting, Boca Raton, Florida, June, 2002.
337. **Steiner M**, Brown E, Macdougall M. The burden of illness of premenstrual symptoms. XII World Congress of Psychiatry, Yokohama, Japan, August 2002.
338. **Steiner M**, Fairman M, Jansen K, Causey S. Can postpartum depression be prevented? The Marce Society, Sydney, Australia, September 2002.
339. Born L, **Steiner M**, Koren G. Female specific irritability: a new measure. The Marce Society, Sydney, Australia, September 2002.
340. Cohen LS, Soares CN, Yonkers KA, Bellew KM, Rolfe TE, **Steiner M**, Paroxetine controlled-release (CR) is effective in the treatment of premenstrual dysphoric disorder (PMDD): results from a randomized placebo controlled trial. US Psych Congress, Chicago, Illinois, October 2002.
341. Yonkers KA, Cohen LS, Soares CN, Bellew KM, Rolfe TE, **Steiner M**, Paroxetine controlled-release (CR) improves social functioning in patients with PMDD. US Psych Congress, Chicago, Illinois, October 2002.
342. Pearlstein TB, Bellew KM, Endicott J, Holland FJ, **Steiner M**. Paroxetine controlled-release (CR) is effective in the treatment of PMDD. 41st ACNP Annual Meeting, San Juan, Puerto Rico, December 2002.
343. Endicott J, Pearlstein TB, Hunter BN, Holland FJ, **Steiner M**. Paroxetine controlled-release (CR) improves social functioning in patients with PMDD. 41st ACNP Annual Meeting, San Juan, Puerto Rico, December 2002.
344. Shea, AK, **Steiner M**, Walsh CA, Gensey SD, Spree S, Jamieson E, MacMillan HL, Hypothalamic-Pituitary-Adrenal axis dysfunction following child maltreatment and its role in the etiology of women's mental illness. NASPOG, Kauai, HI, February 2003
345. Cohen LS, Soares CN, Yonkers KA, Bellew KM, Rolfe TE, **Steiner M**, Paroxetine controlled-release (CR) is effective in the treatment of PMDD. NASPOG, Kauai, HI, February 2003
346. Yonkers KA, Cohen LS, Soares CN, Bellew KM, Rolfe TE, **Steiner M**. Paroxetine controlled-release (CR) improves social functioning in patients with PMDD. NASPOG, Kauai, HI, February 2003.
347. **Steiner M**, Macdougall M, Mailing S, Born L, Brown E. The burden of illness of premenstrual symptoms in adolescents. NASPOG, Kauai, HI, February 2003.
348. Krpan KM, Zinga D, Coombs R, Coote M, Fleming, AS, **Steiner M**. Experiential and hormonal correlates of teen maternal behaviour. NASPOG, Kauai, HI, February 2003.
349. Fairman M, Jansen K. **Steiner M**. Psychoeducational group intervention for women with postpartum depression. NASPOG, Kauai, HI, February 2003.
350. Jansen K, Fairman M, **Steiner M**. Use of ante-natal group intervention as prophylaxis for postpartum depression. NASPOG, Kauai, HI, February 2003.
351. **Steiner M**, Allgulander C, Ravindran A, Fayyad R, Austin C. Generalized anxiety disorder (GAD): gender differences in clinical presentation and response to sertraline. Anxiety Disorders Association of America, Toronto, March 2003.

352. Yonkers KA, Hunter BN, Bellew KM, Rolfe TE, **Steiner M**, Heller VL. Paroxetine controlled release is effective in treating premenstrual dysphoric disorder: a pooled analysis of three trials. American College of Obstetricians and Gynecologists (ACOG) 51st Annual Clinical Meeting, New Orleans, April 2003. Abstract: *Obstetrics & Gynecology* 2003;101 Suppl 4:110-111.
353. **Steiner M**, Allgulander C, Ravindran A, Fayyad R, Austin C. Generalized anxiety disorder (GAD): gender differences in clinical presentation and response to sertraline. APA Annual Meeting, San Francisco, CA, May 2003.
354. Born L, Koren G, **Steiner M**. Irritability in women: a new clinical measure. APA Annual Meeting, San Francisco, CA, May 2003.
355. **Steiner M**, Allgulander C, Ravindran A, Fayyad R, Austin C. Generalized anxiety disorder (GAD): gender differences in clinical presentation and response to sertraline. CCNP, Montreal, June 2003.
356. Ravindran A, Kutcher S, Sjodin I, Fayyad R, Austin C, **Steiner M**. Efficacy of sertraline in improving quality of life and functioning in Generalized Anxiety Disorder (GAD). CCNP, Montreal, June 2003.
357. **Steiner M**, Allgulander C, Ravindran A, Fayyad R, Austin C. Generalized anxiety disorder (GAD): gender differences in clinical presentation and response to sertraline. 16th ECNP Congress, Prague, Czech Republic, September 2003.
358. Sawka AM, Huh A, Adachi JD, Papaioannou A, Dolovich L, Gafni A, Thabane L, Cullimore A, Macdougall M, **Steiner M**. Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. ASBMR 25th Annual Meeting, Minneapolis, Minnesota, September 2003.
359. **Steiner M**, Allgulander C, Ravindran A, Fayyad R, Austin C. Generalized anxiety disorder (GAD): gender differences in clinical presentation and response to sertraline. ECNP, Prague, September 2003.
360. Sawka A, Huh A, Papaioannou A, Dolovich L, Eva K, Thabane L, Gafni A, Cullimore A, MacDougall M, **Steiner M**, Adachi JD. Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: the aware survey. Fourth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Nice, France, November 2003. Abstract: *Osteoporos Int* 2003;14 Suppl 7:S60.
361. Born L, **Steiner M**, Koren G. A new gender-specific measure of irritability: the Born-Steiner irritability scale. 2nd World Congress on Women's Mental Health, Washington, March 2004.
362. Macdougall M, **Steiner M**. Assessment of sexual drive and desire in women with premenstrual dysphoria who have been treated with fluoxetine. 2nd World Congress on Women's Mental Health, Washington, March 2004.
363. Sawka AM, Hugh A, Dolovich L, Papaioannou A, Adachi JK, Eva K, Cullimore A, Thabane L, Macdougall, **Steiner M**. Beliefs of women who have recently taken menopausal hormone therapy: results of the AWARE survey. 2nd World Congress on Women's Mental Health, Washington, March 2004.
364. Shea AK, MacMillan HM, Gensey S, Spree S, Schmidt L, Van der Meulen J, Boyle M, Niec A, Walsh C, **Steiner M**. The effect of early child maltreatment on DHEA concentrations at rest and in response to stress in female adolescents. 2nd World Congress on Women's Mental Health, Washington, March 2004.
365. **Steiner M**, Macdougall M. Assessment of sexual drive and desire in women with premenstrual dysphoria who have been treated with fluoxetine. CINP Annual Meeting, Paris, June 2004.

366. Ravindran AV, Woods S, **Steiner M**. The treatment of premenstrual dysphoric disorder: an open study using instant dosing of citalopram. CINP Annual Meeting, Paris, June 2004.
367. **Steiner M**. (Workshop) Current practices and strategies for research on sex differences and the brain. ISPNE 35th Annual Conference, Glasgow, Scotland, July 2004.
368. Shea AK, MacMillan HM, Streiner DL, Gensey S, Spree S, Schmidt L, Van der Meulen J, Boyle M, Niec A, Walsh C, **Steiner M**. The effect of early child maltreatment on DHEA levels at rest and in response to stress in female adolescents. ISPNE 35th Annual Conference, Glasgow, Scotland, July 2004.
369. Shea AK, MacMillan HM, Streiner DL, Gensey S, Spree S, Schmidt L, Van der Meulen J, Boyle M, Niec A, Walsh C, **Steiner M**. The effect of methylphenidate on the cortisol and dehydroepiandrosterone (DHEA) responses to psychosocial stress in female adolescents following child maltreatment. ISPNE 35th Annual Conference, Glasgow, Scotland, July 2004.
370. Ravindran AV, Woods S, **Steiner M**. An open study of instant dose citalopram in premenstrual dysphoric disorder. 17th ECNP Annual Meeting, Sweden, October 2004. Abstract: European Neuropsychopharmacology 2004;14:188.
371. Born L, **Steiner M**. Perinatal mental illness: how can we improve its assessment? A roundtable discussion. 32nd Annual Meeting NASPOG, San Diego, CA, February 2005. Abstract: Archives of Women's Mental Health 2005;8:61-73.
372. Shea AK, Veljko JD, Dragomir A, **Steiner M**. Effects of in utero and postnatal nicotine exposure in rats. 32nd Annual Meeting NASPOG, San Diego, CA, February 2005. Abstract: Archives of Women's Mental Health 2005;8:61-73.
373. Phillips SD, Ross L, Hampson E, **Steiner M**. Hormone levels, mood and cognition in pregnancy and postpartum. 32nd Annual Meeting NASPOG, San Diego, CA, February 2005. Abstract: Archives of Women's Mental Health 2005;8:61-73.
374. **Steiner M**, Born L, Ross L. SSRI's during pregnancy: do they really hurt the babies? 32nd Annual Meeting NASPOG, San Diego, CA, February 2005. Abstract: Archives of Women's Mental Health 2005;8:61-73.
375. **Steiner M**, Ross L, Born L. SSRI's during pregnancy: do they really hurt the babies? 13th AEP Congress, Munich, Germany, April 2005. Abstract: European Psychiatry 2005;20:S142.
376. **Steiner M**, Born L, Ross L. SSRI's during pregnancy: do they really hurt the babies? Society of Biological Psychiatry Annual Meeting, Atlanta, GA, May 2005;57:90S.
377. Shea AK, Djuric VJ, Dragomir A, **Steiner M**. Effects of inutero and postnatal nicotine exposure in rats. Society of Biological Psychiatry Annual Meeting, Atlanta, GA, May 2005;57:96S.
378. Born L, Ross L, **Steiner M**. SSRI's during pregnancy: do they really hurt the babies? 45th Annual NCDEU Meeting, Boca Raton, FL, June 2005.
379. Born L, Soares CN, Phillips SD, Jung M, **Steiner M**. Women and reproductive-related trauma. New York Academy of Sciences - Psychobiology of PTSD, New York, NY, September 2005.
380. Shea AK, **Steiner M**, Newport J, Walker E, Brennan P, Stowe Z. Salivary alpha amylase levels in depressed mothers and their infants. 36th Annual ISPNE Conference, Montreal, QC, September 2005.
381. Giardino J, Gonzalez A, Coote M, **Steiner M**, Fleming A. Affective, autonomic, and hormonal responses to infant cries in teen and adult mothers. 36th Annual ISPNE Conference, Montreal, QC, September 2005.

382. Georgiades K, Schmidt L, MacMillan H, Boyle M, **Steiner M**, Bennett L, Parkin C, Shea A, Duku E. Neuroendocrine functioning in adolescent females exposed to child maltreatment: associations with emotion regulation. Healthy Child Development and Youth (symposium). Offord Centre for Child Studies, Hamilton, ON, October 2005.
383. Shea A, Streiner D, Fleming A, Kamath M, **Steiner M**. Endocrine and autonomic nervous system correlates of stress during pregnancy. 29th Annual Perinatal Investigators Meeting, Kingston, ON, November 2005.
384. **Steiner M**. SSRI's during pregnancy: do they really hurt the babies? Canadian Psychiatric Association, Vancouver, BC, November 2005.
385. Woods SA, Ravindran A, **Steiner M**. Instant dose citalopram in premenstrual dysphoric disorder: an open study. Canadian Psychiatric Association, Vancouver, BC, November 2005.
386. **Steiner M**, Born L, Ross L, Soares C. Is there a relationship between the use of SSRI's during pregnancy and neonatal complications? NASPOG, Hawaii, February 2006. Abstract: Archives of Women's Mental Health 2006;9:161-171.
387. Ker K, Boylan K, **Steiner M**, Born L. Rating irritability in female adolescents: a reliability study (work in progress). NASPOG, Hawaii, February 2006. Abstract: Archives of Women's Mental Health 2006;9:161-171.
388. Shea A, **Steiner M**, Brennan P, Walker E, Newport J, Green P, Stowe ZN. Infant salivary alpha amylase levels and maternal depression. NASPOG, Hawaii, February 2006. Abstract: Archives of Women's Mental Health 2006;9:161-171.
389. Shea A, Streiner D, Fleming A, Kamath M, **Steiner M**. Physiological correlates of stress during pregnancy. NASPOG, Hawaii, February 2006. Abstract: Archives of Women's Mental Health 2006;9:161-171.
390. Shea AK, **Steiner M**, Brennan P, Walker E, Newport J, Stowe ZN. Maternal depression and salivary alpha amylase response to stress in their infants. American Psychosomatic Society 64th Annual Meeting, Denver, March 2006;1565:A-5.
391. Shea A, **Steiner M**, Brennan P, Walker E, Newport J, Stowe Z. Maternal depression and salivary alpha amylase response to stress in their infants: a new marker of vulnerability/resilience? (Symposium). Society of Biological Psychiatry, Toronto, May 2006;59:39S.
392. Shea A, Streiner D, Fleming A, Kamath M, **Steiner M**. Stress during pregnancy and its impact on the newborn. American Psychiatric Association Meeting, Toronto, May 2006;52:NR125.
393. Shea A, Streiner D, Fleming A, Kamath M, **Steiner M**. Endocrine and autonomic nervous system correlates of depression and anxiety during pregnancy. Sixth International Congress of Neuroendocrinology, Pittsburg, PA, June 2006. Abstract: Frontiers in Neuroendocrinology 2006;27:61-62.
394. Shea A., Streiner D., Fleming A., Kamath M., **Steiner M**. Physiologic correlates of adversity in mother-baby diads. 37th ISPNE Annual Meeting, Leiden, Netherland, August 2006.
395. Shea A, Kamath MK, Fleming A, Streiner DL, **Steiner M**. The effect of depression, anxiety and antidepressant use on maternal physiological correlates during pregnancy. NASPOG, Oregon, February 2007.
396. Shea AK, Kamath MV, Fleming A, Streiner DL, **Steiner M**. The effects of maternal stress, depression and anxiety on birth outcomes are sex-dependant. 1st OSSD Annual Meeting, Washington, DC, May 2007.

397. Pinsonneault J, Papp A, Coote, M, **Steiner M**, Sadee W. Perinatal mood and anxiety disorders: a genetic data association analysis. 1st OSSD Annual Meeting, Washington, DC, May 2007.
398. Juric S, Brennan P, Newport DJ, Shea A, Fernandez SV, **Steiner M**, Stowe ZN. Neuroendocrine markers of stress reactivity in the infants of women with bipolar disorder. APA Annual Meeting, San Diego, May 2007.
399. **Steiner M**, Soares C, Kirby L, Yu H, Bobula J, Olivier S. Symptom reduction in women treated with Desvenlafaxine for menopausal hot flushes: impact on bothersomeness. APA Annual Meeting, San Diego, CA, May 2007.
400. **Steiner M**, Kirby L, Yu H, Bobula J, Olivier S. Desvenlafaxine improves mood in women for vasomotor symptoms: Effect on baseline mood states. APA Annual Meeting, San Diego, CA, May 2007.
401. Wyrwich K, Yu H, **Steiner M**, Bobula J, Olivier S. Validation of POMS questionnaire in postmenopausal women. APA Annual Meeting, San Diego, CA, May 2007.
402. Shea AK, Kamath MV, Fleming A, Streiner DL, **Steiner M**. The relationship between maternal salivary alpha amylase (AA) levels during pregnancy on the infant AA response to stress, heart rate variability and temperament. ISPNE, Wisconsin, August 2007.
403. Shea A, **Steiner M**, Streiner D, Fleming A, Toth R, Kamath A, Kamath M. Effects of maternal adversity and antidepressant treatment on the infant heart rate variability. Los Angeles, CA, September 2007.
404. **Steiner M**, Kirby L, Yu H, Bobula J, Oliver S. Desvenlafaxine improves mood in postmenopausal women treated for vasomotor symptoms: effect of baseline mood states. American Academy of Family Physicians, Chicago, October 2007.
405. **Steiner M**, Yu H, Bobula J, Olivier S. The impact of hot flush bothersomeness on symptom reduction with desvenlafaxine succinate in women treated for menopausal vaso motor symptoms. American Academy of Family Physicians, Chicago, October 2007.
406. **Steiner M**, Moore A, Yu H, Bobula J, Olivier S. The impact of bothersomeness on symptom reduction in women treated with desvenlafaxine for menopausal hot flushes. Nurse Practitioners in Women's Health. Philadelphia, October 2007.
407. **Steiner M**, Moore A, Yu H, Bobula J, Olivier S. Desvenlafaxine improves poor mood in postmenopausal women treated for vasomotor symptoms. Nurse Practitioners in Women's Health. Philadelphia, October 2007.
408. **Steiner M**. Antidepressants during pregnancy and infant outcomes. 20th ECNP Congress, Vienna, Austria, October 2007.
409. **Steiner M**, Soares S, Wittchen HU. Women and mental health diagnostic tools. (Brainstorming Session). 20th ECNP Congress, Vienna, Austria, October 2007.
410. MacMillan HL, Georgiades K, Duku E, Shea AK, **Steiner M**, Schmidt L, Boyle MH. Cortisol reactivity differences between female maltreated adolescents and control participants. American Academy of Child and Adolescent Psychiatry. Boston, MA, October 2007. Abstract: 14A, p. 65.
411. **Steiner M**. Women and depression: the role of reproductive age, stress and trauma. (Symposium) 3rd International Congress on Women's Mental Health, Melbourne, Australia, March 2008.

412. **Steiner M**, Guico-Pabia C, Farmer M, Ganguly R, Haller T, Olivier S. Desvenlafaxine succinate improves mood in postmenopausal women treated for vasomotor symptoms. 3rd Internatinal Congress on Women's Mental Health, Melbourne, Australia, March 2008.
413. Lord C, Rieder A, Hall G, Soares C, **Steiner M**. Perinatal obsessive-compulsive scale (POCS). 3rd Internatinal Congress on Women's Mental Health, Melbourne, Australia, March 2008.
414. **Steiner M**, Martini J, Rieder A, Soares C, Wittchen HU. The composite international diagnostic interview for women (CIDI-VENUS): a pilot study. CCNP Annual Meeting, Toronto, ON, June 2008.
415. Shea A, Kamath M, Fleming A, **Steiner M**. Maternal depression, antidepressant use during pregnancy and infant autonomic and endocrine outcomes. (Symposium) CCNP Annual Meeting, Toronto, ON, June 2008.
416. Frey BN, Hall GB, MacQueen GM, **Steiner M**, Soares CN. An 8-week open trial of desvenlafaxine for the treatment of major depression in postmenopausal women: effects on vasomotor symptoms, cognition, brain function, and quality of life. CCNP Annual Meeting, Toronto, ON, June 2008.
417. Grigoriadis S, Ross L, Dennis CL, Cheung A, Bradley L, Mamisashvili L, **Steiner M**, Koren G, Mousmanis P. An evidence-based algorithm to quantify risk-benefit decision-making for use of antidepressant medication during pregnancy and lactation. Research in progress: current state of knowledge. CCNP Annual Meeting, Toronto, ON, June 2008.
418. Soares CN, Frey BN, Chang S, Haber E, **Steiner M**. Seroquel XR for the treatment of midlife women with major depressive disorder: impact on mood and menopause-related symptoms. CCNP Annual Meeting, Toronto, ON, June 2008.
419. Lord C, Rieder A, Hall G, Soares CN, **Steiner M**. Perinatal obsessive-compulsive scale (POCS): preliminary results of a new instrument. CCNP Annual Meeting, Toronto, ON, June 2008.
420. Lord C, Hall G, Carew C, Soares CN, **Steiner M**. Effect of stress on brain activation patterns in women with postpartum obsessive-compulsive and depressive disorders: preliminary results. CCNP Annual Meeting, Toronto, ON, June 2008.
421. **Steiner M**, Martini J, Rieder A, Soares C, Wittchen HU. The composite international diagnostic interview for women (CIDI-VENUS): a pilot study. XXVI CINP Congress, Munich, Germany, July 2008. Abstract: International Journal of Neuropsychopharmacology 2008;11 Suppl 1:301.
422. **Steiner M**, Atkinson L, Gonzalez A, Shea A. Maternal adversity: hormonal and autonomic responses in mother and child (Symposium). 39th ISPNE Conference, Dresden, Germany, July, 2008.
423. **Steiner M**, Martini J, Rieder A, Soares C, Wittchen HU. The composite international diagnostic interview for Women (CIDI-VENUS): a pilot study. 21st ECNP Congress, Barcelona, Spain, August 2008.
424. Lord C, Hall GB, Carew C, Soares CN, **Steiner M**. Effect of stress on brain activation patterns in women with post partum obsessive-compulsive and depressive disorders: preliminary results. 21st ECNP Congress, Barcelona, Spain, August 2008. Abstract: European Neuropsychopharmacology 2008;18 Suppl 4:S501-502.
425. Lord C, Hall G, Soares CN, **Steiner M**. Stress in women with postpartum obsessive-compulsive disorder: a neuroimaging study. European Psychiatric Association, Lisbon, Portugal, January 2009.
426. **Steiner M**, Shea A, Attard SM, Soares CN. The risk of using antidepressants during pregnancy: serious concern or much ado about little? European Psychiatric Association, Lisbon, Portugal, January 2009.

427. Lord C, Hall G, Soares CN, **Steiner M**. Stress in women with postpartum obsessive-compulsive disorder: a neuroimaging study. NASPOG, New Haven, CT, February 2009.
428. Lord C, Rieder A, Hall G, Soares C, **Steiner M**. Perinatal Obsessive-Compulsive Scale (POCS) NASPOG, New Haven, CT, February 2009.
429. Rieder A, Soares CN, Wittchen HU, Martini J, **Steiner M**. Utilization of the composite international diagnostic interview-for women (CIDI-VENUS) in a perinatal population: A pilot study. NASPOG, New Haven, CT, February 2009.
430. Grigoriadis S, Ross LE, Dennis C-L, Cheung A, Bradley L, Mamisashvili L, **Steiner M**, Koren G, Mousmanis P. Use of antidepressant medication during pregnancy and lactation: development of an evidence-based decision tool. NASPOG, New Haven, CT, February 2009.
431. Peer M, Soares CN, Nair PK, **Steiner M**. Asthma, inflammation and perimenstrual changes. NASPOG, New Haven, CT, February 2009.
432. Lokuge S, Nicholls B, Frey BN, Foster J, Coote M, Soares CN, **Steiner M**. Genotype and gene expression of estrogen and serotonin markers in women with premenstrual syndrome. Health Research in the City, Hamilton, ON, February 2009.
433. Soares CN, Chang S, Sooknanan A, Lord C, Peer M, **Steiner M**. Allostatic load, psychiatry morbidity and cortisol responses to awakening in midlife immigrant women. Scandinavian College of Neuro-Psychopharmacology, Copenhagen, Denmark, April 2009. Abstract: Scandinavian Neuropsychopharmacology 2009;2:27.
434. Rieder AD, Soares CN, Lord C, Wittchen H-U, Martini J, **Steiner M** (2009) Validation of the Composite International Diagnostic Interview – for Women (CIDI-VENUS) in a perinatal psychiatric population. Biological Psychiatry, Vancouver, BC, May 2009;65:128S.
435. Lord C, Soares CN, **Steiner M**. Physiological stress response in postpartum women with obsessive-compulsive disorder: a pilot study. Society of Biological Psychiatry, Vancouver, BC, May 2009;65:127S.
436. Lord C, Hall G, Soares CN, **Steiner M**. Stress and error monitoring in postpartum women with obsessive-compulsive disorder: a postpartum neuroimaging study. 67th Annual Meeting of the Society of Biological Psychiatry, Vancouver, BC, May 2009;65:127S.
437. Lord C, Hall G, Soares CN, **Steiner M**. Stress, postpartum et TOC, comprendre avec l'imagerie fonctionnelle. (Symposium) Neuroimagerie et Santé Mentale, 77^{ème} congrès de l'Association francophone pour le savoir (ACFAS), Ottawa, ON, May 2009.
438. Nichols B, Frey BN, Lokuge S, McKinnon M, Hall G, Soares CN, **Steiner M**. Cognitive functions in women with moderate to severe premenstrual syndrome or premenstrual dysphoric disorder. 39th Annual Ontario Psychology Undergraduate Thesis Conference, Hamilton, ON, May 2009. Abstract: #66.
439. **Steiner M**. The use of anti depressants during pregnancy and their effects on the HPA axis and heart rate variability in both mothers and their babies. 40th Annual ISPNE Conference, San Francisco, CA, July 2009.
440. Lord C, Soares CN, **Steiner M**. Stress response in postpartum women with obsessive-compulsive disorder: a pilot study. ISPNE, San Francisco, CA, August 2009.
441. Martini J, Wittchen H-U, Soares CN, Rieder A, **Steiner M**. Die standardisierte diagnostische Erfassung psychischer Störungen bei Frauen: The Composite International Diagnostik Interview for Women (CIDI-

- VENUS) (Abstract). Posterpräsentation auf dem 9. Kongress der Interdisziplinären Gesellschaft für psychische Gesundheit von Frauen und Genderfragen, Basel, Switzerland, September 2009.
442. **Steiner M**, Rieder A, Soares C. New advances and diagnostic tools to assess psychiatric disorders across the female life cycle. (Symposium) Women's Mental Health in Ontario: Building Networks and Research Capacity, Toronto, October 2009.
443. Martini J, Wittchen H-U, Soares C.N., Rieder, A. **Steiner M**. Die standardisierte diagnostische Erfassung psychischer Störungen bei Frauen: The Composite International Diagnostik Interview for Women (CIDI-VENUS). (Abstract). Posterpräsentation auf dem Kongress der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin, Germany, November 2009.
444. Nicholls B, Frey BN, McKinnon M, Hall G, Lokuge S, Soares CN, **Steiner M**. Effects of premenstrual symptoms on cognitive functioning – preliminary results. NASPOG, Richmond, VA, February 2010.
445. Lokuge S, Frey BN, Foster J, Coote M, Soares CN, **Steiner M**. Gene expression of estrogen receptor alpha and serotonin reuptake transporter in women with premenstrual syndrome and premenstrual dysphoric disorder. NASPOG, Richmond, VA, February 2010.
446. Hampson E, Pinsonneault J, **Steiner M**, Sadee W. The neurochemistry of spatial working memory: insights from genetic association analysis. The 20th Annual Rotman Research Institute Conference, Toronto, ON, March 2010.
447. Peer M, **Steiner M**, Waserman S, Soares C. Does perceived stress in pregnant immigrant women predispose their infants to allergic disease development? 2010 Canadian Neuroscience Meeting Jointly presented by CAN and CCNP, Ottawa, ON, May 2010.
448. Lokuge S, Frey BN, Foster JA, Coote M, Nicholls B, Soares CN, **Steiner M**. Gene expression of estrogen receptor alpha and serotonin transporter in women with premenstrual syndrome and premenstrual dysphoric disorder. 2010 Canadian Neuroscience Meeting Jointly presented by CAN and CCNP, Ottawa, ON, May 2010.
449. Frey BN, Hall GBC, Attard S, Yucel K, **Steiner M**, Soares CN. Neuronal correlates of regulation of emotional conflict in women during menopausal transition. 65th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, New Orleans, LA, May 2010;67 Suppl 9:137S.
450. Nicholls B, Frey BN, McKinnon M, Hall GBC, Lokuge S, Soares CN, **Steiner M**. Are neurocognitive complaints persistent during the follicular phase in women with premenstrual syndrome and premenstrual dysphoric disorder. 65th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, New Orleans, LA, May 2010;67 Suppl 9:66S.
451. Lokuge S, Frey BN, Foster JA, Coote M, Nicholls B, Soares CN, **Steiner M**. Gene expression of estrogen receptor alpha and serotonin transporter in women with premenstrual syndrome and premenstrual dysphoric disorder. 65th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, New Orleans, LA, May 2010;67 Suppl 9:55S.
452. Bouvette-Turcot A, Minde K, **Steiner M**, Meaney M, Wazana A. The 3 month stability of a parent-reported measure of infant temperament. 12th World Congress of the World Association for Infant Mental Health, Leipzig, Germany, July 2010. Abstract: Infant Mental Health Journal, 2010;32 Suppl:214.
453. Bouvette-Turcot A, Minde K, **Steiner M**, Meaney M, Fleming A, Wazana A. The influence of prenatal adversity on parent-reported infant temperament. 12th World Congress of the World Association for Infant Mental Health, Leipzig, Germany, July 2010. Abstract: Infant Mental Health Journal, 2010;32 Suppl:276.

454. Barrett J, Wonch K, Hall G, **Steiner M**, Fleming A. The baby drug: brain regions involved in affect, reward and motivation are important in maternal responsiveness to own infant. Society for Behavioral Neuroendocrinology Annual Meeting, Toronto, ON, July 2010.
455. Chico E, Gonzalez A, **Steiner M**, Eaton H, Ali N, Wonch K, Katter J, Fleming AS. Sensitive mothering requires good executive function: challenges faced by teenage mothers? Society for Behavioral Neuroendocrinology Annual Meeting, Toronto, ON, July 2010.
456. Wonch K, Barrett J, Hall G, Gonzalez A, Ali N, **Steiner M**, Fleming, AS. Response of prefrontal cortex to emotional infant stimuli is related to quality of early experience reported by recently postpartum mothers. Society for Behavioral Neuroendocrinology Annual Meeting, Toronto, ON, July 2010.
457. Grigoriadis S, Ross L, Dennis C-L, Bradley L, Mamisashvili L, Cheung A, **Steiner M**, Koren G, Mousmanis P. Outcomes associated with antidepressant medication use during pregnancy: a meta-analysis. 60th Annual Conference of the Canadian Psychiatric Association, Toronto, ON, September 2010. Abstract: #PS6b.
458. Peer M, **Steiner M**, Soares CN. Stress, depression and HPA-Axis in pregnant immigrant women. 60th Annual Conference of the Canadian Psychiatric Association, Toronto, ON, September 2010. Abstract: #P56.
459. **Steiner M**, Lokuge S, Frey B, Foster JA, Cote M, Nicholls B, Soares C. Differences in Gene expression of estrogen receptor alpha and serotonin transporter in women with premenstrual syndrome and premenstrual dysphoric disorder. 60th Annual Conference of the Canadian Psychiatric Association, Toronto, ON, September 2010. Abstract: #P59.
460. Skelin I, Frey BN, Hall GB, Attard S, **Steiner M**, Soares CN. Brain activation during the performance on the working memory task in unmedicated midlife depressed patients: functional magnetic resonance study. Society for Neuroscience, San Diego, CA, November 2010.
461. Bouvette-Turcot A, Kennedy J, Atkinson L, Sokolowski M, Gaudreau H, Lydon J, **Steiner M**, Gonzalez A, Meaney M, Fleming A. Maternal history of early adversity: impacts on offspring temperament. International Society for Traumatic Stress Studies, Montreal, QC, November 2010.
462. Peer M, **Steiner M**, Wasserman S, Soares CN. Depression and stress are associated with blunted cortisol activity in pregnant immigrant women. AllerGen's 6th Annual Conference, Vancouver, BC, Feb 2011.
463. Mileva-Seitz V, Kenedy J, Atkinson L, **Steiner M**, Levitan R, Matthews SG, Meaney MJ, Sokolowski MB, Fleming AS. Serotonin transporter allelic variation in mothers predict maternal sensitivity, behavior, and attitude toward 6-month old infants. 4th World Congress on Women's Mental Health, Madrid, Spain, March 2011.
464. Lord C, **Steiner M**, Soares CN, Carew CL, Hall GB. Stress response in postpartum women with and without obsessive-compulsive symptoms: a fMRI study. 4th World Congress on Women's Mental Health, Madrid, Spain, March 2011.
465. Barrett J, Wonch KE, Hall GB, Gonzalez A, Ali N, **Steiner M**, Fleming AS. Brain regions involved in affect, reward and motivation are important in maternal responsiveness to own infant. 4th World Congress on Women's Mental Health, Madrid, Spain, March 2011.
466. Peer M, **Steiner M**, Soares CN. Stress, depression and HPA axis in pregnant immigrant women. 4th World Congress on Women's Mental Health, Madrid, Spain, March 2011.

467. Nicholls B, **Steiner M**, McKinnon M, Hall GBC, Lokuge S, Soares CN, Frey BN. (Symposium) Persistent working memory deficits in women with premenstrual syndrome and premenstrual dysphoric disorder. 4th World Congress on Women's Mental Health, Madrid, Spain, March 2011.
468. Bouvette-Turcot A-A, Wazana A, Kennedy J, Atkinson L, Sokolowski MB, Gaudreau H, Lydon JE, **Steiner M**, Deslauriers J, Meaney M, Fleming A. The impact on infant temperament of genotype, maternal care and maternal history of adversity. From temperament to psychopathology: the role of genes and maternal care in the development of children with prenatal adversity. Society for Research in Child Development Biennial Meeting, Montreal, QC, April 2011.
469. Fleming A, Lovic V, Palombo D, Gonzalez A, Chico E, **Steiner M**. Mothering, reward, and executive function in rat and human mothers. Biological and cognitive factors in maternal parenting behavior. Society for Research in Child Development Biennial Meeting, Montreal, QC, April 2011.
470. Wonch KE, Barrett JA, Hall GBC, Gonzalez A, **Steiner M**, Fleming A. Consistency of early care is related to bold response in the maternal neural circuit. Society for Research in Child Development Biennial Meeting, Montreal, QC, April 2011.
471. Frey BN, Hall GB, Fervalha G, Skelin I, Attard S, **Steiner M**, Soares CN. Frontal executive attention network in medication-free women with depression during menopausal transition: normalization of prefrontal cortical hyperactivation after antidepressant treatment. 66th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 2011.
472. Peer M, Soares CN, Waserman S, **Steiner M**. Depression and stress are associated with blunted cortisol activity in pregnant immigrant women. 66th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 2011. Poster: <http://posters.f1000.com/P1467>
473. Minuzzi L, Frey BN, Hall GB, Skelin I, Attard S, **Steiner M**, Soares CN. Cortical thickness analysis in unmedicated women with perimenopausal depression. 66th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 2011.
474. Snaidero R, Lokuge S, Foster JA, Coote M, Nicholls B, Soares CN, **Steiner M**, Frey BN. Decreased tryptophan hydroxylase-1 mRNA expression in premenstrual disorders. 66th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 2011. Poster: <http://posters.f1000.com/P1468>
475. Snaidero R, Lokuge S, Foster JA, Coote M, Nicholls B, Soares CN, **Steiner M**, Frey BN. Decreased tryptophan hydroxylase-1 mRNA expression in premenstrual syndrome and premenstrual dysphoric disorder. 34th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, QC, May 2011.

(a) Accepted:

1. **Steiner M**. Serotonin, depression, and cardiovascular disease: sex-specific issues. 15th World Congress of Psychiatry, Buenos Aires, Argentina, September 2011.
2. Bisceglia R, Sassi RB, Rieder A, Fleming A, Meaney MJ, Gonzalez A, Atkinson L, Soares CN, **Steiner M**. Intergenerational transmission of risk in the MAVAN study: maternal childhood maltreatment, infant behavior and temperament. 58th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, ON, October 2011.

(b) Submitted:

1. Pennestri M-H, Meaney M, **Steiner M**, Gruber R, Minde K, Moss E, Atkinson L, Gaudreau H. A longitudinal evaluation of sleep duration and quality as a function of attachment style in children. World Association of Sleep Medicine, Quebec City, QC, September 2011.
2. Bouvette-Turcot A-A, Pennestri M-H, Meaney M, Fleming A, **Steiner M**, Lydon J, Gruber R, Minde K, Atkinson L, Wazana A, Gaudreau H. Children difficult temperament, mothers' depression and nightmares: A MAVAN study. World Association of Sleep Medicine, Quebec City, QC, September 2011.
3. Ooi C, Silveira PP, Portella AK, Kennedy JL, Gaudreau H, **Steiner M**, Soares CN, Matthews ST, Meaney MJ, Levitan RD; MAVAN Study Team. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased carbohydrate intake in four year-old children. 58th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, ON, October 2011.
4. Stuart J, Bairey-Merz N, Berga S, Miller V, Ouyang P, Shaw L, **Steiner M**, Wenger N, Rich-Edwards J. Hypertensive disorders during pregnancy predict cardiovascular events: can we trust maternal recall of pregnancy complications? American Physiological Society Conference, Jackson, MS, October 2011.